TNF and Fas ligand induce apoptosis in tumor cells; however, their severe toxicity toward normal tissues hampers their application to cancer therapy. Apo2 ligand (Apo2L, or TRAIL) is a related molecule that triggers tumor cell apoptosis. Apo2L mRNA is expressed in many tissues, suggesting that the ligand may be nontoxic to normal cells. To investigate Apo2L’s therapeutic potential, we generated in bacteria a potently active soluble version of the native human protein. Several normal cell types were resistant in vitro to apoptosis induction by Apo2L. Repeated intravenous injections of Apo2L in nonhuman primates did not cause detectable toxicity to tissues and organs examined. Apo2L exerted cytostatic or cytotoxic effects in vitro on 32 of 39 cell lines from colon, lung, breast, kidney, brain, and skin cancer. Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence. Apo2L treatment of mice bearing solid tumors induced tumor cell apoptosis, suppressed tumor progression, and improved survival. Apo2L cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation. Thus, Apo2L may have potent anticancer activity without significant toxicity toward normal tissues.
Avi Ashkenazi, Roger C. Pai, Sharon Fong, Susan Leung, David A. Lawrence, Scot A. Marsters, Christine Blackie, Ling Chang, Amy E. McMurtrey, Andrea Hebert, Laura DeForge, Iphigenia L. Koumenis, Derf Lewis, Louise Harris, Jeanine Bussiere, Hartmut Koeppen, Zahra Shahrokh, Ralph H. Schwall
Title and authors | Publication | Year |
---|---|---|
Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
Kawakatsu R, Tadagaki K, Yamasaki K, Kuwahara Y, Yoshida T |
Diseases | 2025 |
Advances in the study of death receptor 5
Qiao X, Guo S, Meng Z, Gan H, Wu Z, Sun Y, Liu S, Dou G, Gu R |
Frontiers in Pharmacology | 2025 |
Anticancer Mechanisms of Ginsenoside Compound K: A Review
Lee YP, Chan HT, Li TH, Chu L(, Lee SL, Chang YQ, Wang RY |
Diseases | 2025 |
Tumor-tropic Trojan horses: Using mesenchymal stem cells as cellular nanotheranostics
Rosu A, Ghaemi B, Bulte JW, Shakeri-Zadeh A |
Theranostics | 2024 |
Interferon-β Overexpression in Adipose Tissue-Derived Stem Cells Induces HepG2 and Macrophage Cell Death in Liver Tumor Organoids via Induction of TNF-Related Apoptosis-Inducing Ligand Expression
Yoon Y, Kim CW, Kim MY, Baik SK, Jung PY, Eom YW |
International journal of molecular sciences | 2024 |
Death-associated protein 3 in cancer—discrepant roles of DAP3 in tumours and molecular mechanisms
Song H, Liu H, Wang X, Yang Y, Zhao X, Jiang WG, Sui L, Song X |
Frontiers in Oncology | 2024 |
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Kawakatsu R, Tadagaki K, Yamasaki K, Yoshida T |
Scientific Reports | 2024 |
Strophanthidin Induces Apoptosis of Human Lung Adenocarcinoma Cells by Promoting TRAIL-DR5 Signaling
Tian X, Gu L, Zeng F, Liu X, Zhou Y, Dou Y, Han J, Zhao Y, Zhang Y, Luo Q, Wang F |
Molecules (Basel, Switzerland) | 2024 |
Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.
Luo Y, Hao H, Wang Z, Ong CY, Dutcher R, Xu Y, Liu J, Pedersen LC, Xu D |
eLife | 2024 |
TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.
Guerrache A, Micheau O |
Cells | 2024 |
Bacteriophage-based particles carrying the TNF-related apoptosis-inducing ligand (TRAIL) gene for targeted delivery in hepatocellular carcinoma.
Sittiju P, Wudtiwai B, Chongchai A, Hajitou A, Kongtawelert P, Pothacharoen P, Suwan K |
Nanoscale | 2024 |
MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer.
Kim S, Lee KW, Yoo Y, Park SH, Lee JW, Jeon S, Illia S, Joshi P, Park HW, Lo HE, Seo J, Kim Y, Chang M, Lee TJ, Seo JB, Kim SH, Croce CM, Kim I, Suh SS, Jeon YJ |
Animal Cells and Systems | 2024 |
Spatial distribution of tumor-associated macrophages in an orthotopic prostate cancer mouse model.
Grayson KA, Greenlee JD, Himmel LE, Hapach LA, Reinhart-King CA, King MR |
Pathology oncology research : POR | 2024 |
Advances in the targeted theragnostics of osteomyelitis caused by Staphylococcus aureus.
Abdulrehman T, Qadri S, Haik Y, Sultan A, Skariah S, Kumar S, Mendoza Z, Yadav KK, Titus A, Khader S |
Archives of Microbiology | 2024 |
Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells
De Wilt L, Sobocki BK, Jansen G, Tabeian H, de Jong S, Peters GJ, Kruyt F |
2024 | |
The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies
Luo C, He S, Shi F, Zhou J, Shang L |
Biology | 2024 |
Chemical synthetic approaches to mimic the TRAIL: promising cancer therapeutics.
Masum AA, Aoki S, Rahman MM, Hisamatsu Y |
RSC medicinal chemistry | 2024 |
Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma.
Grisendi G, Dall'Ora M, Casari G, Spattini G, Farshchian M, Melandri A, Masicale V, Lepore F, Banchelli F, Costantini RC, D'Esposito A, Chiavelli C, Spano C, Spallanzani A, Petrachi T, Veronesi E, Ferracin M, Roncarati R, Vinet J, Magistri P, Catellani B, Candini O, Marra C, Eccher A, Bonetti LR, Horwtiz EM, Di Benedetto F, Dominici M |
Cell reports. Medicine | 2024 |
E3 ubiquitin ligase gene BIRC3 modulates TNF-induced cell death pathways and promotes aberrant proliferation in rheumatoid arthritis fibroblast-like synoviocytes.
Meng Q, Wei K, Shan Y |
Frontiers in immunology | 2024 |
Tumor necrosis factor superfamily signaling: life and death in cancer
Ababneh O, Nishizaki D, Kato S, Kurzrock R |
Cancer Metastasis Reviews | 2024 |
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
Jung P, Glaser SP, Han J, Popa A, Pisarsky L, Feng N, Geyer A, Haderk F, Alpar D, Bristow C, Schmittner S, Traexler PE, Mahendra M, Poehn B, Gandhi P, Fiorelli R, Awate S, Budano N, Martin F, Albrecht C, Drobits-Handl B, Anand SS, Kasturirangan S, Trapani F, Schweifer N, Marszalek JR, Tontsch-Grunt U, Pearson M, Heffernan TP, Kraut N, Vellano CP, García-Martínez JM |
mAbs | 2024 |
Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication
Goldmacher VS, Gershteyn IM, Kovtun Y |
Antibody Therapeutics | 2024 |
Therapeutic targeting of TRAIL death receptors
Di Cristofano F, George A, Tajiknia V, Ghandali M, Wu L, Zhang Y, Srinivasan P, Strandberg J, Hahn M, Sanchez Sevilla Uruchurtu A, Seyhan AA, Carneiro BA, Zhou L, Huntington KE, El-Deiry WS |
Biochemical Society Transactions | 2023 |
Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding
Riera-Domingo C, Leite-Gomes E, Charatsidou I, Zhao P, Carrá G, Cappellesso F, Mourao L, De Schepper M, Liu D, Serneels J, Alameh MG, Shuvaev VV, Geukens T, Isnaldi E, Prenen H, Weissman D, Muzykantov VR, Soenen S, Desmedt C, Scheele CL, Sablina A, Di Matteo M, Martín-Pérez R, Mazzone M |
Science Advances | 2023 |
Enhancer Clusters Drive Type I Interferon-Induced TRAIL Overexpression in Cancer, and Its Intracellular Protein Accumulation Fails to Induce Apoptosis.
Di Benedetto C, Khan T, Serrano-Saenz S, Rodriguez-Lemus A, Klomsiri C, Beutel TM, Thach A, Walczak H, Betancur P |
Cancers | 2023 |
RNA-seq and Single-Cell Transcriptome Analyses of TRAIL Receptors Gene Expression in Human Osteosarcoma Cells and Tissues.
Feng W, Lin H, Rothzerg E, Song D, Zhao W, Ning T, Wei Q, Zhao J, Wood D, Liu Y, Xu J |
Cancer informatics | 2023 |
The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer
Pimentel JM, Zhou JY, Wu GS |
Cancers | 2023 |
Current approaches in enhancing TRAIL therapies in glioblastoma.
Thang M, Mellows C, Mercer-Smith A, Nguyen P, Hingtgen S |
2023 | |
TNF superfamily control of tissue remodeling and fibrosis
Steele H, Cheng J, Willicut A, Dell G, Breckenridge J, Culberson E, Ghastine A, Tardif V, Herro R |
Frontiers in immunology | 2023 |
Anti-tumor Effects of IL-1β Induced TRAIL-Expressing hUCMSCs on Embelin Treated Breast Cancer Cell Lines.
Teng JW, Hung E, Wu JM, Liang YH, Chiu YH, Tyan YS, Wang HS |
Asian Pacific Journal of Cancer Prevention | 2023 |
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BP |
Clinical cancer research | 2023 |
Dose-related immunomodulatory effects of recombinant TRAIL in the tumor immune microenvironment.
Wang X, Wang L, Liu W, Liu X, Jia X, Feng X, Li F, Zhu R, Yu J, Zhang H, Wu H, Wu J, Wang C, Yu B, Yu X |
Journal of experimental & clinical cancer research : CR | 2023 |
TRAIL and its receptors in cardiac diseases.
Grisanti LA |
Frontiers in physiology | 2023 |
Anti-Cancer Effect of Neural Stem Cells Transfected with Carboxylesterase and sTRAIL Genes in Animals with Brain Lesions of Lung Cancer.
Kim JH, Ahn JS, Lee DS, Hong SH, Lee HJ |
Pharmaceuticals (Basel, Switzerland) | 2023 |
IL-1β stimulated human umbilical cord mesenchymal stem cells ameliorate rheumatoid arthritis via inducing apoptosis of fibroblast-like synoviocytes.
Chiu YH, Liang YH, Hwang JJ, Wang HS |
Scientific Reports | 2023 |
Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.
Luo Y, Hao H, Wang Z, Ong C, Dutcher R, Xu Y, Liu J, Pedersen LC, Xu D |
bioRxiv : the preprint server for biology | 2023 |
Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
El Yousfi Y, Mora-Molina R, López-Rivas A, Yerbes R |
Cells | 2023 |
Generation of magnetic biohybrid microrobots based on MSC.sTRAIL for targeted stem cell delivery and treatment of cancer.
Gundersen RA, Chu T, Abolfathi K, Dogan SG, Blair PE, Nago N, Hamblin M, Brooke GN, Zwacka RM, Hoshiar AK, Mohr A |
Cancer Nanotechnology | 2023 |
Emerging role of mesenchymal stromal cells in gynecologic cancer therapy.
Song Y, Liu H, Pan S, Xiang X, Ye M, Zhu X |
Stem Cell Research & Therapy | 2023 |
The tumor suppressive effect and apoptotic mechanism of TRAIL gene-containing recombinant NDV in TRAIL-resistant colorectal cancer HT-29 cells and TRAIL-nonresistant HCT116 cells, with each cell bearing a mouse model.
Jung BK, An YH, Jang SH, Ryu G, Jung SB, Kim S, Kim CS, Jang H |
Cancer Medicine | 2023 |
Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary.
Le Sauteur-Robitaille J, Crosley P, Hitt M, Jenner AL, Craig M |
Cancer biology & therapy | 2023 |
Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation
Du G, Zhao L, Zheng Y, Belfetmi A, Cai T, Xu B, Heyninck K, Van Den Heede K, Buyse MA, Fontana P, Bowman M, Lin LL, Wu H, Chou JJ |
Cell Research | 2023 |
Construction and Validation of a Ferroptosis-Related Prognostic Signature for Melanoma Based on Single-Cell RNA Sequencing
Y Liu, Y Shou, R Zhu, Z Qiu, Q Zhang, J Xu |
Frontiers in Cell and Developmental Biology | 2022 |
Receptor Specificity Engineering of TNF Superfamily Ligands
F Suo, X Zhou, R Setroikromo, W Quax |
Pharmaceutics | 2022 |
Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A
Narayan S, Raza A, Mahmud I, Koo N, Garrett TJ, Law ME, Law BK, Sharma AK |
iScience | 2022 |
Recent Progress on Heparin–Protamine Particles for Biomedical Application
Hata Y, Miyazaki H, Ishihara M, Nakamura S |
Polymers | 2022 |
Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.
Moser R, Annis J, Nikolova O, Whatcott C, Gurley K, Mendez E, Moran-Jones K, Dorrell C, Sears RC, Kuo C, Han H, Biankin A, Grandori C, Von Hoff DD, Kemp CJ |
Cancer research | 2022 |
Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries.
Montinaro A, Walczak H |
Cell Death and Differentiation | 2022 |
Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist
A Soto-Gamez, Y Wang, X Zhou, L Seras, W Quax, M Demaria |
Cancer Letters | 2022 |
Kaempferol: A potential agent in the prevention of colorectal cancer
Nejabati HR, Roshangar L |
Physiological Reports | 2022 |
Limonoids From the Genus Melia (Meliaceae): Phytochemistry, Synthesis, Bioactivities, Pharmacokinetics, and Toxicology.
Fan W, Fan L, Wang Z, Yang L |
Frontiers in pharmacology | 2022 |
Identification of UAP1L1 as a critical factor for prostate cancer and underlying molecular mechanism in tumorigenicity.
Wu XC, Yu YZ, Zuo YZ, Song XL, Zhou ZE, Xiao Y, Luo DS, Yan WG, Zhao SC |
Journal of Translational Medicine | 2022 |
The Ongoing Journey of a Shigella Bioconjugate Vaccine.
Martin P, Alaimo C |
Human vaccines | 2022 |
Site-Specific Integration of TRAIL in iPSC-Derived Mesenchymal Stem Cells for Targeted Cancer Therapy.
Wang Z, Chen H, Wang P, Zhou M, Li G, Hu Z, Hu Q, Zhao J, Liu X, Wu L, Liang D |
Stem Cells Translational Medicine | 2022 |
Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity.
Yagolovich AV, Artykov AA, Isakova AA, Vorontsova YV, Dolgikh DA, Kirpichnikov MP, Gasparian ME |
International journal of molecular sciences | 2022 |
Proscillaridin A Sensitizes Human Colon Cancer Cells to TRAIL-Induced Cell Death.
Semba M, Takamatsu S, Komazawa-Sakon S, Miyoshi E, Nishiyama C, Nakano H, Moriwaki K |
International journal of molecular sciences | 2022 |
Role of phloretin as a sensitizer to TRAIL-induced apoptosis in colon cancer.
Kim JL, Lee DH, Pan CH, Park SJ, Oh SC, Lee SY |
Oncology Letters | 2022 |
Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells.
Rambow AC, Aschenbach I, Hagelund S, Tawfik D, Gundlach JP, Weiße S, Maass N, Trauzold A |
Frontiers in Cell and Developmental Biology | 2022 |
Inhibition of induced-hepatic cancer in vivo through IQGAP1-shRNA gene therapy and modulation of TRAIL-induced apoptosis pathway.
Zoheir KMA, Abd-Rabou AA, Darwish AM, Abdelhafez MA, Mahrous KF |
Frontiers in Oncology | 2022 |
Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cells.
Yerbes R, Mora-Molina R, Fernández-Farrán FJ, Hiraldo L, López-Rivas A, Palacios C |
Cell Death and Disease | 2022 |
EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.
Su K, Yuan Q, Hou H, Ke C, Huang C, Li S, Sun J, Yuan X, Lin Y, Chen Y, Xin H, Liang X, Du Z, Yuan Z |
Journal of Molecular Medicine | 2022 |
TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems.
Alizadeh Zeinabad H, Szegezdi E |
Cancers | 2022 |
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN |
Cancers | 2022 |
Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma.
Piechna K, Żołyniak A, Jabłońska E, Noyszewska-Kania M, Szydłowski M, Żerek B, Kulecka M, Rumieńczyk I, Mikula M, Juszczyński P |
Frontiers in Oncology | 2022 |
Exosomal delivery of TRAIL and miR-335 for the treatment of hepatocellular carcinoma (Review)
Thapa N, Chwae YJ, Yoo KH, Won TB, Kang D, Choi D, Kim J |
International journal of molecular medicine | 2022 |
Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy
Kundu M, Greer YE, Dine JL, Lipkowitz S |
Cells | 2022 |
TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake
B Toffoli, F Tonon, V Tisato, G Zauli, P Secchiero, B Fabris, S Bernardi |
Cell Death and Disease | 2021 |
Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo
D Winterberg, L Lenk, M Oßwald, F Vogiatzi, CL Gehlert, FS Frielitz, K Klausz, T Rösner, T Valerius, A Trauzold, M Peipp, C Kellner, DM Schewe |
Journal of Clinical Medicine | 2021 |
Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
NK Moorthy, O Seifert, S Eisler, S Weirich, RE Kontermann, M Rehm, G Fullstone |
Molecules (Basel, Switzerland) | 2021 |
S1P signaling, its interactions and cross-talks with other partners and therapeutic importance in colorectal cancer
RS Sattar, MP Sumi, Nimisha, Apurva, A Kumar, AK Sharma, E Ahmad, A Ali, B Mahajan, SS Saluja |
Cellular Signalling | 2021 |
Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
C Ternet, C Kiel |
Cell Communication and Signaling | 2021 |
A Dual Role for Death Receptor 5 in Regulating Cardiac Fibroblast Function
MA Tanner, LA Grisanti |
Frontiers in Cardiovascular Medicine | 2021 |
Intravenously Infused Stem Cells for Cancer Treatment
AR Mercer-Smith, IA Findlay, HN Bomba, SD Hingtgen |
Stem Cell Reviews and Reports | 2021 |
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
SA Nalawade, P Shafer, P Bajgain, MK McKenna, A Ali, L Kelly, J Joubert, S Gottschalk, N Watanabe, A Leen, R Parihar, JF Valdes, V Hoyos |
Journal for ImmunoTherapy of Cancer | 2021 |
Overcoming TRAIL Resistance for Glioblastoma Treatment
L Deng, X Zhai, P Liang, H Cui |
Biomolecules | 2021 |
Therapeutics Targeting the Core Apoptotic Machinery
C Hamilton, JP Fox, DB Longley, CA Higgins |
Cancers | 2021 |
Stem cells for the treatment of glioblastoma: a 20-year perspective
AA Calinescu, MK Kauss, Z Sultan, WN Al-Holou, SK OShea |
CNS Oncology | 2021 |
Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health
GE Barreto, A Sahebkar |
2021 | |
Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health
GE Barreto, A Sahebkar |
2021 | |
Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1.
Yoshida T, Yamasaki K, Tadagaki K, Kuwahara Y, Matsumoto A, Sofovic AE, Kondo N, Sakai T, Okuda T |
International journal of oncology | 2021 |
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
Ishii Y, Kolluri KK, Pennycuick A, Zhang X, Nigro E, Alrifai D, Borg E, Falzon M, Shah K, Kumar N, Janes SM |
The Journal of biological chemistry | 2021 |
Modes of Regulated Cell Death in Cancer
E Koren, Y Fuchs |
Cancer Discovery | 2021 |
Application of Emerging Plant-Derived Nanoparticles as a Novel Approach for Nano-Drug Delivery Systems
P Sarvarian, P Samadi, E Gholipour, KS Asenjan, M Hojjat-Farsangi, R Motavalli, FM Khiavi, M Yousefi |
Immunological Investigations | 2021 |
Immunoediting role for major vault protein in apoptotic signaling induced by bacterial N -acyl homoserine lactones
J Rayo, R Gregor, NT Jacob, R Dandela, L Dubinsky, A Yashkin, A Aranovich, M Thangaraj, O Ernst, E Barash, S Malitsky, BI Florea, BP Krom, EA Wiemer, VA Kickhoefer, LH Rome, JC Mathison, GF Kaufmann, HS Overkleeft, BF Cravatt, T Zor, KD Janda, RJ Ulevitch, VV Kravchenko, MM Meijler |
Proceedings of the National Academy of Sciences | 2021 |
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
Y Ishii, KK Kolluri, A Pennycuick, X Zhang, E Nigro, D Alrifai, E Borg, M Falzon, K Shah, N Kumar, SM Janes |
The Journal of biological chemistry | 2021 |
Trichostatin A and Zebularine along with E-cadherin re-expression enhance tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell cycle arrest in human breast adenocarcinoma cells
SH Wong, CM Fang, HS Loh, SC Ngai |
2021 | |
Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress
KA Grayson, JM Hope, W Wang, CA Reinhart-King, MR King |
Molecular cancer therapeutics | 2021 |
TRIM21, a New Component of the TRAIL-Induced Endogenous Necrosome Complex
MS Eugénio, F Faurez, GH Kara-Ali, M Lagarrigue, P Uhart, MC Bonnet, I Gallais, E Com, C Pineau, M Samson, JL Seyec, MT Dimanche-Boitrel |
Frontiers in Molecular Biosciences | 2021 |
Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells
A Yagolovich, A Kuskov, P Kulikov, L Kurbanova, D Bagrov, A Artykov, M Gasparian, S Sizova, V Oleinikov, A Gileva, M Kirpichnikov, D Dolgikh, E Markvicheva |
Pharmaceutics | 2021 |
Chemo-Sensitization of CD133+ Cancer Stem Cell Enhances the Effect of Mesenchymal Stem Cell Expressing TRAIL in Non-Small Cell Lung Cancer Cell Lines
KS Fakiruddin, MN Lim, N Nordin, R Rosli, S Abdullah |
Biology : open access journal | 2021 |
Vanillin oxime inhibits lung cancer cell proliferation and activates apoptosis through JNK/ERK-CHOP pathway
J Shen, Z Su |
The Korean Journal of Physiology & Pharmacology | 2021 |
The non‐peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis
G Knoll, M Ehrenschwender |
FEBS Open Bio | 2021 |
Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy
D Singh, M Tewari, S Singh, G Narayan |
Future Oncology | 2021 |
Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC
S Liu, EV Polsdofer, L Zhou, S Ruan, H Lyu, D Hou, H Liu, AD Thor, Z He, B Liu |
Molecular Therapy — Oncolytics | 2021 |
Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis
OH Voss, D Arango, JC Tossey, MA Calero, AI Doseff |
Cell Death and Disease | 2021 |
First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer
S Wang, H Zhu, Y Li, J Ding, F Wang, L Ding, X Wang, J Zhao, Y Zhang, Y Yao, T Zhou, N Li, A Wu, Z Yang |
Journal for ImmunoTherapy of Cancer | 2021 |
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
A Montinaro, IA Zubiaur, J Saggau, AL Kretz, RM Ferreira, O Hassan, E Kitzig, I Müller, MA El-Bahrawy, S von Karstedt, D Kulms, G Liccardi, J Lemke, H Walczak |
Cell Death and Differentiation | 2021 |
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
C Wu, M You, D Nguyen, M Wangpaichitr, YY Li, LG Feun, MT Kuo, N Savaraj |
International journal of molecular sciences | 2021 |
Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer
HJ Vaughan, CG Zamboni, NP Radant, P Bhardwaj, ER Lechtich, LF Hassan, K Shah, JJ Green |
Molecular Therapy — Oncolytics | 2021 |
Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes
KA Grayson, N Jyotsana, N Ortiz-Otero, MR King, IV Lebedeva |
PloS one | 2021 |
Arginine-tocopherol bioconjugated lipid vesicles for selective pTRAIL delivery and subsequent apoptosis induction in glioblastoma cells
V Ravula, YL Lo, YT Wu, CW Chang, SV Patri, LF Wang |
Materials science & engineering. C, Materials for biological applications | 2021 |
TRAIL‐Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582)
H Hou, K Su, C Huang, Q Yuan, S Li, J Sun, Y Lin, Z Du, C Ke, Z Yuan |
Advanced Healthcare Materials | 2021 |
The Anti-Tumor Effect of Lactococcus lactis Bacteria-Secreting Human Soluble TRAIL Can Be Enhanced by Metformin Both In Vitro and In Vivo in a Mouse Model of Human Colorectal Cancer
K Kaczmarek, J Więckiewicz, K Węglarczyk, M Siedlar, J Baran |
Cancers | 2021 |
TRAIL-receptor 2—a novel negative regulator of p53
A Willms, H Schupp, M Poelker, A Adawy, JF Debus, T Hartwig, T Krichel, J Fritsch, S Singh, H Walczak, S von Karstedt, H Schäfer, A Trauzold |
Cell Death and Disease | 2021 |
Say no to drugs: Bioactive macromolecular therapeutics without conventional drugs
M Rütter, N Milošević, A David |
Journal of Controlled Release | 2021 |
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro
P Crosley, A Farkkila, AL Jenner, C Burlot, O Cardinal, KG Potts, K Agopsowicz, M Pihlajoki, M Heikinheimo, M Craig, Y Fu, MM Hitt |
International journal of molecular sciences | 2021 |
Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers
W Jiang, Y Yang, AR Mercer-Smith, A Valdivia, JR Bago, AS Woodell, AA Buckley, MH Marand, L Qian, CK Anders, SD Hingtgen |
Science Advances | 2021 |
Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects
JU Choi, J Kim, SW Chung, NK Lee, J Park, S Kweon, YS Cho, HR Kim, SM Lim, JW Park, KC Lee, Y Byun |
Journal of Controlled Release | 2021 |
Paving the Road Toward Exploiting the Therapeutic Effects of Ginsenosides: An Emphasis on Autophagy and Endoplasmic Reticulum Stress.
Ashrafizadeh M, Tavakol S, Mohammadinejad R, Ahmadi Z, Yaribeygi H, Jamialahmadi T, Johnston TP, Sahebkar A |
Advances in experimental medicine and biology | 2021 |
Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified.
Nasrollahzadeh Sabet M, Movahedi Asl M, Kazemi Esfeh M, Nasrabadi N, Shakarami M, Alani B, Alimolaie A, Azhdari S, Cheraghi E |
Iranian Journal of Basic Medical Sciences | 2021 |
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199.
Wang BT, Kothambawala T, Wang L, Matthew TJ, Calhoun SE, Saini AK, Kotturi MF, Hernandez G, Humke EW, Peterson MS, Sinclair AM, Keyt BA |
Molecular cancer therapeutics | 2021 |
Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress.
Grayson KA, Hope JM, Wang W, Reinhart-King CA, King MR |
Molecular cancer therapeutics | 2021 |
Stress Management: Death Receptor Signalling and Cross-Talks with the Unfolded Protein Response in Cancer
E Lafont |
Cancers | 2020 |
Assessing the Current State of Lung Cancer Chemoprevention: A Comprehensive Overview
AU, A Bhalerao, CM Mikelis, L Cucullo, NA German |
Cancers | 2020 |
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
S von Karstedt, H Walczak |
Cell Death Discovery | 2020 |
Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
C Sordo-Bahamonde, S Lorenzo-Herrero, ÁR Payer, S Gonzalez, A López-Soto |
International journal of molecular sciences | 2020 |
Insight into the divergent role of TRAIL in non‐neoplastic neurological diseases
S Gao, Y Fang, S Tu, H Chen, A Shao |
Journal of Cellular and Molecular Medicine | 2020 |
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
W Mu, Q Chu, Y Liu, N Zhang |
Nano-Micro Letters | 2020 |
PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR
J Lv, T Guo, X Qu, X Che, C Li, S Wang, J Gong, P Wu, Y Liu, Y Liu, L Xu |
Frontiers in Oncology | 2020 |
TRAIL therapy and prospective developments for cancer treatment
B Thapa, R KC, H Uludağ |
Journal of Controlled Release | 2020 |
Reduction in MLKL-mediated endosomal trafficking enhances the TRAIL-DR4/5 signal to increase cancer cell death
SY Park, HH Park, SY Park, SM Hong, S Yoon, MJ Morgan, YS Kim |
Cell Death and Disease | 2020 |
Cancer Immunology: A Translational Medicine Context
N Rezaei |
2020 | |
The multifaceted role of TRAIL signaling in cancer and immunity
LC Alves, N Corazza, O Micheau, P Krebs |
The FEBS journal | 2020 |
Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
JM García-Martínez, S Wang, C Weishaeupl, A Wernitznig, P Chetta, C Pinto, J Ho, D Dutcher, PN Gorman, R Kroe-Barrett, J Rinnenthal, C Giragossian, MA Impagnatiello, I Tirapu, F Hilberg, N Kraut, M Pearson, KP Kuenkele |
Molecular cancer therapeutics | 2020 |
Heat Shock Proteins in Inflammatory Diseases
AA Asea, P Kaur |
2020 | |
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
HS Tuli |
2020 | |
Personalized‐induced neural stem cell therapy: Generation, transplant, and safety in a large animal model
HN Bomba, KT Sheets, A Valdivia, S Khagi, L Ruterbories, CL Mariani, LB Borst, DA Tokarz, SD Hingtgen |
Bioengineering & Translational Medicine | 2020 |
Periplocin mediates TRAIL-induced apoptosis and cell cycle arrest in human myxofibrosarcoma cells via the ERK/p38/JNK pathway
B Lohberger, E Bernhart, N Stuendl, D Glaenzer, A Leithner, B Rinner, R Bauer, N Kretschmer |
Phytomedicine : international journal of phytotherapy and phytopharmacology | 2020 |
TRAIL of Hope Meeting Resistance in Cancer
D Deng, K Shah |
Trends in Cancer | 2020 |
Micelle-in-Liposomes for Sustained Delivery of Anticancer Agents That Promote Potent TRAIL-Induced Cancer Cell Apoptosis
Z Zhang, SB Patel, MR King |
Molecules (Basel, Switzerland) | 2020 |
Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer
Y Shi, J Wang, J Liu, G Lin, F Xie, X Pang, Y Pei, Y Cheng, Y Zhang, Z Lin, Z Yin, X Wang, G Niu, X Chen, G Liu |
Biomaterials | 2020 |
TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway
I Sur-Erdem, K Muslu, N Pınarbası, M Altunbek, F Seker-Polat, A Cingöz, SO Aydın, M Kahraman, M Culha, I Solaroglu, T Bagcı-Önder |
Neurological Research | 2020 |
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models
MC Johnston, JA Nicoll, KM Redmond, P Smyth, MK Greene, WJ McDaid, DK Chan, N Crawford, KJ Stott, JP Fox, NL Straubinger, S Roche, M Clynes, RM Straubinger, DB Longley, CJ Scott |
Journal of Controlled Release | 2020 |
The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model
J He, Y An, J Qi, L Cui, K Yang, M Liu, B Qu, S Yan, J Yin, X Jing, H Dong, Q Yu, D Li, Y Wu |
Journal of Medical Virology | 2020 |
A simplified method for the efficient purification and refolding of recombinant human TRAIL
Z Zhang, SB Hahn, TM Cao, MR King |
Biotechnology Progress | 2020 |
A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells
F Hartung, T Krüwel, X Shi, K Pfizenmaier, R Kontermann, P Chames, F Alves, LA Pardo |
Frontiers in pharmacology | 2020 |
Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand
N Vunnam, S Szymonski, P Hirsova, GJ Gores, JN Sachs, BJ Hackel |
Biochemistry | 2020 |
Mcl‐1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells
Z Sarif, B Tolksdorf, H Fechner, J Eberle |
Molecular Carcinogenesis | 2020 |
Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile
AV Yagolovich, AA Artykov, TA Karmakova, MS Vorontsova, AA Pankratov, AA Andreev-Andrievsky, DA Dolgikh, MP Kirpichnikov, ME Gasparian |
Translational oncology | 2020 |
The MUDENG Augmentation: A Genesis in Anti-Cancer Therapy?
M Muthu, S Chun, J Gopal, GS Park, A Nile, J Shin, J Shin, TH Kim, JW Oh |
International journal of molecular sciences | 2020 |
Pichia fermentans originates apoptosis in human oral squamous cell carcinoma by over-expressing BAX and CASP 9 genes
HB Shamloo, A Shahabi, Z Aghazadeh, AY Khosroushahi |
Cytotechnology | 2020 |
Suppression of TRPM7 enhances TRAIL‐induced apoptosis in triple‐negative breast cancer cells
C Song, S Choi, KB Oh, T Sim |
Journal of Cellular Physiology | 2020 |
Strategies for treating oesophageal diseases with stem cells
Y Gao, SZ Jin |
World journal of stem cells | 2020 |
Doxorubicin hydrochloride enhanced antitumour effect of CEA‐regulated oncolytic virotherapy in live cancer cells and a mouse model
B Xiao, C Ying, Y Chen, F Huang, B Wang, H Fang, W Guo, T Liu, X Zhou, B Huang, X Liu, Y Wang |
Journal of Cellular and Molecular Medicine | 2020 |
Fabrication and Characterization of Tumor Nano-Lysate as a Preventative Vaccine for Breast Cancer
JA Dombroski, N Jyotsana, DW Crews, Z Zhang, MR King |
Langmuir | 2020 |
Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
JD Yoo, SM Bae, J Seo, IS Jeon, SM Vadevoo, SY Kim, IS Kim, B Lee, S Kim |
Scientific Reports | 2020 |
Akkermansia muciniphila Aspartic Protease Amuc_1434* Inhibits Human Colorectal Cancer LS174T Cell Viability via TRAIL-Mediated Apoptosis Pathway
X Meng, J Zhang, H Wu, D Yu, X Fang |
International journal of molecular sciences | 2020 |
TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer
D Singh, CB Prasad, D Biswas, M Tewari, AG Kar, MA Ansari, S Singh, G Narayan |
Pathology | 2020 |
Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP
MI Elmallah, S Cogo, AA Constantinescu, S Elifio-Esposito, MS Abdelfattah, O Micheau |
Cells | 2020 |
Targeting of keloid with TRAIL and TRAIL-R2/DR5
P Sun, Z Hu, B Pan, X Lu |
Journal of Dermatological Treatment | 2020 |
Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4.
Bi R, Deng Y, Tang C, Xuan L, Xu B, Du Y, Wang C, Wei W |
Oncology reports | 2020 |
Personalized-induced neural stem cell therapy: Generation, transplant, and safety in a large animal model.
Bomba HN, Sheets KT, Valdivia A, Khagi S, Ruterbories L, Mariani CL, Borst LB, Tokarz DA, Hingtgen SD |
Bioengineering & Translational Medicine | 2020 |
Hispidulin Enhances TRAIL-Mediated Apoptosis via CaMKKβ/AMPK/USP51 Axis-Mediated Bim Stabilization
SM Woo, SU Seo, SH Kim, JO Nam, S Kim, JW Park, K Min, TK Kwon |
Cancers | 2019 |
Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
Lim, Greer, Lipkowitz, Takebe |
Cancers | 2019 |
Cellular demolition: Proteins as molecular players of programmed cell death
YK Dhuriya, D Sharma, AA Naik |
International Journal of Biological Macromolecules | 2019 |
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
A Stamatopoulos, T Stamatopoulos, Z Gamie, E Kenanidis, RD Ribeiro, KS Rankin, C Gerrand, K Dalgarno, E Tsiridis |
Journal of Bone Oncology | 2019 |
Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation
MA Tanner, TP Thomas, LA Grisanti |
Journal of Molecular and Cellular Cardiology | 2019 |
Human Embryonic Stem Cells Acquire Responsiveness to TRAIL upon Exposure to Cisplatin
L Pešková, V Vinarský, T Bárta, A Hampl |
Stem Cells International | 2019 |
A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
A Satta, G Grazia, F Caroli, B Frigerio, MD Nicola, F Raspagliesi, D Mezzanzanica, N Zaffaroni, AM Gianni, A Anichini, M Figini |
Frontiers in immunology | 2019 |
Destined to Die: Apoptosis and Pediatric Cancers
Choo, Loh, Chen |
Cancers | 2019 |
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
R Jan, GS Chaudhry |
Advanced pharmaceutical bulletin | 2019 |
Regulation of death receptor signaling by the autophagy protein TP53INP2
S Ivanova, M Polajnar, AJ NarbonaPerez, MI HernandezAlvarez, P Frager, K Slobodnyuk, N Plana, AR Nebreda, M Palacin, RR Gomis, C Behrends, A Zorzano |
The EMBO Journal | 2019 |
Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells
N Mungra, S Jordaan, P Hlongwane, K Naran, S Chetty, S Barth |
Oncotarget | 2019 |
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma
JJ Noonan, M Jarzabek, FA Lincoln, BL Cavanagh, AR Pariag, V Juric, LS Young, KL Ligon, H Jahns, D Zheleva, JH Prehn, M Rehm, AT Byrne, BM Murphy |
Cancers | 2019 |
Hantavirus Inhibits TRAIL-Mediated Killing of Infected Cells by Downregulating Death Receptor 5
C Solà-Riera, S Gupta, KT Maleki, P González-Rodriguez, D Saidi, CL Zimmer, S Vangeti, L Rivino, YS Leo, DC Lye, PA MacAry, C Ahlm, A Smed-Sörensen, B Joseph, NK Björkström, HG Ljunggren, J Klingström |
Cell Reports | 2019 |
Mechanisms and biomarkers of liver regeneration after drug-induced liver injury
Clemens MM, McGill MR, Apte U |
Advances in pharmacology (San Diego, Calif.) | 2019 |
Acetaminophen Hepatotoxicity - A Mitochondrial Perspective
Ramachandran A, Jaeschke H |
Advances in pharmacology (San Diego, Calif.) | 2019 |
Biomarkers of Drug-induced Liver Injury
McGill MR, Jaeschke H |
Advances in pharmacology (San Diego, Calif.) | 2019 |
PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism
S Serrano-Saenz, C Palacios, D Delgado-Bellido, L López-Jiménez, A Garcia-Diaz, Y Soto-Serrano, JI Casal, RA Bartolomé, JL Fernández-Luna, A López-Rivas, FJ Oliver |
Cell Death and Disease | 2019 |
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
C Spano, G Grisendi, G Golinelli, F Rossignoli, M Prapa, M Bestagno, O Candini, T Petrachi, A Recchia, F Miselli, G Rovesti, G Orsi, A Maiorana, P Manni, E Veronesi, MS Piccinno, A Murgia, M Pinelli, EM Horwitz, S Cascinu, P Conte, M Dominici |
Scientific Reports | 2019 |
Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization
A Dubuisson, C Favreau, E Fourmaux, S Lareure, R Rodrigues-Saraiva, C Pellat-Deceunynck, SE Alaoui, O Micheau |
Cell Death and Disease | 2019 |
Death receptor 5 is activated by fucosylation in colon cancer cells
B Zhang, IA van Roosmalen, CR Reis, R Setroikromo, WJ Quax |
The FEBS journal | 2019 |
Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
R Fadeev, A Chekanov, M Solovieva, O Bezborodova, E Nemtsova, N Dolgikh, I Fadeeva, A Senotov, M Kobyakova, Y Evstratova, R Yakubovskaya, V Akatov |
International journal of molecular sciences | 2019 |
Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling
L Pan, TM Fu, W Zhao, L Zhao, W Chen, C Qiu, W Liu, Z Liu, A Piai, Q Fu, S Chen, H Wu, JJ Chou |
Cell | 2019 |
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
C Dostert, M Grusdat, E Letellier, D Brenner |
Physiological reviews | 2019 |
Insight into the role of TRAIL in liver diseases
W Jiang, DB Wu, SY Fu, EQ Chen, H Tang, TY Zhou |
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie | 2019 |
The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection
L Miarka, C Hauser, O Helm, D Holdhof, S Beckinger, JH Egberts, JP Gundlach, L Lenk, S Rahn, W Mikulits, A Trauzold, S Sebens |
Cancers | 2019 |
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
B Zhang, B Liu, D Chen, R Setroikromo, HJ Haisma, WJ Quax |
Cancers | 2019 |
TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells
E Díaz-Rodríguez, J Pérez-Peña, C Ríos-Luci, J Arribas, A Ocaña, A Pandiella |
Cancer Letters | 2019 |
TRAIL ‐expressing recombinant Lactococcus lactis induces apoptosis in human colon adenocarcinoma SW 480 and HCT 116 cells
E Bohlul, F Hasanlou, AH Taromchi, S Nadri |
Journal of Applied Microbiology | 2019 |
Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells
A Willms, H Schittek, S Rahn, J Sosna, U Mert, D Adam, A Trauzold, A Krieg |
PloS one | 2019 |
Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer
AF Wali, S Majid, S Rasool, SB Shehada, SK Abdulkareem, A Firdous, S Beigh, S Shakeel, S Mushtaq, I Akbar, H Madhkali, MU Rehman |
Saudi Pharmaceutical Journal | 2019 |
TRAILblazing Strategies for Cancer Treatment
AL Kretz, A Trauzold, A Hillenbrand, U Knippschild, D Henne-Bruns, S von Karstedt, J Lemke |
Cancers | 2019 |
Combined effects of XAF1 and TRAIL on the apoptosis of lung adenocarcinoma cells
F Zhang, D Chen, W Yang, S Duan, Y Chen |
Experimental and therapeutic medicine | 2019 |
Engineered human mesenchymal stem cells for neuroblastoma therapeutics
V Nieddu, R Piredda, D Bexell, J Barton, J Anderson, N Sebire, K Kolluri, S Janes, E Karteris, A Sala |
Oncology reports | 2019 |
TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors
U Mert, A Adawy, E Scharff, P Teichmann, A Willms, V Haselmann, C Colmorgen, J Lemke, S von Karstedt, J Fritsch, A Trauzold |
Cancers | 2019 |
Zebularine and trichostatin A sensitized human breast adenocarcinoma cells towards tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis
WY Kong, ZY Yee, CW Mai, CM Fang, S Abdullah, SC Ngai |
Heliyon | 2019 |
TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis
R Baskar, HG Fienberg, Z Khair, P Favaro, S Kimmey, DR Green, GP Nolan, S Plevritis, SC Bendall |
2019 | |
Tumour necrosis factor‐related apoptosis‐inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro
M Goto, K Owaki, A Hirata, T Yanai, H Sakai |
Veterinary and Comparative Oncology | 2019 |
Loss of MCL1 function sensitizes the MDA‐MB‐231 breast cancer cells to rh‐TRAIL by increasing DR4 levels
A Blasio, G Pratelli, R DragoFerrante, C Saliba, S Baldacchino, G Grech, G Tesoriere, C Scerri, R Vento, RD Fiore |
Journal of Cellular Physiology | 2019 |
Prediction of genes and protein-protein interaction networking for miR-221-5p using bioinformatics analysis
Shanmugapriya, N Othman, S Sasidharan |
Gene Reports | 2019 |
E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway
Seon Min Woo, Taeg Kyu Kwon |
BMB Reports | 2019 |
Monocyte-Macrophage Differentiation Suppresses the Expression of Proapoptotic Receptors to Apo2L/TRAIL and Increases Resistance to TRAIL-Induced Apoptosis
YV Evstratova, MI Kobyakova, VV Novikova, AS Senotov, VS Akatov, RS Fadeev |
Biophysics | 2019 |
Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors
M GOTO, A HIRATA, M MURAKAMI, H SAKAI |
Journal of Veterinary Medical Science | 2019 |
Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy
L Han, S Dai, Z Li, C Zhang, S Wei, R Zhao, H Zhang, L Zhao, B Shan |
Journal of Experimental & Clinical Cancer Research | 2019 |
TRAIL-based gene delivery and therapeutic strategies
H Zhong, H Wang, J Li, Y Huang |
Acta Pharmacologica Sinica | 2019 |
TRAIL‐Inspired Multivalent Dextran Conjugates Efficiently Induce Apoptosis upon DR5 Receptor Clustering
H Schneider, D Yanakieva, A Macarrón, L Deweid, B Becker, S Englert, O Avrutina, H Kolmar |
Chembiochem : a European journal of chemical biology | 2019 |
Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein
Y Zhang, Y Zhang, Q Guo, Z Guo, X Chen, L Liu, C Li, Q Chen, , Y Lu, T Sun, Y Huang, C Jiang |
ACS Applied Materials & Interfaces | 2019 |
Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential
DD Miguel, A Gallego-Lleyda, M Martinez-Ara, J Plou, A Anel, L Martinez-Lostao |
Cancers | 2019 |
Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients
T Heilmann, F Vondung, C Borzikowsky, S Szymczak, S Krüger, I Alkatout, A Wenners, M Bauer, W Klapper, C Röcken, N Maass, S von Karstedt, C Schem, A Trauzold |
Journal of Molecular Medicine | 2019 |
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway
M Wang, ME Law, BJ Davis, E Yaaghubi, AF Ghilardi, RB Ferreira, CW Chiang, OA Guryanova, D Kopinke, CD Heldermon, RK Castellano, BK Law |
Cell Death Discovery | 2019 |
Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers
S Goklany, P Lu, S Godeshala, A Hall, E Garrett-Mayer, C Voelkel-Johnson, K Rege |
Journal of Materials Chemistry B | 2019 |
Targeted Inhibition of ULK1 Promotes Apoptosis and Suppresses Tumor Growth and Metastasis in Neuroblastoma
CM Dower, N Bhat, MT Gebru, L Chen, CA Wills, BA Miller, HG Wang |
Molecular cancer therapeutics | 2018 |
A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma
E Oh, JW Hong, OJ Kwon, CO Yun |
Scientific Reports | 2018 |
Involvement of AMP-activated protein kinase and Death Receptor 5 in TRAIL-Berberine-induced apoptosis of cancer cells
R Ke, K Vishnoi, N Viswakarma, S Santha, S Das, A Rana, B Rana |
Scientific Reports | 2018 |
Downregulation of TRAIL-Receptor 1 Increases TGFβ Type II Receptor Expression and TGFβ Signalling Via MicroRNA-370-3p in Pancreatic Cancer Cells
D Radke, Q Ling, R Häsler, G Alp, H Ungefroren, A Trauzold |
Cancers | 2018 |
Attenuation of autophagy flux by 6-shogaol sensitizes human liver cancer cells to TRAIL-induced apoptosis via p53 and ROS
U Nazim, SY Park |
International journal of molecular medicine | 2018 |
Divergent Roles for TRAIL in Lung Diseases
AT Braithwaite, HM Marriott, A Lawrie |
Frontiers in Medicine | 2018 |
Peptides/Proteins Encoded by Non-coding RNA: A Novel Resource Bank for Drug Targets and Biomarkers
S Zhu, J Wang, Y He, N Meng, GR Yan |
Frontiers in pharmacology | 2018 |
Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells
M Mauro-Lizcano, A López-Rivas |
Cell Death and Disease | 2018 |
3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5
Y Chen, L Wei, X Zhang, X Liu, Y Chen, S Zhang, L Zhou, Q Li, Q Pan, S Zhao, H Liu |
Oncology reports | 2018 |
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase
E Brin, K Wu, E Dagostino, MM Kuo, Y He, WJ Shia, LC Chen, M Stempniak, R Hickey, R Almassy, R Showalter, J Thomson |
Oncotarget | 2018 |
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
M Timaner, N Letko-Khait, R Kotsofruk, M Benguigui, O Beyar-Katz, C Rachman-Tzemah, Z Raviv, T Bronshtein, M Machluf, Y Shaked |
Cancer research | 2018 |
Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma
C Trejo-Solís, N Serrano-Garcia, Á Escamilla-Ramírez, R Castillo-Rodríguez, D Jimenez-Farfan, G Palencia, M Calvillo, M Alvarez-Lemus, A Flores-Nájera, A Cruz-Salgado, J Sotelo |
International journal of molecular sciences | 2018 |
Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells
KK Kolluri, C Alifrangis, N Kumar, Y Ishii, S Price, M Michaut, S Williams, S Barthorpe, H Lightfoot, S Busacca, A Sharkey, Z Yuan, EK Sage, S Vallath, JL Quesne, DA Tice, D Alrifai, S von Karstedt, A Montinaro, N Guppy, DA Waller, A Nakas, R Good, A Holmes, H Walczak, DA Fennell, M Garnett, F Iorio, L Wessels, U McDermott, SM Janes |
eLife | 2018 |
Developing TRAIL/TRAIL death receptor-based cancer therapies
X Yuan, A Gajan, Q Chu, H Xiong, K Wu, S Wu |
Cancer and Metastasis Reviews | 2018 |
TRAIL pathway targeting therapeutics
MD Ralff, WS El-Deiry |
Expert Review of Precision Medicine and Drug Development | 2018 |
Structural principles of tumor necrosis factor superfamily signaling
ÉS Vanamee, DL Faustman |
Science signaling | 2018 |
Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy
AL Kretz, S von Karstedt, A Hillenbrand, D Henne-Bruns, U Knippschild, A Trauzold, J Lemke |
Cancers | 2018 |
CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors
C Reinshagen, D Bhere, SH Choi, S Hutten, I Nesterenko, H Wakimoto, EL Roux, A Rizvi, W Du, C Minicucci, K Shah |
Science Translational Medicine | 2018 |
Relationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention
E Teringova, M Kozel, J Knot, V Kocka, K Benesova, P Tousek |
BioMed Research International | 2018 |
Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin:
KA Turner, JM Manouchehri, M Kalafatis |
Melanoma Research | 2018 |
Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages
M Kih, EJ Lee, NK Lee, YK Kim, KE Lee, C Jeong, Y Yang, DH Kim, IS Kim |
Biomaterials | 2018 |
Mcl-1 and Bcl-xL sequestration of Bak confers differential resistance to BH3-only proteins
C Hockings, AE Alsop, SC Fennell, EF Lee, WD Fairlie, G Dewson, RM Kluck |
Cell Death and Differentiation | 2018 |
Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells
RM Fancy, H Kim, T Napier, DJ Buchsbaum, KR Zinn, Y Song |
Journal of Cellular Biochemistry | 2018 |
Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps
L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak, YH Hsieh |
PloS one | 2018 |
CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3
X Jin, L Cai, C Wang, X Deng, S Yi, Z Lei, Q Xiao, H Xu, H Luo, J Sun |
Cell Death and Disease | 2018 |
The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
K Legler, C Hauser, JH Egberts, A Willms, C Heneweer, S Boretius, C Röcken, CC Glüer, T Becker, M Kluge, O Hill, C Gieffers, H Fricke, H Kalthoff, J Lemke, A Trauzold |
Cell Death and Disease | 2018 |
Interleukin-4 Enhances the Sensitivity of Human Monocytes to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Through Upregulation of Death Receptor 4
S Zhang, Z Li, W Huang |
Journal of Interferon & Cytokine Research | 2018 |
Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells
J Liu, Q Gao, T Xie, Y Liu, L Luo, C Xu, L Shen, F Wan, T Lei, F Ye |
Clinical and Experimental Medicine | 2018 |
Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors
S Sirtl, G Knoll, DT Trinh, I Lang, D Siegmund, S Gross, B Schuler-Thurner, P Neubert, J Jantsch, H Wajant, M Ehrenschwender |
Oncogene | 2018 |
Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death
AA Masum, Y Hisamatsu, K Yokoi, S Aoki |
Bioinorganic Chemistry and Applications | 2018 |
Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
M Hutt, S Fellermeier-Kopf, O Seifert, LC Schmitt, K Pfizenmaier, RE Kontermann |
Oncotarget | 2018 |
Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells
C You, Y Sun, S Zhang, G Tang, N Zhang, C Li, X Tian, S Ma, Y Luo, W Sun, F Wang, X Liu, Y Xiao, Y Gong, J Zhang, C Xie |
International journal of biological sciences | 2018 |
Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations
ME Melendez, RJ Silva-Oliveira, AL Vicente, LM Arantes, AC de Carvalho, AL Epstein, RM Reis, AL Carvalho |
Oncotarget | 2018 |
Ciprofloxacin Enhances TRAIL-Induced Apoptosis in Lung Cancer Cells by Upregulating the Expression and Protein Stability of Death Receptors through CHOP Expression
E Lim, Y Yoon, J Heo, T Lee, YH Kim |
International journal of molecular sciences | 2018 |
Ferrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure–Activity Relationships
P Bárány, RS Oláh, I Kovács, T Czuczi, CL Szabó, A Takács, E Lajkó, O Láng, L Kőhidai, G Schlosser, S Bősze, G Mező, F Hudecz, A Csámpai |
Molecules (Basel, Switzerland) | 2018 |
Targeted nonviral gene therapy in prostate cancer
N Altwaijry, S Somani, C Dufès |
International Journal of Nanomedicine | 2018 |
Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism
FA Lincoln, D Imig, C Boccellato, V Juric, J Noonan, RE Kontermann, F Allgöwer, BM Murphy, M Rehm |
Cell Death and Disease | 2018 |
Design and synthesis of a luminescent iridium complex-peptide hybrid (IPH) that detects cancer cells and induces their apoptosis
AA Masum, K Yokoi, Y Hisamatsu, K Naito, B Shashni, S Aoki |
Bioorganic & Medicinal Chemistry | 2018 |
Early Drug Development: Bringing a Preclinical Candidate to the Clinic
FG Giordanetto |
2018 | |
15d-PGJ2 is a new hope for controlling tumor growth
Qingli Bie, Haixin Dong, Chengqiang Jin, Hao Zhang, Bin Zhang |
American journal of translational research | 2018 |
Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2/Death Receptor 5
K Nihira, K Nan-ya, M Kakuni, Y Ono, Y Yoshikawa, T Ota, M Hiura, K Yoshinari |
Toxicological Sciences | 2018 |
C-27-carboxylated oleanane triterpenoids up-regulate TRAIL DISC assembly via p38 MAPK and CHOP-mediated DR5 expression in human glioblastoma cells
HS Byun, W Zhou, IW Park, K Kang, SR Lee, X Piao, JB Park, TK Kwon, MK Na, GM Hur |
Biochemical Pharmacology | 2018 |
Recent Advances in Anti-cancer Protein/Peptide Delivery
X Liu, F Wu, Y Ji, L Yin |
Bioconjugate Chemistry | 2018 |
Zoledronik asit uygulamasının meme kanseri hücre hattı (mcf 7) kanser kök hücrelerinin üzerine otofaji gen seviyesindeki etkilerinin araştırılması
F Oltulu, A Uysal, H Rouhrazi, KD Kılıç, DÇ Kocatürk, G Öktem |
2018 | |
Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL‑induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species
U Nazim, H Yin, SY Park |
Molecular medicine reports | 2018 |
Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis
WP Bozza, Y Zhang, B Zhang |
Oncotarget | 2018 |
Luteolin sensitizes human liver cancer cells to TRAIL‑induced apoptosis via autophagy and JNK‑mediated death receptor 5 upregulation
U Nazim, SY Park |
International journal of oncology | 2018 |
β-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors
C You, S Zhang, Y Sun, S Zhang, G Tang, F Tang, X Liu, Y Xiao, J Zhang, Y Gong, C Xie |
International journal of oncology | 2018 |
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
A Dubuisson, O Micheau |
Antibodies | 2017 |
Yin Yang 1 (YY1): Regulation of Survivin and Its Role In Invasion and Metastasis
NR Galloway, KF Ball, TR Stiff, NR Wall |
Critical Reviews in Oncogenesis | 2017 |
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
V Liapis, A Zysk, M DeNichilo, I Zinonos, S Hay, V Panagopoulos, A Shoubridge, C Difelice, V Ponomarev, W Ingman, GJ Atkins, DM Findlay, AC Zannettino, A Evdokiou |
Cancer Medicine | 2017 |
Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells
X Zhang, X Zhang, S Hu, M Zheng, J Zhang, J Zhao, X Zhang, B Yan, L Jia, J Zhao, K Wu, A Yang, R Zhang |
Nucleic Acids Research | 2017 |
A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
LY Dimberg, CG Towers, K Behbakht, TJ Hotz, J Kim, S Fosmire, CC Porter, AC Tan, A Thorburn, HL Ford |
Molecular cancer research : MCR | 2017 |
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
S von Karstedt, A Montinaro, H Walczak |
Nature Reviews Cancer | 2017 |
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
X Ouyang, M Shi, F Jie, Y Bai, P Shen, Z Yu, X Wang, C Huang, M Tao, Z Wang, C Xie, Q Wu, Y Shu, B Han, F Zhang, Y Zhang, C Hu, X Ma, Y Liang, A Wang, B Lu, Y Shi, J Chen, Z Zhuang, J Wang, J Huang, C Wang, C Bai, X Zhou, Q Li, F Chen, H Yu, J Feng |
Investigational New Drugs | 2017 |
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
A Forero, JC Bendell, P Kumar, L Janisch, M Rosen, Q Wang, C Copigneaux, M Desai, G Senaldi, ML Maitland |
Investigational New Drugs | 2017 |
The linear ubiquitin chain assembly complex regulates TRAIL‐induced gene activation and cell death
E Lafont, C KantariMimoun, P Draber, DD Miguel, T Hartwig, M Reichert, S Kupka, Y Shimizu, L Taraborrelli, M Spit, MR Sprick, H Walczak |
The EMBO Journal | 2017 |
TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer.
Wei B, Liang J, Hu J, Mi Y, Ruan J, Zhang J, Wang Z, Hu Q, Jiang H, Ding Q |
Medical science monitor : international medical journal of experimental and clinical research | 2017 |
Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer
C Geismann, F Grohmann, A Dreher, R Häsler, P Rosenstiel, K Legler, C Hauser, JH Egberts, B Sipos, S Schreiber, A Linkermann, Z Hassan, G Schneider, H Schäfer, A Arlt |
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | 2017 |
Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin
X Li, M You, Y Liu, L Ma, P Jin, R Zhou, ZX Zhang, B Hua, X Ji, X Cheng, F Yin, Y Chen, W Yin |
Scientific Reports | 2017 |
TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation
CR Reis, PH Chen, N Bendris, SL Schmid |
Proceedings of the National Academy of Sciences | 2017 |
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
T Hartwig, A Montinaro, S Karstedt, A Sevko, S Surinova, A Chakravarthy, L Taraborrelli, P Draber, E Lafont, FA Vargas, MA El-Bahrawy, SA Quezada, H Walczak |
Molecular Cell | 2017 |
Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP
BR Seo, K Min, SM Woo, M Choe, KS Choi, YK Lee, G Yoon, TK Kwon |
Antioxidants & Redox Signaling | 2017 |
Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway:
X Guo, Y Meng, X Sheng, Y Guan, F Zhang, Z Han, Y Kang, G Tai, Y Zhou, H Cheng |
Anti-Cancer Drugs | 2017 |
Analysis of TNF-related apoptosis-inducing ligand and receptors and implications in thymus biology and myasthenia gravis
I Kanatli, B Akkaya, H Uysal, S Kahraman, AD Sanlioglu |
Neuromuscular Disorders | 2017 |
Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage
SS Park, E Jwa, SH Shin, EJ Ju, I Park, JH Pak, JJ Hwang, DH Cho, BM Kim, SB Kim, JS Lee, SY Song, SY Jeong, EK Choi |
The International Journal of Biochemistry & Cell Biology | 2017 |
Imaging and Focal Therapy of Early Prostate Cancer
TJ Polascik |
Imaging and Focal Therapy of Early Prostate Cancer | 2017 |
Renaissance of protein crystallization and precipitation in biopharmaceuticals purification
R Santos, AL Carvalho, AC Roque |
Biotechnology Advances | 2017 |
sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
Y Huang, X Li, H Sha, L Zhang, X Bian, X Han, B Liu |
Scientific Reports | 2017 |
An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis
IT Chyuan, HF Tsai, HJ Liao, CS Wu, PN Hsu |
Cellular and Molecular Immunology | 2017 |
Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein
I Marini, M Siegemund, M Hutt, RE Kontermann, K Pfizenmaier |
Frontiers in immunology | 2017 |
MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis
EM Hennenberg, A Eyking, H Reis, E Cario, J Karhausen |
PloS one | 2017 |
MDL-12330A potentiates TRAIL-induced apoptosis in gastric cancer cells through CHOP-mediated DR5 upregulation
SC Lim, SI Han |
The Korean Journal of Physiology & Pharmacology | 2017 |
Biodegradable and bioreducible poly(beta-amino ester) nanoparticles for intracellular delivery to treat brain cancer
Y Rui, G Quiñones, JJ Green |
AIChE Journal | 2017 |
Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells: CaM B INDING T o DR5-M EDIATED DISC I N B REAST C ANCER C ELLS
RM Fancy, H Kim, T Zhou, KR Zinn, DJ Buchsbaum, Y Song |
Journal of Cellular Biochemistry | 2017 |
TRAIL–NP hybrids for cancer therapy: a review
H Belkahla, G Herlem, F Picaud, T Gharbi, M Hémadi, S Ammar, O Micheau |
Nanoscale | 2017 |
Partial p53-dependence of anisomycin-induced apoptosis in PC12 cells
R Schipp, J Varga, J Bátor, M Vecsernyés, Z Árvai, M Pap, J Szeberényi |
Molecular and Cellular Biochemistry | 2017 |
miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-κB Signaling
S Wang, L Feng, B Hu, Y Lu, W Wang, W Guo, C Suen, B Jiao, J Pang, W Fu, J Zhang |
Molecular Therapy - Nucleic Acids | 2017 |
Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog
TB Prigozhina, F Szafer, A Aronin, K Tzdaka, S Amsili, E Makdasi, N Shani, MD Elhalel |
Cancer Letters | 2017 |
Cellular Injury in Liver Diseases
WX Ding, XM Yin |
Cellular Injury in Liver Diseases | 2017 |
Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy
F Yan, X Li, N Li, R Zhang, Q Wang, Y Ru, X Hao, J Ni, H Wang, G Wu |
Cancer Letters | 2017 |
Human menstrual blood-derived mesenchymal stem cells as a cellular vehicle for malignant glioma gene therapy
X Wang, B Xiang, Y Ding, L Chen, H Zou, X Mou, C Xiang |
Oncotarget | 2017 |
Journey of TRAIL from bench to bedside and its potential role in immuno-oncology
GE Naoum, DJ Buchsbaum, F Tawadros, A Farooqi, WO Arafat |
Oncology Reviews | 2017 |
Multifunctional Nucleus-targeting Nanoparticles with Ultra-high Gene Transfection Efficiency for In Vivo Gene Therapy
L Li, X Li, Y Wu, L Song, X Yang, T He, N Wang, S Yang, Y Zeng, Q Wu, Z Qian, Y Wei, C Gong |
Theranostics | 2017 |
Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells: CaM B INDING T o DR5-M EDIATED DISC I N B REAST C ANCER C ELLS
RM Fancy, H Kim, T Zhou, KR Zinn, DJ Buchsbaum, Y Song |
Journal of Cellular Biochemistry | 2017 |
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects
H Tenshin, J Teramachi, A Oda, R Amachi, M Hiasa, A Bat-Erdene, K Watanabe, M Iwasa, T Harada, S Fujii, K Kagawa, K Sogabe, S Nakamura, H Miki, K Kurahashi, S Yoshida, K Aihara, I Endo, E Tanaka, T Matsumoto, M Abe |
Blood Advances | 2017 |
TRAIL, Fas Ligand, TNF and TLR3 in Cancer
O Micheau |
TRAIL, Fas Ligand, TNF and TLR3 in Cancer | 2017 |
Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL
A Elia, R Henry-Grant, C Adiseshiah, C Marboeuf, RJ Buckley, MJ Clemens, S Mudan, S Pyronnet |
Cell Death and Disease | 2017 |
cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition
C Padmanabhan, EJ Rellinger, J Zhu, H An, LG Woodbury, DH Chung, AG Waterson, CW Lindsley, AL Means, RD Beauchamp |
Oncotarget | 2017 |
The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B1
ME Gasparian, ML Bychkov, AV Yagolovich, MP Kirpichnikov, DA Dolgikh |
Doklady Biochemistry and Biophysics | 2017 |
Up-regulation of 5-lipoxygenase by inhibition of cathepsin G enhances TRAIL-induced apoptosis through down-regulation of survivin
SM Woo, KJ Min, SU Seo, S Kim, JW Park, DK Song, HS Lee, SH Kim, TK Kwon |
Oncotarget | 2017 |
Overexpression of miR-101 promotes TRAIL-induced mitochondrial apoptosis in papillary thyroid carcinoma by targeting c-met and MCL-1
J Zhu, Z Li |
Oncotarget | 2017 |
TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data
Z Gamie, K Kapriniotis, D Papanikolaou, E Haagensen, RD Ribeiro, K Dalgarno, A Krippner-Heidenreich, C Gerrand, E Tsiridis, KS Rankin |
Cancer Letters | 2017 |
Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy
X Wu, S Wang, M Li, A Wang, Y Zhou, P Li, Y Wang |
Nanoscale | 2017 |
Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi-1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP
X Kong, J Luo, T Xu, Y Zhou, Z Pan, Y Xie, L Zhao, Y Lu, X Han, Z Li, L Liu |
Oncology reports | 2017 |
SPAG6 regulates cell apoptosis through the TRAIL signal pathway in myelodysplastic syndromes
X Li, B Yang, L Wang, L Chen, X Luo, L Liu |
Oncology reports | 2017 |
Ginkgetin inhibits proliferation of human leukemia cells via the TNF-α signaling pathway
LL Pan, WJ Wu, GF Zheng, XY Han, JS He, Z Cai |
Zeitschrift für Naturforschung C | 2017 |
TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer
B Wei, J Liang, J Hu, Y Mi, J Ruan, J Zhang, Z Wang, Q Hu, H Jiang, Q Ding |
Medical science monitor : international medical journal of experimental and clinical research | 2017 |
Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery: Novel targets for sensitizing breast cancer cells
B Thapa, RB KC, H Uludağ |
International Journal of Cancer | 2017 |
Multifunctional Nucleus-targeting Nanoparticles with Ultra-high Gene Transfection Efficiency for In Vivo Gene Therapy
L Li, X Li, Y Wu, L Song, X Yang, T He, N Wang, S Yang, Y Zeng, Q Wu, Z Qian, Y Wei, C Gong |
Theranostics | 2017 |
Chaetospirolactone reverses the apoptotic resistance towards TRAIL in pancreatic cancer
W Hu, X Jia, Y Gao, Q Zhang |
Biochemical and Biophysical Research Communications | 2017 |
Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5
Y Zhao, B Tian, Y Wang, H Ding |
Medical science monitor : international medical journal of experimental and clinical research | 2017 |
Paving TRAIL’s Path with Ubiquitin
E Lafont, T Hartwig, H Walczak |
Trends in Biochemical Sciences | 2017 |
TRAIL-induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor
Z Nahacka, J Svadlenka, M Peterka, M Ksandrova, S Benesova, J Neuzil, L Andera |
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | 2017 |
Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model
B Xiao, Y Qin, C Ying, B Ma, B Wang, F Long, R Wang, L Fang, Y Wang |
Molecular medicine reports | 2017 |
Ophiopogonin B sensitizes TRAIL-induced apoptosis through activation of autophagy flux and downregulates cellular FLICE-like inhibitory protein
U Nazim, JK Jeong, SY Park |
Oncotarget | 2017 |
Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine
O OrtegaRivera, JL Quintanar, SD ToroArreola, ï½ngel AlpucheSolis, M EsparzaAraiza, E Salinas |
Oncology Letters | 2017 |
Generation of a novel TRAIL mutant by proline to arginine substitution based on codon bias and its antitumor effects
A Zhu, X Wang, M Huang, C Chen, J Yan, Q Xu, L Wei, X Huang, H Zhu, C Yi |
Molecular medicine reports | 2017 |
RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND SELECTIVELY INDUCES APOPTOSIS IN MALIGNANT MELANOMA
M Kalafatis, KA Turner, DJ Lindner, M Kalafatis |
International Journal of Cancer and Oncology | 2017 |
TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors.
Yang X, Li Z, Wu Q, Chen S, Yi C, Gong C |
Drug Delivery | 2017 |
Partial p53-dependence of anisomycin-induced apoptosis in PC12 cells.
Schipp R, Varga J, Bátor J, Vecsernyés M, Árvai Z, Pap M, Szeberényi J |
Molecular and Cellular Biochemistry | 2017 |
Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y, Tian B, Wang Y, Ding H |
Medical science monitor : international medical journal of experimental and clinical research | 2017 |
Activation of autophagy flux by metformin downregulates cellular FLICE–like inhibitory protein and enhances TRAIL- induced apoptosis
UM Nazim, JH Moon, JH Lee, YJ Lee, JW Seol, SK Eo, JH Lee, SY Park |
Oncotarget | 2016 |
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
D Hendriks, Y He, I Koopmans, VR Wiersma, RJ van Ginkel, DF Samplonius, W Helfrich, E Bremer |
OncoImmunology | 2016 |
Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
P Hirsova, SH Ibrabim, GJ Gores, H Malhi |
Journal of lipid research | 2016 |
The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy
B Lohberger, B Steinecker-Frohnwieser, N Stuendl, H Kaltenegger, A Leithner, B Rinner, V Trajkovic |
PloS one | 2016 |
Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in�vivo
K Harati, S Emmelmann, B Behr, O Goertz, T Hirsch, N Kapalschinski, J Kolbenschlag, I Stricker, A Tannapfel, M Lehnhardt, A Daigeler |
Oncology Letters | 2016 |
Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer
U Mert, AD Sanlioglu |
Cellular and Molecular Life Sciences | 2016 |
A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression
K Piras-Straub, K Khairzada, P Kocabayoglu, A Paul, G Gerken, K Herzer |
Cancer Medicine | 2016 |
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
S Bernardi, F Bossi, B Toffoli, B Fabris |
BioMed Research International | 2016 |
Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey
CL de Zafra, A Ashkenazi, WC Darbonne, M Cheu, K Totpal, S Ortega, H Flores, MD Walker, B Kabakoff, BL Lum, BJ Mounho-Zamora, SA Marsters, NO Dybdal |
Cell Death and Disease | 2016 |
Redox signaling and oxidative stress: cross talk with TNF-related apoptosis inducing ligand activity
R Voltan, P Secchiero, F Casciano, D Milani, G Zauli, V Tisato |
The International Journal of Biochemistry & Cell Biology | 2016 |
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl
JL Dine, CC OSullivan, D Voeller, YE Greer, KJ Chavez, CM Conway, S Sinclair, B Stone, L Amiri-Kordestani, AS Merchant, SM Hewitt, SM Steinberg, SM Swain, S Lipkowitz |
Breast Cancer Research and Treatment | 2016 |
Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses
H Niess, MN Thomas, TS Schiergens, A Kleespies, KW Jauch, C Bruns, J Werner, PJ Nelson, MK Angele |
Innovative Surgical Sciences | 2016 |
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
S Baig, I Seevasant, J Mohamad, A Mukheem, HZ Huri, T Kamarul |
Cell Death and Disease | 2016 |
Co-delivery of chemotherapeutics and proteins for synergistic therapy
C He, Z Tang, H Tian, X Chen |
Advanced Drug Delivery Reviews | 2016 |
TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy
ZQ Yuan, KK Kolluri, KH Gowers, SM Janes |
Journal of Extracellular Vesicles | 2016 |
Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5
JW Eng, TA Mace, R Sharma, DY Twum, P Peng, JF Gibbs, R Pitoniak, CB Reed, SI Abrams, EA Repasky, BL Hylander |
Journal for ImmunoTherapy of Cancer | 2016 |
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
KG Fleten, VA Flørenes, L Prasmickaite, O Hill, J Sykora, GM Mælandsmo, B Engesæter |
Cell Death Discovery | 2016 |
USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability
M Jeong, EW Lee, D Seong, J Seo, JH Kim, S Grootjans, SY Kim, P Vandenabeele, J Song |
Oncogene | 2016 |
Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin
F Hartung, LA Pardo |
European Biophysics Journal | 2016 |
TRAIL restores DCA/metformin-mediated cell death in hypoxia
SE Hong, CS Kim, S An, HA Kim, SG Hwang, JY Song, JK Lee, J Hong, JI Kim, WC Noh, HO Jin, IC Park |
Biochemical and Biophysical Research Communications | 2016 |
Combinatorial treatment with anacardic acid followed by TRAIL augments induction of apoptosis in TRAIL resistant cancer cells by the regulation of p53, MAPK and NFκβ pathways
MH Raj, B Yashaswini, J Rössler, BP Salimath |
Apoptosis | 2016 |
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2 kinases
CL Kline, AP van Heuvel, JE Allen, VV Prabhu, DT Dicker, WS El-Deiry |
Science signaling | 2016 |
Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer
PT Yin, S Shah, NJ Pasquale, OB Garbuzenko, T Minko, KB Lee |
Biomaterials | 2016 |
Lipid- and polyion complex-based micelles as agonist platforms for TNFR superfamily receptors
RN Gilbreth, S Novarra, L Wetzel, S Florinas, H Cabral, K Kataoka, J Rios-Doria, RJ Christie, M Baca |
Journal of Controlled Release | 2016 |
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL
M Iaboni, V Russo, R Fontanella, G Roscigno, D Fiore, E Donnarumma, CL Esposito, C Quintavalle, PH Giangrande, V Franciscis, G Condorelli |
Molecular Therapy — Nucleic Acids | 2016 |
Resveratrol Enhances Apoptosis in Endometriotic Stromal Cells
A Taguchi, K Koga, K Kawana, T Makabe, F Sue, M Miyashita, M Yoshida, Y Urata, G Izumi, M Tkamura, M Harada, T Hirata, Y Hirota, O Wada-Hiraike, T Fujii, Y Osuga |
American Journal of Reproductive Immunology | 2016 |
Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells
MA Han, DH Lee, SM Woo, BR Seo, K Min, S Kim, JW Park, SH Kim, YH Choi, TK Kwon |
Scientific Reports | 2016 |
Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1
DI Radke, H Ungefroren, O Helm, S Voigt, G Alp, H Braun, S Hübner, J Dilchert, S Sebens, D Adam, H Kalthoff, A Trauzold |
Cellular Signalling | 2016 |
Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma: Osteoprotegerin
FA de Voogd, RB Gearry, CJ Mulder, AS Day |
Journal of Gastroenterology and Hepatology | 2016 |
TRAIL-CM4 fusion protein shows in vitro antibacterial activity and a stronger antitumor activity than solo TRAIL protein
M Sang, J Zhang, B Li, Y Chen |
Protein Expression and Purification | 2016 |
Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation
L Chen, Y Meng, Q Sun, Z Zhang, X Guo, X Sheng, G Tai, H Cheng, Y Zhou |
Cell Death and Disease | 2016 |
Protein engineering strategies with potential applications for altering clinically relevant cellular pathways at the protein level
L Regan, MR Hinrichsen, C Oi |
Expert Review of Proteomics | 2016 |
Ethanolic extract of Descurainia sophia seeds sensitizes A549 human lung cancer cells to TRAIL cytotoxicity by upregulating death receptors
JS Park, CJ Lim, OS Bang, NS Kim |
BMC complementary and alternative medicine | 2016 |
Selective activation of TNFR1 and NF-κB inhibition by a novel biyouyanagin analogue promotes apoptosis in acute leukemia cells
CG Savva, S Totokotsopoulos, KC Nicolaou, CM Neophytou, AI Constantinou |
BMC Cancer | 2016 |
Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation
L Chen, Y Meng, X Guo, X Sheng, G Tai, F Zhang, H Cheng, Y Zhou |
Apoptosis | 2016 |
Opposing roles of TGF-β and EGF in the regulation of TRAIL-induced apoptosis in human breast epithelial cells
A Cano-González, A López-Rivas |
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | 2016 |
Fully human monoclonal antibodies to TRAIL-R1 enhance TRAIL-induced apoptosis via activation of caspase-8 pathway
Z Hao, X Han, X Sun, M Shen, J Huang, Y Li, T Ozawa, D Pang, S Jin, H Kishi, A Muraguchi, A Jin |
Biochemical and Biophysical Research Communications | 2016 |
Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer
AK Singh, SS Chauhan, SK Singh, VV Verma, A Singh, RK Arya, S Maheshwari, MS Akhtar, J Sarkar, VM Rangnekar, PM Chauhan, D Datta |
Carcinogenesis | 2016 |
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy
J Wang, H Wang, LY Wang, D Cai, Z Duan, Y Zhang, P Chen, JX Zou, J Xu, X Chen, HJ Kung, HW Chen |
Cell Death and Differentiation | 2016 |
Onto better TRAILs for cancer treatment
D Miguel, J Lemke, A Anel, H Walczak, L Martinez-Lostao |
Cell Death and Differentiation | 2016 |
An Apoptosis-Inducing Peptidic Heptad That Efficiently Clusters Death Receptor 5
B Valldorf, H Fittler, L Deweid, A Ebenig, S Dickgiesser, C Sellmann, J Becker, S Zielonka, M Empting, O Avrutina, H Kolmar |
Angewandte Chemie (International ed. in English) | 2016 |
Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer
R Zhang, X Zhang, B Ma, B Xiao, F Huang, P Huang, C Ying, T Liu, Y Wang |
Cancer Gene Therapy | 2016 |
TRAIL causes deletions at the HPRT and TK1 loci of clonogenically competent cells
MA Miles, TM Shekhar, NE Hall, CJ Hawkins |
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis | 2016 |
Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application
V Taucher, H Mangge, J Haybaeck |
Cellular Oncology | 2016 |
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
T Ciuleanu, I Bazin, D Lungulescu, L Miron, I Bondarenko, A Deptala, M Rodriguez-Torres, B Giantonio, NL Fox, P Wissel, J Egger, M Ding, RN Kalyani, R Humphreys, M Gribbin, W Sun |
Annals of Oncology | 2016 |
Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL
B Jancekova, E Ondrouskova, L Knopfova, J Smarda, P Benes |
Tumor Biology | 2016 |
Fed-batch production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in soluble form in Escherichia coli and its purification and characterization
P Li, Q Gu, X Wu |
Protein Expression and Purification | 2016 |
Non-viral nucleic acid containing nanoparticles as cancer therapeutics
KL Kozielski, Y Rui, JJ Green |
Expert Opinion on Drug Delivery | 2016 |
Gingival Mesenchymal Stem/Progenitor Cells: A Unique Tissue Engineering Gem
KM El-Sayed, CE Dörfer |
Stem Cells International | 2016 |
Role of nanotechnology and gene delivery systems in TRAIL based therapies
GE Naoum, F Tawadros, AA Farooqi, MZ Qureshi, S Tabassum, DJ Buchsbaum, W Arafat |
ecancermedicalscience | 2016 |
Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs
Y Huang, X Yang, T Xu, Q Kong, Y Zhang, Y Shen, Y Wei, G Wang, KJ Chang |
International journal of oncology | 2016 |
Adipose‑derived mesenchymal stem cell‑facilitated TRAIL expression in melanoma treatment in�vitro
H Jing, D Duan, H Zhou, Q Hu, T Lei |
Molecular medicine reports | 2016 |
Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY
RM Fancy, L Wang, Q Zeng, H Wang, T Zhou, DJ Buchsbaum, Y Song |
The Journal of biological chemistry | 2016 |
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies
G Pistritto, D Trisciuoglio, C Ceci, A Garufi, G D'Orazi |
Aging | 2016 |
Snake Venom synergized Cytotoxic Effect of Natural Killer Cells on NCI H358 Human Lung Cancer Cell Growth through Induction of Apoptosis
JW Oh, HS Song |
The Acupuncture | 2016 |
Antitumor and radiosensitization effect of 12C6+ heavy-ion irradiation mediated by radiation-inducible gene therapy
H Liu, CF Jin, SF Ge, LJ Wu |
Nuclear Science and Techniques | 2016 |
Ein Apoptose-induzierendes Heptamer, das effizient den Todesrezeptor 5 bündelt
B Valldorf, H Fittler, L Deweid, A Ebenig, S Dickgiesser, C Sellmann, J Becker, S Zielonka, M Empting, O Avrutina, H Kolmar |
Angewandte Chemie | 2016 |
Encyclopedia of Signaling Molecules
S Choi |
Encyclopedia of Signaling Molecules | 2016 |
Genetically modified mesenchymal stromal cells in cancer therapy
EK Sage, RM Thakrar, SM Janes |
Cytotherapy | 2016 |
Protective effects of a polymethoxy flavonoids-rich Citrus aurantium peel extract on liver fibrosis induced by bile duct ligation in mice
SW Lim, DR Lee, BK Choi, HS Kim, SH Yang, JW Suh, KS Kim |
Asian Pacific Journal of Tropical Medicine | 2016 |
Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma
J Zhou, Z Huang, Z Wang, S Liu, A Grandien, I Ernberg, Z He, X Zhang |
Oncotarget | 2016 |
The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation
AM el Zawily, BM Toosi, T Freywald, VV Indukuri, FJ Vizeacoumar, SC Leary, A Freywald |
Oncotarget | 2016 |
Inhibition of never in mitosis A (NIMA)-related kinase-4 reduces survivin expression and sensitizes cancer cells to TRAIL-induced cell death
SJ Park, DS Jo, SY Jo, DW Shin, S Shim, YK Jo, JH Shin, YJ Ha, SY Jeong, JJ Hwang, YS Kim, YA Suh, JW Chang, JC Kim, DH Cho |
Oncotarget | 2016 |
Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane
Y Su, K Tatzel, X Wang, B Belt, P Binder, L Kuroki, MA Powell, DG Mutch, WG Hawkinsand, D Spitzer |
Oncotarget | 2016 |
Involvement of DR4/JNK pathway-mediated autophagy in acquired TRAIL resistance in HepG2 cells
SC Lim, HJ Jeon, KH Kee, MJ Lee, R Hong, SI Han |
International journal of oncology | 2016 |
A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression
K Piras-Straub, K Khairzada, P Kocabayoglu, A Paul, G Gerken, K Herzer |
Cancer Medicine | 2016 |
The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer.
Cousin FJ, Jouan-Lanhouet S, Théret N, Brenner C, Jouan E, Le Moigne-Muller G, Dimanche-Boitrel MT, Jan G |
Oncotarget | 2016 |
Targeting the extrinsic apoptosis pathway in cancer: lessons learned and future directions
Avi Ashkenazi |
Journal of Clinical Investigation | 2015 |
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
MH Tuthill, A Montinaro, J Zinngrebe, K Prieske, P Draber, S Prieske, T Newsom-Davis, S Karstedt, J Graves, H Walczak |
Oncogene | 2015 |
Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer
L Lu, ZJ Li, LF Li, WK Wu, J Shen, L Zhang, RL Chan, L Yu, YW Liu, SX Ren, KM Chan, CH Cho |
Journal of Controlled Release | 2015 |
HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
DH Lee, KS Sung, DL Bartlett, YT Kwon, YJ Lee |
Cellular Signalling | 2015 |
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-Troglitazone-induced Apoptosis in Prostate Cancer Cells Involve AMP-activated Protein Kinase
S Santha, N Viswakarma, S Das, A Rana, B Rana |
The Journal of biological chemistry | 2015 |
Protein Glycosylation in Cancer
SR Stowell, T Ju, RD Cummings |
Annual review of pathology | 2015 |
Therapeutic applications of TRAIL receptor agonists in cancer and beyond
GP Amarante-Mendes, TS Griffith |
Pharmacology & Therapeutics | 2015 |
TRAIL Modulates the Immune System and Protects against the Development of Diabetes
F Bossi, S Bernardi, G Zauli, P Secchiero, B Fabris |
Journal of Immunology Research | 2015 |
The double trouble of metabolic diseases: the diabetes-cancer link
S Tudzarova, MA Osman |
Molecular biology of the cell | 2015 |
Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
E Strekalova, D Malin, DM Good, VL Cryns |
Clinical cancer research | 2015 |
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy
X Dai, J Zhang, F Arfuso, A Chinnathambi, ME Zayed, SA Alharbi, AP Kumar, KS Ahn, G Sethi |
Experimental biology and medicine (Maywood, N.J.) | 2015 |
Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis
S von Karstedt, A Conti, M Nobis, A Montinaro, T Hartwig, J Lemke, K Legler, F Annewanter, AD Campbell, L Taraborrelli, A Grosse-Wilde, JF Coy, MA El-Bahrawy, F Bergmann, R Koschny, J Werner, TM Ganten, T Schweiger, K Hoetzenecker, I Kenessey, B Hegedüs, M Bergmann, C Hauser, JH Egberts, T Becker, C Röcken, H Kalthoff, A Trauzold, KI Anderson, OJ Sansom, H Walczak |
Cancer Cell | 2015 |
Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity
L O'Leary, AM van der Sloot, CR Reis, S Deegan, AE Ryan, SP Dhami, LS Murillo, RH Cool, PC de Sampaio, K Thompson, G Murphy, WJ Quax, L Serrano, A Samali, E Szegezdi |
Oncogene | 2015 |
Tumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype
J Gao, D Wang, D Liu, M Liu, Y Ge, M Jiang, Y Liu, D Zheng |
Molecular biology of the cell | 2015 |
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
R Trivedi, DP Mishra |
Frontiers in Oncology | 2015 |
Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors
Y Oh, M Swierczewska, TH Kim, SM Lim, HN Eom, JH Park, DH Na, K Kim, KC Lee, MG Pomper, S Lee |
Journal of Controlled Release | 2015 |
Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model
BL Hylander, A Sen, SH Beachy, R Pitoniak, S Ullas, JF Gibbs, J Qiu, JD Prey, GJ Fetterly, EA Repasky |
Journal of Controlled Release | 2015 |
Intranasal delivery of stem cells as therapy for central nervous system disease
Y Li, L Feng, GX Zhang, C Ma |
Experimental and Molecular Pathology | 2015 |
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Y Liu, OE Hawkins, AE Vilgelm, JS Pawlikowski, JA Ecsedy, JA Sosman, MC Kelley, A Richmond |
Clinical cancer research | 2015 |
Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation
JW Eng, CB Reed, KM Kokolus, R Pitoniak, A Utley, MJ Bucsek, WW Ma, EA Repasky, BL Hylander |
Nature Communications | 2015 |
Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
PM Nair, H Flores, A Gogineni, S Marsters, DA Lawrence, RF Kelley, H Ngu, M Sagolla, L Komuves, R Bourgon, J Settleman, A Ashkenazi |
Proceedings of the National Academy of Sciences | 2015 |
Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas: Adipose MSC with TRAIL Target Sarcomas
G Grisendi, C Spano, N D'souza, V Rasini, E Veronesi, M Prapa, T Petrachi, S Piccinno, F Rossignoli, JS Burns, S Fiorcari, D Granchi, N Baldini, EM Horwitz, V Guarneri, P Conte, P Paolucci, M Dominici |
Stem Cells | 2015 |
Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis
P Hirsova, GJ Gores |
CMGH Cellular and Molecular Gastroenterology and Hepatology | 2015 |
Safety and tolerability of TRAIL receptor agonists in cancer treatment
S Fulda |
European Journal of Clinical Pharmacology | 2015 |
Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis
H Han, B Xu, P Hou, C Jiang, L Liu, M Tang, X Yang, Y Zhang, Y Liu |
Cell Biochemistry and Biophysics | 2015 |
A novel adenoviral vector carrying an all-in-one Tet-On system with an autoregulatory loop for tight, inducible transgene expression
H Chen, D Wang, R Xia, Q Mao, H Xia |
BMC Biotechnology | 2015 |
Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator
SM Loya, X Zhang |
Gene Therapy | 2015 |
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
KP Papadopoulos, R Isaacs, S Bilic, K Kentsch, HA Huet, M Hofmann, D Rasco, N Kundamal, Z Tang, J Cooksey, A Mahipal |
Cancer Chemotherapy and Pharmacology | 2015 |
Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells: Oncolytic adenoviruses for MSC delivery to pancreatic cancer
K Hammer, A Kazcorowski, L Liu, M Behr, P Schemmer, I Herr, DM Nettelbeck |
International Journal of Cancer | 2015 |
PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
YS Youn, HJ Byeon, I Kim, JS Choi, ES Lee, BS Shin |
International Journal of Nanomedicine | 2015 |
Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment
S Yin, A Rishi, K Reddy |
Oncology reports | 2015 |
Mesenchymal stromal cell delivery of full-length tumor necrosis factor–related apoptosis-inducing ligand is superior to soluble type for cancer therapy
ZQ Yuan, KK Kolluri, EK Sage, KH Gowers, SM Janes |
Cytotherapy | 2015 |
A Humanized Leucine Zipper-TRAIL Hybrid Induces Apoptosis of Tumors both In Vitro and In Vivo
D Rozanov, P Spellman, A Savinov, AY Strongin, C Yan |
PloS one | 2015 |
Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis
S Philipp, J Sosna, J Plenge, H Kalthoff, D Adam |
Cell Communication and Signaling | 2015 |
Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells
GA Alexiou, KI Tsamis, E Vartholomatos, E Peponi, E Tzima, I Tasiou, E Lykoudis, P Tsekeris, AP Kyritsis |
Journal of Neuro-Oncology | 2015 |
Proteomic tools for the characterization of cell death mechanisms in drug discovery
VG Anania, JR Lill |
PROTEOMICS – CLINICAL APPLICATIONS | 2015 |
Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells
R Tanaka, M Tomosugi, M Horinaka, Y Sowa, T Sakai, AR Amin |
PloS one | 2015 |
Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines
CC Chang, CP Kuan, JY Lin, JS Lai, TF Ho |
Chemical Research in Toxicology | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein
J Zhitao, L Long, L Jia, B Yunchao, W Anhua |
Tumor Biology | 2015 |
TRAIL and TRAIL receptors in patients with laryngeal cancer: TRAIL Receptors in Laryngeal Carcinoma
E Erkul, Z Kucukodaci, D Pinar, A Gungor, MA Babayigit, O Kurt, H Cincik |
Head & Neck | 2015 |
Targeting TRAIL in the treatment of cancer: new developments
B Lim, JE Allen, VV Prabhu, MK Talekar, NK Finnberg, WS El-Deiry |
Expert Opinion on Therapeutic Targets | 2015 |
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib
PJ Neeson, AK Hsu, YR Chen, HM Halse, J Loh, R Cordy, K Fielding, J Davis, J Noske, AJ Davenport, CA Lindqvist-Gigg, R Humphreys, T Tai, HM Prince, JA Trapani, MJ Smyth, DS Ritchie |
OncoImmunology | 2015 |
State of the art paper Does aspirin-induced oxidative stress cause asthma exacerbation?
D Kacprzak, R Pawliczak |
Archives of Medical Science : AMS | 2015 |
Elevated pressure enhanced TRAIL-induced apoptosis in hepatocellular carcinoma cells via ERK1/2-inactivation
E Hong, E Lee, J Kim, D Kwon, Y Lim |
Cellular & Molecular Biology Letters | 2015 |
DED or alive: assembly and regulation of the death effector domain complexes
JS Riley, A Malik, C Holohan, DB Longley |
Cell Death and Disease | 2015 |
Foods and Dietary Supplements in the Prevention and Treatment of Disease in Older Adults
G Ntaios |
Foods and Dietary Supplements in the Prevention and Treatment of Disease in Older Adults | 2015 |
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
CY Cheah, D Belada, MA Fanale, A Janikova, MS Czucman, IW Flinn, AV Kapp, A Ashkenazi, S Kelley, GL Bray, S Holden, JF Seymour |
The Lancet Haematology | 2015 |
Oncotoxic proteins in cancer therapy: Mechanisms of action
YN Lezhnin, YE Kravchenko, EI Frolova, PM Chumakov, SP Chumakov |
Molecular Biology | 2015 |
Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells
S Seah, IC Low, JL Hirpara, K Sachaphibulkij, G Kroemer, C Brenner, S Pervaiz |
Cell Death and Disease | 2015 |
Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma
K Wang, FM Kievit, M Jeon, JR Silber, RG Ellenbogen, M Zhang |
Advanced Healthcare Materials | 2015 |
Periplasmic Expression of TNF Related Apoptosis Inducing Ligand (TRAIL) in E.coli
Omid Tavallaei, Mojgan Bandehpour, Nastaran Nafissi-Varcheh, Bahram Kazemi |
IRAN J PHARM RES | 2015 |
Detection of Anticancer and Apoptotic Effect of the Produced IgYs against the Three Extracellular Domain of Human DR5 Protein
Shaghayegh Amirijavid, Mehrdad Hashemi |
Iranian journal of cancer prevention | 2015 |
Mutations enhancing selectivity of antitumor cytokine TRAIL to DR5 receptor increase its cytotoxicity against tumor cells
ME Gasparian, ML Bychkov, AV Yagolovich, DA Dolgikh, MP Kirpichnikov |
Biochemistry (Moscow) | 2015 |
Suppression of casein kinase 2 sensitizes tumor cells to antitumor TRAIL therapy by regulating the phosphorylation and localization of p65 in prostate cancer
X Gang, Y Wang, Y Wang, Y Zhao, L Ding, J Zhao, L Sun, G Wang |
Oncology reports | 2015 |
The Role of Selected Flavonols in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor–1 (TRAIL-R1) Expression on Activated RAW 264.7 Macrophages
M Warat, T Sadowski, E Szliszka, W Król, Z Czuba |
Molecules (Basel, Switzerland) | 2015 |
TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
T Tamada, D Shinmi, M Ikeda, Y Yonezawa, S Kataoka, R Kuroki, E Mori, K Motoki |
Scientific Reports | 2015 |
Partial Protection of PC12 Cells from Cellular Stress by Low-Dose Sodium Nitroprusside Pre-treatment
J Varga, J Bátor, G Nádasdi, Z Árvai, R Schipp, J Szeberényi |
Cellular and Molecular Neurobiology | 2015 |
Genistein enhances TRAIL-induced cancer cell death via inactivation of autophagic flux
U Nazim, SY Park |
Oncology reports | 2015 |
First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
JE Allen, R Crowder, WS El-Deiry, SY Sun |
PloS one | 2015 |
Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death
S Raimondo, F Naselli, S Fontana, F Monteleone, AL Dico, L Saieva, G Zito, A Flugy, M Manno, MA di Bella, GD Leo, R Alessandro |
Oncotarget | 2015 |
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells
R Sriraksa, T Limpaiboon |
Asian Pacific Journal of Cancer Prevention | 2015 |
Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells
Yang Lin, Tianmin Xu, Hong Teng, Manhua Cui |
International journal of clinical and experimental pathology | 2015 |
TRAIL-Expressing Gingival-Derived Mesenchymal Stem Cells Inhibit Tumorigenesis of Tongue Squamous Cell Carcinoma
L Xia, R Peng, W Leng, R Jia, X Zeng, X Yang, M Fan |
Journal of dental research | 2015 |
MSCs: Is this the future therapeutic for cancer?
A Kakouri |
Acta Medica International | 2015 |
Resistance of Cancer Cells to CTL-Mediated Immunotherapy
B Bonavida, S Chouaib |
2015 | |
Proteases in Apoptosis: Pathways, Protocols and Translational Advances
K Bose |
2015 | |
FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells
SM Woo, BR Seo, K Min, TK Kwon |
Oncotarget | 2015 |
Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells
KJ Jung, K Min, JH Bae, TK Kwon |
Oncotarget | 2015 |
Induction of cellular prion protein (PrPc) under hypoxia inhibits apoptosis caused by TRAIL treatment
JY Park, JK Jeong, JH Lee, JH Moon, SW Kim, YJ Lee, SY Park |
Oncotarget | 2015 |
TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model
H Fritsche, T Heilmann, RJ Tower, C Hauser, A von Au, D El-Sheikh, GM Campbell, G Alp, D Schewe, S Hübner, S Tiwari, D Kownatzki, S Boretius, D Adam, W Jonat, T Becker, CC Glüer, M Zöller, H Kalthoff, C Schem, A Trauzold |
Oncotarget | 2015 |
Brazilian Red Propolis Induces Apoptosis-Like Cell Death and Decreases Migration Potential in Bladder Cancer Cells
KR Begnini, PM de Leon, H Thurow, E Schultze, VF Campos, FM Rodrigues, S Borsuk, OA Dellagostin, L Savegnago, M Roesch-Ely, S Moura, FF Padilha, T Collares, JA Henriques, FK Seixas |
Evidence-Based Complementary and Alternative Medicine | 2014 |
Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients: Relationship between TRAIL and VEGF in MM patients
L Bolkun, D Lemancewicz, J Piszcz, M Moniuszko, U Bolkun-Skornicka, M Szkiladz, E Jablonska, J Kloczko, J Dzieciol |
Hematological Oncology | 2014 |
Roles of ligands from the TNF superfamily in B cell development, function, and regulation
WA Figgett, FB Vincent, D Saulep-Easton, F Mackay |
Seminars in Immunology | 2014 |
Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System
D Sarhan, P D'Arcy, A Lundqvist |
International journal of molecular sciences | 2014 |
The Interruption of PKC-ι Signaling and TRAIL Combination Therapy Against Glioblastoma Cells
AN McCray, S Desai, M Acevedo-Duncan |
Neurochemical Research | 2014 |
Delaying mitotic exit downregulates FLIP expression and strongly sensitizes tumor cells to TRAIL
T Sánchez-Pérez, RH Medema, A López-Rivas |
Oncogene | 2014 |
TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate-induced colitis and colitis-associated carcinogenesis
J Zhu, L Chen, J Shi, S Liu, Y Liu, D Zheng |
Immunology | 2014 |
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab
J Tabernero, SP Chawla, H Kindler, K Reckamp, EG Chiorean, NS Azad, AC Lockhart, CP Hsu, NF Baker, F Galimi, P Beltran, J Baselga |
Targeted Oncology | 2014 |
Targeting the apoptosis pathway in hematologic malignancies
S Zaman, R Wang, V Gandhi |
Leukemia & Lymphoma | 2014 |
Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor
HW Lee, TD Singh, SW Lee, JH Ha, A Rehemtulla, BC Ahn, YH Jeon, J Lee |
The FASEB Journal | 2014 |
Regulation of the Extrinsic Apoptotic Pathway by MicroRNA-21 in Alcoholic Liver Injury
H Francis, K McDaniel, Y Han, X Liu, L Kennedy, F Yang, J McCarra, T Zhou, S Glaser, J Venter, L Huang, P Levine, JM Lai, CG Liu, G Alpini, F Meng |
The Journal of biological chemistry | 2014 |
Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway
AR Jazirehi, SK Kurdistani, JS Economou |
Journal of immunology (Baltimore, Md. : 1950) | 2014 |
Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging
Y Xie, Z Xie |
Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging | 2014 |
Identification of novel molecular regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening
SV Garimella, K Gehlhaus, JL Dine, JJ Pitt, M Grandin, S Chakka, MM Nau, NJ Caplen, S Lipkowitz |
Breast Cancer Research | 2014 |
Getting TRAIL back on track for cancer therapy
J Lemke, S Karstedt, J Zinngrebe, H Walczak |
Cell Death and Differentiation | 2014 |
Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice
XG Wang, T Jandl, E Dadachova, E Revskaya |
Therapeutic Delivery | 2014 |
Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L)
K Min, BR Seo, YC Bae, YH Yoo, TK Kwon |
Cell Death and Disease | 2014 |
Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma
EK Sage, KK Kolluri, K McNulty, SD Lourenco, TL Kalber, KL Ordidge, D Davies, YC Lee, A Giangreco, SM Janes |
Thorax | 2014 |
Ion channels and apoptosis in cancer
CD Bortner, JA Cidlowski |
Philosophical Transactions of the Royal Society B: Biological Sciences | 2014 |
Inhibition of eIF2α dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells
Y Teng, M Gao, J Wang, Q Kong, H Hua, T Luo, Y Jiang |
Cell Death and Disease | 2014 |
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3
G Garg, J Gibbs, B Belt, MA Powell, DG Mutch, P Goedegebuure, L Collins, D Piwnica-Worms, WG Hawkins, D Spitzer |
BMC Cancer | 2014 |
Influence of the Implantation Site on the Sensitivity of Patient Pancreatic Tumor Xenografts to Apo2L/TRAIL Therapy:
R Sharma, S Buitrago, R Pitoniak, JF Gibbs, L Curtin, M Seshadri, EA Repasky, BL Hylander |
Pancreas | 2014 |
Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis
ÁC Murphy, B Weyhenmeyer, J Noonan, SM Kilbride, S Schimansky, KP Loh, D Kögel, AG Letai, JH Prehn, BM Murphy |
Apoptosis | 2014 |
Exercise-induced lung cancer regression: Mechanistic findings from a mouse model: Exercise and Lung Cancer
KA Higgins, D Park, GY Lee, WJ Curran, X Deng |
Cancer | 2014 |
The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma
IA van Roosmalen, CR Reis, R Setroikromo, S Yuvaraj, JV Joseph, PG Tepper, FA Kruyt, WJ Quax |
SpringerPlus | 2014 |
Multi-layered nanoparticles for combination gene and drug delivery to tumors
A Ediriwickrema, J Zhou, Y Deng, WM Saltzman |
Biomaterials | 2014 |
Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2
U Bertsch, C Röder, H Kalthoff, A Trauzold |
Cell Death and Disease | 2014 |
Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells
M Horinaka, T Yoshida, M Tomosugi, S Yasuda, Y Sowa, T Sakai |
Scientific Reports | 2014 |
Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4
ML Bychkov, ME Gasparian, DA Dolgikh, MP Kirpichnikov, SA Rizza |
PloS one | 2014 |
A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells
E Kobayashi, H Kishi, T Ozawa, H Hamana, H Nakagawa, A Jin, Z Lin, A Muraguchi |
Biochemical and Biophysical Research Communications | 2014 |
Sensitization of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Resistant Primary Prostate Cancer Cells by Isoegomaketone from Perilla frutescens
JH Lee, HD Cho, IY Jeong, MK Lee, KI Seo |
Journal of Natural Products | 2014 |
Anti-breast cancer activity of Fine Black ginseng (Panax ginseng Meyer) and ginsenoside Rg5
SJ Kim, AK Kim |
Journal of Ginseng Research | 2014 |
Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells
W Zhou, A Cao, L Wang, D Wu |
Cell Biochemistry and Biophysics | 2014 |
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer
R Yu, SM Albarenque, RH Cool, WJ Quax, A Mohr, RM Zwacka |
Cancer biology & therapy | 2014 |
RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages
Z Yao, P Zhang, H Guo, J Shi, S Liu, Y Liu, D Zheng |
Molecular Oncology | 2014 |
Potential Application of Temozolomide in Mesenchymal Stem Cell-Based TRAIL Gene Therapy Against Malignant Glioma
SM Kim, JS Woo, CH Jeong, CH Ryu, JD Jang, SS Jeun |
Stem Cells Translational Medicine | 2014 |
Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies
JR Foster, G Lund, S Sapelnikova, DL Tyrrell, NM Kneteman |
Xenobiotica | 2014 |
Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma:
G Pasello, L Urso, M Silic-Benussi, M Schiavon, I Cavallari, G Marulli, N Nannini, F Rea, V Ciminale, A Favaretto |
Journal of Thoracic Oncology | 2014 |
Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model
HJ Byeon, SH Choi, JS Choi, TH Kim, ES Lee, KC Lee, YS Youn |
Biomedicine & Pharmacotherapy | 2014 |
ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34
MH Park, SY Kim, YJ Kim, YH Chung |
Biochemical and Biophysical Research Communications | 2014 |
Cancer therapeutics: Targeting the apoptotic pathway
KH Khan, M Blanco-Codesido, LR Molife |
Critical Reviews in Oncology/Hematology | 2014 |
Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter
C Yan, M Yang, Z Li, S Li, X Hu, D Fan, Y Zhang, J Wang, D Xiong |
Biomaterials | 2014 |
Pharmacophore Reassignment for Induction of the Immunosurveillance Cytokine TRAIL
NT Jacob, JW Lockner, VV Kravchenko, KD Janda |
Angewandte Chemie | 2014 |
GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial
J Jiang, X Liu, L Deng, P Zhang, G Wang, S Wang, H Liu, Y Su |
European Journal of Pharmacology | 2014 |
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
J Pawel, JH Harvey, DR Spigel, M Dediu, M Reck, CL Cebotaru, RC Humphreys, MJ Gribbin, NL Fox, DR Camidge |
Clinical Lung Cancer | 2014 |
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
XW Meng, BD Koh, JS Zhang, KS Flatten, PA Schneider, DD Billadeau, AD Hess, BD Smith, JE Karp, SH Kaufmann |
The Journal of biological chemistry | 2014 |
Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer
S Lv, X Wang, N Zhang, M Sun, W Qi, Y Li, Q Yang |
International journal of oncology | 2014 |
Pathobiology of Human Disease
S Akilesh |
Pathobiology of Human Disease | 2014 |
Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells
HO Jin, YH Lee, JA Park, HN Lee, JH Kim, JY Kim, BR Kim, SE Hong, HA Kim, EK Kim, WC Noh, JI Kim, YH Chang, SI Hong, YJ Hong, IC Park, JK Lee |
Journal of Cancer Research and Clinical Oncology | 2014 |
Sandwich-Type Au-PEI/DNA/PEI-Dexa Nanocomplex for Nucleus-Targeted Gene Delivery in Vitro and in Vivo
Z Chen, L Zhang, Y He, Y Li |
ACS Applied Materials & Interfaces | 2014 |
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
JD Graves, JJ Kordich, TH Huang, J Piasecki, TL Bush, T Sullivan, IN Foltz, W Chang, H Douangpanya, T Dang, JW O’Neill, R Mallari, X Zhao, DG Branstetter, JM Rossi, AM Long, X Huang, PM Holland |
Cancer Cell | 2014 |
Anisomycin, an Inhibitor of Protein Synthesis, Overcomes TRAIL Resistance in Human Hepatocarcinoma Cells via Caspases Activation and Bid Downregulation
CY Jin, C Park, SH Hong, YH Choi |
Journal of Life Science | 2014 |
Caspase-8 as a regulator of tumor cell motility
R P Graf, N Keller, S Barbero, D Stupack |
Current molecular medicine | 2014 |
Caspase-8 as a Regulator of Tumor Cell Motility
Ryon P. Graf, Nadine Keller, Simone Barbero, Dwayne Stupack |
Current molecular medicine | 2014 |
Effects of TNF Secreting HEK Cells on B Lymphocytes' Apoptosis in Human Chronic Lymphocytic Leukemias
A Valizadeh, A Ahmadzadeh, A Teimoori, A Khodadadi, G Saki |
Asian Pacific Journal of Cancer Prevention | 2014 |
RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages
Z Yao, P Zhang, H Guo, J Shi, S Liu, Y Liu, D Zheng |
Molecular Oncology | 2014 |
TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer
K Zhu, W Fang, Y Chen, S Lin, X Chen |
Oncology reports | 2014 |
Production of functional native human interleukin-2 in tobacco chloroplasts.
Zhang XH, Keating P, Wang XW, Huang YH, Martin J, Hartmann JX, Liu A |
Molecular Biotechnology | 2014 |
Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells.
Jin HO, Lee YH, Park JA, Lee HN, Kim JH, Kim JY, Kim B, Hong SE, Kim HA, Kim EK, Noh WC, Kim JI, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK |
Journal of Cancer Research and Clinical Oncology | 2014 |
Plant Sterols as Anticancer Nutrients: Evidence for Their Role in Breast Cancer
B Grattan |
Nutrients | 2013 |
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy
F Qiu, M Hu, B Tang, X Liu, H Zhuang, J Yang, ZC Hua |
Scientific Reports | 2013 |
Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
T Adachi, N Sugiyama, T Gondai, H Yagita, T Yokoyama |
ACTA HISTOCHEMICA ET CYTOCHEMICA | 2013 |
Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb
M Kouno, C Lin, NM Schechter, D Siegel, X Yang, JT Seykora, JR Stanley |
Journal of Investigative Dermatology | 2013 |
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family
K Azijli, B Weyhenmeyer, GJ Peters, S Jong, FA Kruyt |
Cell Death and Differentiation | 2013 |
Small-Molecule IAP Antagonists Sensitize Cancer Cells to TRAIL-Induced Apoptosis: Roles of XIAP and cIAPs
D Finlay, M Vamos, M Gonzalez-Lopez, RJ Ardecky, SR Ganji, H Yuan, Y Su, TR Cooley, CT Hauser, K Welsh, JC Reed, ND Cosford, K Vuori |
Molecular cancer therapeutics | 2013 |
Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth
A Aronin, S Amsili, TB Prigozhina, K Tzdaka, J Rachmilewitz, N Shani, ML Tykocinski, MD Elhalel |
PloS one | 2013 |
The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer
N Zhang, X Wang, Q Huo, X Li, H Wang, P Schneider, G Hu, Q Yang |
The Journal of biological chemistry | 2013 |
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
JE Allen, G Krigsfeld, PA Mayes, L Patel, DT Dicker, AS Patel, NG Dolloff, E Messaris, KA Scata, W Wang, JY Zhou, GS Wu, WS El-Deiry |
Science Translational Medicine | 2013 |
Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential
K Takahashi, K Takeda, I Saiki, T Irimura, Y Hayakawa |
Cancer Science | 2013 |
Facilitating Cytokine-Mediated Cancer Cell Death by Proteobacterial N -Acylhomoserine Lactones
V Kravchenko, AL Garner, J Mathison, A Seit-Nebi, J Yu, IP Gileva, R Ulevitch, KD Janda |
ACS chemical biology | 2013 |
Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand
NS Azahri, MM Kavurma |
Cellular and Molecular Life Sciences | 2013 |
Real-time detection of cellular death receptor-4 activation by fluorescence resonance energy transfer
Z Dereli-Korkut, H Gandhok, LG Zeng, S Waqas, X Jiang, S Wang |
Biotechnology and Bioengineering | 2013 |
Fluid shear stress sensitizes cancer cells to receptor-mediated apoptosis via trimeric death receptors
MJ Mitchell, MR King |
New Journal of Physics | 2013 |
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects
R Yu, L Deedigan, SM Albarenque, A Mohr, RM Zwacka |
Cell Death and Disease | 2013 |
The Synergistic Apoptotic Interaction of Indole-3-Carbinol and Genistein with TRAIL on Endometrial Cancer Cells
B Parajuli, SJ Shin, SH Kwon, SD Cha, HG Lee, I Bae, CH Cho |
Journal of Korean Medical Science | 2013 |
TRAIL on trial: preclinical advances in cancer therapy
DW Stuckey, K Shah |
Trends in Molecular Medicine | 2013 |
Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer
W Zhu, H Zhang, Y Shi, M Song, B Zhu, L Wei |
Cancer biology & therapy | 2013 |
Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine
P Sridevi, MK Nhiayi, RL Setten, JY Wang |
PloS one | 2013 |
Down-regulation of RIP1 by 2-deoxy-D-glucose sensitizes breast cancer cells to TRAIL-induced apoptosis
YY Huang, H Liu, Y Li, LJ Pu, CC Jiang, JC Xu, ZW Jiang |
European Journal of Pharmacology | 2013 |
Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins
L Yang, Q Wang, D Li, Y Zhou, X Zheng, H Sun, J Yan, L Zhang, Y Lin, X Wang |
Apoptosis | 2013 |
Resistance of cancer cells to the TRAIL-induced apoptosis in confluent cultures
RS Fadeev, AV Chekanov, NV Dolgikh, VS Akatov |
Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology | 2013 |
PMN and anti-tumor immunity—The case of bladder cancer immunotherapy
EL Brincks, MC Risk, TS Griffith |
Seminars in Cancer Biology | 2013 |
Fabrication of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/ALG modified CaCO3 as drug carriers with the function of tumor selective recognition
W Cui, Y Cui, J Zhao, J Li |
Journal of Materials Chemistry B | 2013 |
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib
K Wahl, M Siegemund, F Lehner, F Vondran, A Nüssler, F Länger, T Krech, R Kontermann, MP Manns, K Schulze-Osthoff, K Pfizenmaier, H Bantel |
Hepatology | 2013 |
Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential
K Takahashi, K Takeda, I Saiki, T Irimura, Y Hayakawa |
Cancer Science | 2013 |
Targeting apoptosis pathways in glioblastoma
G Eisele, M Weller |
Cancer Letters | 2013 |
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells
A Giacomini, M Righi, L Cleris, SL Locatelli, S Mitola, MG Daidone, AM Gianni, C Carlo-Stella |
Angiogenesis | 2013 |
Tissue decellularization by activation of programmed cell death
PE Bourgine, BE Pippenger, A Todorov, L Tchang, I Martin |
Biomaterials | 2013 |
Cytotherapies in multiple myeloma: a complementary approach to current treatments?
S Ciavarella, A Caselli, A Savonarola, AV Tamma, M Tucci, F Silvestris |
Expert Opinion on Biological Therapy | 2013 |
Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation
MJ Yoon, YJ Kang, IY Kim, EH Kim, JA Lee, JH Lim, TK Kwon, KS Choi |
Carcinogenesis | 2013 |
Inhibition of vacuolar ATPase attenuates the TRAIL-induced activation of caspase-8 and modulates the trafficking of TRAIL receptosomes
V Horova, N Hradilova, I Jelinkova, M Koc, J Svadlenka, J Brazina, M Klima, J Slavik, AH Vaculova, L Andera |
FEBS Journal | 2013 |
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins
S Park, DH Cho, L Andera, N Suh, I Kim |
Molecular and Cellular Biochemistry | 2013 |
The TRAIL of oncogenes to apoptosis: Oncogenes, TRAIL and Apoptosis for Cancer Therapy
E Oikonomou, A Pintzas |
BioFactors | 2013 |
Stem Cell Therapeutics for Cancer: Shah/Stem Cell Therapeutics for Cancer
A Pessina, A Bonomi, E Parati, R Pallini, G Alessandri |
Stem Cell Therapeutics for Cancer: Shah/Stem Cell Therapeutics for Cancer | 2013 |
Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
LQ Pan, HB Wang, J Lai, YC Xu, C Zhang, SQ Chen |
Biomaterials | 2013 |
Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis
T He, S Haapa-Paananen, VO Kaminskyy, P Kohonen, V Fey, B Zhivotovsky, O Kallioniemi, M Perälä |
Oncogene | 2013 |
Targeting apoptosis pathways in cancer stem cells
M Signore, L Ricci-Vitiani, RD Maria |
Cancer Letters | 2013 |
Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer
HJ Byeon, SH Choi, JS Choi, I Kim, BS Shin, ES Lee, ES Park, KC Lee, YS Youn |
Acta Biomaterialia | 2013 |
A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
ZA Wainberg, WA Messersmith, PF Peddi, AV Kapp, A Ashkenazi, S Royer-Joo, CC Portera, MF Kozloff |
Clinical Colorectal Cancer | 2013 |
Aortic valvular interstitial cells apoptosis and calcification is mediated by TNF-related apoptosis-inducing ligand
A Galeone, G Brunetti, A Oranger, G Greco, AD Benedetto, G Mori, S Colucci, A Zallone, D Paparella, M Grano |
International Journal of Cardiology | 2013 |
Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and 1 H MR spectroscopy: MRI/MRS of Breast Tumor Xenografts
G Zhai, H Kim, D Sarver, S Samuel, L Whitworth, H Umphrey, DK Oelschlager, TM Beasley, KR Zinn |
Journal of Magnetic Resonance Imaging | 2013 |
Polyphenols Isolated from Propolis Augment TRAIL-Induced Apoptosis in Cancer Cells
E Szliszka, W Krol |
Evidence-Based Complementary and Alternative Medicine | 2013 |
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
J Lemke, S Karstedt, MA el Hay, A Conti, F Arce, A Montinaro, K Papenfuss, MA El-Bahrawy, H Walczak |
Cell Death and Differentiation | 2013 |
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
A Meijer, FA Kruyt, AG van der Zee, H Hollema, P Le, KA Hoor, GM Groothuis, WJ Quax, EG de Vries, S Jong |
British Journal of Cancer | 2013 |
Ethanolic Extract of Polish Propolis: Chemical Composition and TRAIL-R2 Death Receptor Targeting Apoptotic Activity against Prostate Cancer Cells
E Szliszka, A Sokół-Łętowska, AZ Kucharska, D Jaworska, ZP Czuba, W Król |
Evidence-Based Complementary and Alternative Medicine | 2013 |
Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis
B Bonavida, A Jazirehi, MI Vega, S Huerta-Yepez, S Baritaki |
Forum on immunopathological diseases and therapeutics | 2013 |
Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27
G Mellier, D Liu, G Bellot, AL Holme, S Pervaiz |
Cell Death and Disease | 2013 |
Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker
A Krieg, S Mersch, N Wolf, NH Stoecklein, PE Verde, JS 2nd, S Heikaus, HE Gabbert, WT Knoefel, C Mahotka |
BMC Cancer | 2013 |
Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
M Dijk, A Halpin-McCormick, T Sessler, A Samali, E Szegezdi |
Cell Death and Disease | 2013 |
Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy
Y Zheng, H Chen, X Zeng, Z Liu, X Xiao, Y Zhu, D Gu, L Mei |
Nanoscale research letters | 2013 |
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer
B Lim, A Scicchitano, C Beachler, N Gusani, N Sarwani, Z Yang, K Staveley-O’Carroll, A Ashkenazi, C Portera, WS El-Deiry |
Cancer biology & therapy | 2013 |
Manipulating the apoptotic pathway: potential therapeutics for cancer patients
DJ Bates, LD Lewis |
British Journal of Clinical Pharmacology | 2013 |
Death receptors as targets in cancer
O Micheau, S Shirley, F Dufour |
British Journal of Pharmacology | 2013 |
Down-Modulation of Expression, or Dephosphorylation, of IG20/MADD in Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Resistant Thyroid Cancer Cells Makes Them Susceptible to Treatment with This Ligand
LC Li, S Jayarama, T Pilli, L Qian, F Pacini, BS Prabhakar |
Thyroid | 2013 |
Targeted Therapies in Oncology, Second Edition
JY Blay, A Dufresne, O Derbel, I Ray-Coquard |
Targeted Therapies in Oncology, Second Edition | 2013 |
Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity
E Riddick, S Evans, J Rousch, E Gwebu, HN Banerjee |
Journal of Solid Tumors | 2013 |
Azadirone, a Limonoid Tetranortriterpene, Induces Death Receptors and Sensitizes Human Cancer Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) through a p53 Protein-independent Mechanism: EVIDENCE FOR THE ROLE OF THE ROS-ERK-CHOP-DEATH RECEPTOR PATHWAY
SC Gupta, SK Francis, MS Nair, YY Mo, BB Aggarwal |
The Journal of biological chemistry | 2013 |
Increased Serum S-TRAIL Level in Newly Diagnosed Stage-IV Lung Adenocarcinoma but not Squamous Cell Carcinoma is Correlated with Age and Smoking
A Kargi, A Bisgin, AD Yalcin, AB Kargi, E Sahin, S Gumuslu |
Asian Pacific Journal of Cancer Prevention | 2013 |
Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells
P Xia, W Wang, Y Bai |
Apoptosis | 2013 |
Production of Functional Native Human Interleukin-2 in Tobacco Chloroplasts
XH Zhang, P Keating, XW Wang, YH Huang, J Martin, JX Hartmann, A Liu |
Molecular Biotechnology | 2013 |
The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases
R Liu, X Ma, H Wang, Y Xi, M Qian, W Yang, D Luo, L Fan, X Xia, J Zhou, L Meng, S Wang, D Ma, L Xi |
Journal of Molecular Medicine | 2013 |
Antibody-Free LC-MS/MS Quantification of rhTRAIL in Human and Mouse Serum
D Wilffert, CR Reis, J Hermans, N Govorukhina, T Tomar, S Jong, WJ Quax, NC van de Merbel, R Bischoff |
Analytical Chemistry | 2013 |
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance
AR Jazirehi, D Arle |
American Journal of Clinical and Experimental Immunology | 2013 |
AXL mediates TRAIL resistance in esophageal adenocarcinoma
J Hong, A Belkhiri |
Neoplasia (New York, N.Y.) | 2013 |
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
H Walczak |
Cold Spring Harbor perspectives in biology | 2013 |
Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5
X Di, G Zhang, Y Zhang, K Takeda, LA Rosado, B Zhang |
Oncotarget | 2013 |
TRAIL induces apoptosis in oral squamous carcinoma cells: a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5
J Chen, CM Mikelis, Y Zhang, JS Gutkind, B Zhang |
Oncotarget | 2013 |
Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance
SA Maxwell, S Mousavi-Fard |
Experimental biology and medicine (Maywood, N.J.) | 2013 |
Persistent Inhibition of ABL Tyrosine Kinase Causes Enhanced Apoptotic Response to TRAIL and Disrupts the Pro-Apoptotic Effect of Chloroquine
P Sridevi, MK Nhiayi, RL Setten, JY Wang, A Villunger |
PloS one | 2013 |
Fn14•Trail Effectively Inhibits Hepatocellular Carcinoma Growth
A Aronin, S Amsili, TB Prigozhina, K Tzdaka, J Rachmilewitz, N Shani, ML Tykocinski, MD Elhalel, T Takehara |
PloS one | 2013 |
Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma
C KARLISCH, K HARATI, A Chromik, D BULUT, L Klein-Hitpass, O GOERTZ, T HIRSCH, M LEHNHARDT, W UHL, A DAIGELER |
International journal of oncology | 2013 |
Peroxisome proliferator-activated receptor γ ligand troglitazone and TRAIL synergistically induce apoptosis
M Koyama, Y Sowa, M Horinaka, AE Goda, J Fujiwara, T Sakai |
Oncology reports | 2013 |
Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy
KI Pishas, SJ Neuhaus, MT Clayer, A Adwal, MP Brown, A Evdokiou, DF Callen, PM Neilsen |
Oncology reports | 2013 |
CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells
EY Kim, JH Ryu, AK Kim |
International journal of oncology | 2013 |
Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation
M Todo, M Horinaka, M Tomosugi, R Tanaka, H Ikawa, Y Sowa, H Ishikawa, H Fujiwara, E Otsuji, T Sakai |
Oncology reports | 2013 |
Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes
J Pospisilova, O Vit, L Lorkova, M Klanova, J Zivny, P Klener, J Petrak |
International journal of molecular medicine | 2013 |
Analysis of oncology research from 2001 to 2010: A scientometric perspective
H Shao, QI YU, X Bo, Z Duan |
Oncology reports | 2013 |
Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8
M Shinnoh, M Horinaka, T Yasuda, S Yoshikawa, M Morita, T Yamada, T Miki, T Sakai |
International journal of oncology | 2013 |
Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein
Y Han, S Park, AW Kinyua, L Andera, KW Kim, I Kim |
Oncology reports | 2013 |
Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells
X Liu, J Wang, H Wang, S Liu, YE LIANG, Z Lv, Q Zhou, W Ding |
Oncology reports | 2013 |
Cancer Targeted Drug Delivery
YH Bae, RJ Mrsny, K Park |
2013 | |
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
B Bonavida |
2013 | |
Role of Capsaicin in Oxidative Stress and Cancer
SK Srivastava |
2013 | |
TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
Chen JJ, Mikelis CM, Zhang Y, Gutkind JS, Zhang B |
Oncotarget | 2013 |
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
Park S, Cho DH, Andera L, Suh N, Kim I |
Molecular and Cellular Biochemistry | 2013 |
The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases.
Liu R, Ma X, Wang H, Xi Y, Qian M, Yang W, Luo D, Fan L, Xia X, Zhou J, Meng L, Wang S, Ma D, Xi L |
Journal of Molecular Medicine | 2013 |
The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells
BI Koh, Y Kang |
EMBO reports | 2012 |
Epirubicin potentiates recombinant adeno-associated virus type 2/5-mediated TRAIL expression in fibroblast-like synoviocytes and augments the antiarthritic effects of rAAV2/5-TRAIL
J Shi, Z Diao, J Zhou, J Zhu, H Yuan, X You, Y Liu, D Zheng |
Arthritis & Rheumatism | 2012 |
TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what’s new?
A Neve, A Corrado, FP Cantatore |
Clinical and Experimental Medicine | 2012 |
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
S Jouan-Lanhouet, MI Arshad, C Piquet-Pellorce, C Martin-Chouly, GL Moigne-Muller, FV Herreweghe, N Takahashi, O Sergent, D Lagadic-Gossmann, P Vandenabeele, M Samson, MT Dimanche-Boitrel |
Cell Death and Differentiation | 2012 |
Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth
BR James, A Tomanek-Chalkley, EJ Askeland, T Kucaba, TS Griffith, LA Norian |
Journal of immunology (Baltimore, Md. : 1950) | 2012 |
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to TRAIL-Induced Apoptosis
S Mamaghani, CD Simpson, PM Cao, M Cheung, S Chow, B Bandarchi, AD Schimmer, DW Hedley |
PloS one | 2012 |
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist
V Subbiah, RE Brown, J Buryanek, J Trent, A Ashkenazi, R Herbst, R Kurzrock |
Molecular cancer therapeutics | 2012 |
Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma
D Toiyama, N Takaha, M Shinnoh, T Ueda, Y Kimura, T Nakamura, F Hongo, K Mikami, K Kamoi, A Kawauchi, T Miki |
Molecular and Clinical Oncology | 2012 |
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
LY Dimberg, CK Anderson, R Camidge, K Behbakht, A Thorburn, HL Ford |
Oncogene | 2012 |
Apigenin Sensitizes Huh-7 Human Hepatocellular Carcinoma Cells to TRAIL-induced Apoptosis
EY Kim, AK Kim |
Biomolecules and Therapeutics | 2012 |
Effect of Smac on TRAIL-induced apoptosis of prostate cancer cell line PC-3 and the molecular mechanism
M Wang, T Huang, F Zeng, G Jiang, L Wang, L Zheng, Q Tong |
Journal of Huazhong University of Science and Technology [Medical Sciences] | 2012 |
Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer
C Stolfi, F Pallone, G Monteleone |
International journal of molecular sciences | 2012 |
Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL*
E Szegezdi, AM van der Sloot, D Mahalingam, L O'Leary, RH Cool, IG Muñoz, G Montoya, WJ Quax, S Jong, A Samali, L Serrano |
Molecular & cellular proteomics : MCP | 2012 |
The Transmembrane Domains of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Receptors 1 and 2 Co-Regulate Apoptotic Signaling Capacity
S Neumann, T Bidon, M Branschädel, A Krippner-Heidenreich, P Scheurich, M Doszczak |
PloS one | 2012 |
Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer
L Guo, L Fan, J Ren, Z Pang, Y Ren, J Li, Z Wen, Y Qian, L Zhang, H Ma, X Jiang |
International Journal of Nanomedicine | 2012 |
Mesenchymal Stem Cell-Based Tumor-Targeted Gene Therapy in Gastrointestinal Cancer
Q Bao, Y Zhao, H Niess, C Conrad, B Schwarz, KW Jauch, R Huss, PJ Nelson, CJ Bruns |
Stem Cells and Development | 2012 |
Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo
S Vitovski, AD Chantry, MA Lawson, PI Croucher |
PloS one | 2012 |
PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting
TH Kim, YG Jo, HH Jiang, SM Lim, YS Youn, S Lee, X Chen, Y Byun, KC Lee |
Journal of Controlled Release | 2012 |
Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation
C Qiao, M Hu, L Guo, M Lv, Z Lin, J Geng, X Lang, X Li, Y Li, Y Ma, J Feng, B Shen |
BMC Immunology | 2012 |
Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice
L Zheng, Z Weilun, J Minghong, Z Yaxi, L Shilian, L Yanxin, Z Dexian |
BMC Cancer | 2012 |
Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells
K Kajitani, Y Tanaka, K Arihiro, T Kataoka, H Ohdan |
Breast Cancer Research and Treatment | 2012 |
An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation
BS Lee, SU Kang, HS Hwang, YS Kim, ES Sung, YS Shin, YC Lim, CH Kim |
Cancer Letters | 2012 |
In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells
S Ciavarella, G Grisendi, M Dominici, M Tucci, O Brunetti, F Dammacco, F Silvestris |
British Journal of Haematology | 2012 |
Isoobtusilactone A Sensitizes Human Hepatoma Hep G2 Cells to TRAIL-Induced Apoptosis via ROS and CHOP-Mediated Up-regulation of DR5
CY Chen, SJ Yiin, JL Hsu, WC Wang, SC Lin, CL Chern |
Journal of Agricultural and Food Chemistry | 2012 |
Apoptosis-Modulating Drugs for Improved Cancer Therapy
M Ocker, M Höpfner |
European Surgical Research | 2012 |
Novel targeted agents for the treatment of advanced breast cancer
M la Vega, E Díaz-Cantón, RH Alvarez |
Future Medicinal Chemistry | 2012 |
The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: what is next?
AC Bellail, C Hao |
Expert Review of Anticancer Therapy | 2012 |
Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy
Y Cai, X Liu, W Huang, K Zhang, X Liu |
Acta Biochimica et Biophysica Sinica | 2012 |
Mesenchymal Stem Cells as a Novel Carrier for Targeted Delivery of Gene in Cancer Therapy Based on Nonviral Transfection
YL Hu, B Huang, TY Zhang, PH Miao, GP Tang, Y Tabata, JQ Gao |
Molecular Pharmaceutics | 2012 |
The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells
HY Tseng, LH Chen, Y Ye, KH Tay, CC Jiang, ST Guo, L Jin, P Hersey, XD Zhang |
Carcinogenesis | 2012 |
Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth
NS Wilson, A Yang, B Yang, S Couto, H Stern, A Gogineni, R Pitti, S Marsters, RM Weimer, M Singh, A Ashkenazi |
Cancer Cell | 2012 |
Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization
SM Woo, K Min, TK Kwon |
Apoptosis | 2012 |
Antibody–cytokine fusion proteins
RE Kontermann |
Archives of Biochemistry and Biophysics | 2012 |
Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?
LH Wilt, J Kroon, G Jansen, S Jong, GJ Peters, FA Kruyt |
Critical Reviews in Oncology/Hematology | 2012 |
Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
J Molinsky, M Klanova, M Koc, L Beranova, L Andera, Z Ludvikova, M Bohmova, Z Gasova, M Strnad, R Ivanek, M Trneny, E Necas, J Zivny, P Klener |
Leukemia & Lymphoma | 2012 |
Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle–mediated gene expression
L Miao, K Zhang, C Qiao, X Jin, C Zheng, B Yang, H Sun |
Nanomedicine: Nanotechnology, Biology and Medicine | 2012 |
The three Rs along the TRAIL: Resistance, re-sensitization and reactive oxygen species (ROS)
G Mellier, S Pervaiz |
Free Radical Research | 2012 |
Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors
X Zhang, T Inukai, K Hirose, K Akahane, I Kuroda, H Honna-Oshiro, K Kagami, K Goi, K Nakamura, M Kobayashi, M Endo, H Yagita, H Kurosawa, AT Look, H Honda, T Inaba, S Nakazawa, K Sugita |
Leukemia | 2012 |
Translating TRAIL-receptor targeting agents to the clinic
MW Hollander, JA Gietema, S Jong, AM Walenkamp, AK Reyners, CN Oldenhuis, EG de Vries |
Cancer Letters | 2012 |
Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats
Y Zou, X Zhang, Y Mao, M Huang, B Yuan, Z Chu, G Lu |
Regulatory Toxicology and Pharmacology | 2012 |
Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner
DO Moon, Y Asami, H Long, JH Jang, EY Bae, BY Kim, YH Choi, CH Kang, JS Ahn, GY Kim |
Toxicology in Vitro | 2012 |
TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis
Z Diao, J Shi, J Zhu, H Yuan, Q Ru, S Liu, Y Liu, D Zheng |
Cancer Immunology, Immunotherapy | 2012 |
PRMT5 suppresses DR4-mediated CCL20 release via NF-κB pathway
DS Wang, D Liu, J Gao, M Liu, SL Liu, YX Liu, DX Zheng |
Chinese Science Bulletin | 2012 |
Increase in resistance of A431 cancer cells to TRAIL-induced apoptosis in confluent cultures
RS Fadeev, AV Chekanov, NV Dolgikh, VS Akatov |
Biophysics | 2012 |
Human Umbilical Cord Mesenchymal Stem Cells as Vehicles of CD20-specific TRAIL Fusion Protein Delivery: a Double-target Therapy against non-Hodgkin’s Lymphoma
D Xiong, S Li, Z Li, H Peng, X Yuan, L Jiang, Y Zhang, D Fan, X Hu, D Xiong, M Yang |
Molecular Pharmaceutics | 2012 |
Bax is Essential for Death Receptor-Mediated Apoptosis in Human Colon Cancer Cells
S Zhu, T Li, J Tan, X Yan, D Zhang, C Zheng, Y Chen, Z Xiang, H Cui |
Cancer Biotherapy & Radiopharmaceuticals | 2012 |
Synergistic induction of TRAIL-mediated apoptosis by anisomycin in human hepatoma cells via the BH3-only protein Bid and c-Jun/AP-1 signaling pathway
CY Jin, C Park, SH Hong, MH Han, JW Jeong, HD Xu, HM Liu, GY Kim, WJ Kim, YH Yoo, YH Choi |
Biomedicine & Pharmacotherapy | 2012 |
Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1
BR Seo, K Min, S Kim, JW Park, WK Park, TJ Lee, TK Kwon |
Biochimie | 2012 |
Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma
JS Woo, SM Kim, CH Jeong, CH Ryu, SS Jeun |
Biochemical and Biophysical Research Communications | 2012 |
Inhibition of SIRT1 Sensitizes TRAIL-Resistant MCF-7 Cells by Upregulation of DR5 and Inhibition of c-FLIP
SH Lee, HB Kim, MJ Kim, JW Lee, JH Bae, DW Kim, CD Kang, SH Kim |
Journal of Life Science | 2012 |
Hyperthermia Promotes Apoptosis and Suppresses Invasion in C6 Rat Glioma Cells
DC Wang, Y Zhang, HY Chen, XL Li, LJ Qin, YJ Li, HY Zhang, S Wang |
Asian Pacific Journal of Cancer Prevention | 2012 |
A Novel Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells
F Valen, H Harrer, M Hotfilder, U Dirksen, T Pap, G Gosheger, HU Humpf, H Jürgens |
Sarcoma | 2012 |
HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells
DM Pineda, DW Rittenhouse, CC Valley, JA Cozzitorto, RA Burkhart, B Leiby, JM Winter, MC Weber, ER Londin, I Rigoutsos, CJ Yeo, M Gorospe, AK Witkiewicz, JN Sachs, JR Brody |
Cancer biology & therapy | 2012 |
Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies
EW Duiker, EC Dijkers, HL Heerspink, S Jong, AG van der Zee, PL Jager, JG Kosterink, EG de Vries, MN Hooge |
British Journal of Pharmacology | 2012 |
Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins
VR Yadav, S Prasad, BB Aggarwal |
British Journal of Pharmacology | 2012 |
ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2
R Martín-Pérez, M Niwa, A López-Rivas |
Apoptosis | 2012 |
Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells
JJ Chen, HC Shen, LA Rosado, Y Zhang, X Di, B Zhang |
Oncotarget | 2012 |
TRAIL apoptotic pathway-targeted therapies for NSCLC
Anita C Bellail, Chunhai Hao |
Translational Lung Cancer Research | 2012 |
Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo
S Vitovski, AD Chantry, MA Lawson, PI Croucher, C Bunce |
PloS one | 2012 |
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to TRAIL-Induced Apoptosis
S Mamaghani, CD Simpson, PM Cao, M Cheung, S Chow, B Bandarchi, AD Schimmer, DW Hedley, SB Bratton |
PloS one | 2012 |
Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL
E Szegezdi, AM van der Sloot, D Mahalingam, L O'Leary, RH Cool, IG Muñoz, G Montoya, WJ Quax, S Jong, A Samali, L Serrano |
Molecular & cellular proteomics : MCP | 2012 |
Differential susceptibility of gastric cancer cells to TRAIL-induced apoptosis
NM Song, S Jun, DY Zang, SG Kim, HR Park, D Kang |
Oncology reports | 2012 |
Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo
H Zhang, A Sui, Z Wang, S Liu, R Yao |
International journal of molecular medicine | 2012 |
Tagged and untagged TRAIL show different activity against tumor cells
K Zhao, Y Wang, X Wang, Y Wang, Y Ma |
Oncology Letters | 2012 |
Information Technology and Agricultural Engineering
E Zhu, S Sambath |
2012 | |
Nutrition, Diet and Cancer
S Shankar, RK Srivastava |
2012 | |
TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4(+)CD25 (+) Treg apoptosis.
Diao Z, Shi J, Zhu J, Yuan H, Ru Q, Liu S, Liu Y, Zheng D |
Cancer Immunology, Immunotherapy | 2012 |
2A Peptide-based, Lentivirus-mediated Anti-death Receptor 5 Chimeric Antibody Expression Prevents Tumor Growth in Nude Mice
M Li, Y Wu, Y Qiu, Z Yao, S Liu, Y Liu, J Shi, D Zheng |
Molecular Therapy | 2011 |
Osteoprotegerin (OPG) and Related Proteins (RANK, RANKL and TRAIL) in Thyroid Disease
SK Sood, S Balasubramanian, S Higham, M Fernando, B Harrison |
World Journal of Surgery | 2011 |
KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels
D Llobet, N Eritja, M Domingo, L Bergada, C Mirantes, M Santacana, J Pallares, A Macià, A Yeramian, M Encinas, G Moreno-Bueno, J Palacios, RE Lewis, X Matias-Guiu, X Dolcet |
The American Journal of Pathology | 2011 |
Role of TLR2-dependent inflammation in metastatic progression
S Kim, M Karin |
Annals of the New York Academy of Sciences | 2011 |
Volatile Anesthetics Protect Cancer Cells against Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis via Caveolins
Y Kawaraguchi, YT Horikawa, AN Murphy, F Murray, A Miyanohara, SS Ali, BP Head, PM Patel, DM Roth, HH Patel |
Anesthesiology | 2011 |
Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis
V Kedinger, S Muller, H Gronemeyer |
Molecular Cancer | 2011 |
TNF related apoptosis-inducing ligand and its receptors in ocular tumors
Q Ning, L Hou, M Meng, BR Pan, XH Zhao |
International Journal of Ophthalmology | 2011 |
Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
S Shirley, A Morizot, O Micheau |
Recent Patents on Anti-Cancer Drug Discovery | 2011 |
The therapeutic potential of TRAIL receptor signalling in cancer cells
R Yerbes, C Palacios, A López-Rivas |
Clinical and Translational Oncology | 2011 |
Combined modality therapy with TRAIL or agonistic death receptor antibodies
HM Amm, PG Oliver, CH Lee, Y Li, DJ Buchsbaum |
Cancer biology & therapy | 2011 |
Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells
HM Amm, T Zhou, AD Steg, H Kuo, Y Li, DJ Buchsbaum |
Molecular cancer research : MCR | 2011 |
Modulation of CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)-dependent DR5 Expression by Nelfinavir Sensitizes Glioblastoma Multiforme Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)*
X Tian, J Ye, M Alonso-Basanta, SM Hahn, C Koumenis, JF Dorsey |
The Journal of biological chemistry | 2011 |
Encyclopedia of Life Sciences
B Dahlbäck |
Encyclopedia of Life Sciences | 2011 |
Oxidative Stress and Disease
I Paur, M Carlsen, B Halvorsen, R Blomhoff |
Herbal Medicine | 2011 |
The scavenging of superoxide radicals promotes apoptosis induced by a novel cell-permeable fusion protein, sTRAIL:FeSOD, in tumor necrosis factor-related apoptosis-inducing ligand-resistant leukemia cells
H Tang, Y Qin, J Li, X Gong |
BMC Biology | 2011 |
Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts
Y Liu, F Lang, X Xie, S Prabhu, J Xu, D Sampath, K Aldape, G Fuller, VK Puduvalli |
Cell Death and Disease | 2011 |
Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5
CM van Geelen, B Pennarun, PT Le, EG de Vries, S Jong |
BMC Cancer | 2011 |
Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis
MS Beausoleil, EB Schulze, D Goodale, CO Postenka, AL Allan |
BMC Cancer | 2011 |
Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
EW Duiker, A Meijer, AR van der Bilt, GJ Meersma, N Kooi, AG van der Zee, EG de Vries, S Jong |
British Journal of Cancer | 2011 |
Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway
CE Badr, T Wurdinger, J Nilsson, JM Niers, M Whalen, A Degterev, BA Tannous |
Neuro-Oncology | 2011 |
Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector
BC Ahn, JA Ronald, YI Kim, R Katzenberg, A Singh, R Paulmurugan, S Ray, LV Hofmann, SS Gambhir |
Gene Therapy | 2011 |
Heterogeneity of primary glioblastoma cells in the expression of caspase-8 and the response to TRAIL-induced apoptosis
L Qi, AC Bellail, MR Rossi, Z Zhang, H Pang, S Hunter, C Cohen, CS Moreno, JJ Olson, S Li, C Hao |
Apoptosis | 2011 |
Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo
I Zinonos, A Labrinidis, M Lee, V Liapis, S Hay, V Ponomarev, P Diamond, DM Findlay, AC Zannettino, A Evdokiou |
Journal of Bone and Mineral Research | 2011 |
Targeting AML through DR4 with a novel variant of rhTRAIL
E Szegezdi, CR Reis, AM van der Sloot, A Natoni, A O’Reilly, J Reeve, RH Cool, M O’Dwyer, S Knapper, L Serrano, WJ Quax, A Samali |
Journal of Cellular and Molecular Medicine | 2011 |
TRAIL and DR5 Promote Thyroid Follicular Cell Apoptosis in Iodine Excess-Induced Experimental Autoimmune Thyroiditis in NOD Mice
X Yu, L Li, Q Li, X Zang, Z Liu |
Biological Trace Element Research | 2011 |
SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells
M Horndasch, Z Culig |
The Prostate | 2011 |
Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: Involvement of ROS-dependent ER-stress
DO Moon, SY Park, YH Choi, JS Ahn, GY Kim |
Biochemical Pharmacology | 2011 |
Augmenting the Antitumor Effect of TRAIL by SOCS3 with Double-Regulated Replicating Oncolytic Adenovirus in Hepatocellular Carcinoma
RC Wei, X Cao, JH Gui, XM Zhou, D Zhong, QL Yan, WD Huang, QJ Qian, FL Zhao, XY Liu |
Human Gene Therapy | 2011 |
Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2
ES Yang, SM Woo, KS Choi, TK Kwon |
Experimental Cell Research | 2011 |
CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells
JC Lee, LC Chou, CH Huang, JG Chung, LJ Huang, KH Lee, MC Hung, TD Way, SC Kuo |
European Journal of Pharmacology | 2011 |
Biotherapeutic bioanalysis: a multi-indication case study review
HA Myler, A Given, K Kolz, JR Mora, G Hristopoulos |
Bioanalysis | 2011 |
Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma
C Röder, A Trauzold, H Kalthoff |
European Journal of Cell Biology | 2011 |
Preclinical toxicity of DATR, a recombinant soluble human TRAIL mutant, in rats and cynomolgus monkeys
X Zhang, Y Zou, Y Mao, M Huang, B Yuan, G Lu |
Regulatory Toxicology and Pharmacology | 2011 |
PEGylated TNF-Related Apoptosis-Inducing Ligand (TRAIL) Analogues: Pharmacokinetics and Antitumor Effects
TH Kim, YS Youn, HH Jiang, S Lee, X Chen, KC Lee |
Bioconjugate Chemistry | 2011 |
Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma
S Huang, J Li, L Han, S Liu, H Ma, R Huang, C Jiang |
Biomaterials | 2011 |
Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery
F Fay, KM McLaughlin, DM Small, DA Fennell, PG Johnston, DB Longley, CJ Scott |
Biomaterials | 2011 |
Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis
X Zhang, T Inukai, K Akahane, K Hirose, I Kuroda, H Honna, K Goi, K Kagami, T Tauchi, H Yagita, K Sugita |
Leukemia Research | 2011 |
Chrysin promotes tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced apoptosis in human cancer cell lines
X Li, JN Wang, JM Huang, XK Xiong, MF Chen, CN Ong, HM Shen, XF Yang |
Toxicology in Vitro | 2011 |
Growth Inhibition and Apoptosis Induced by Lupeol, a Dietary Triterpene, in Human Hepatocellular Carcinoma Cells
Y He, F Liu, L Zhang, Y Wu, B Hu, Y Zhang, Y Li, H Liu |
Biological & Pharmaceutical Bulletin | 2011 |
Role of Cell-Death Ligand-Receptor System of Granulosa Cells in Selective Follicular Atresia in Porcine Ovary
N INOUE, F MATSUDA, Y GOTO, N MANABE |
Journal of Reproduction and Development | 2011 |
Effect of β-Phenylethyl Isothiocyanate from Cruciferous Vegetables on Growth Inhibition and Apoptosis of Cervical Cancer Cells through the Induction of Death Receptors 4 and 5
LD Huong, JH Shim, KH Choi, JA Shin, ES Choi, HS Kim, SJ Lee, SJ Kim, NP Cho, SD Cho |
Journal of Agricultural and Food Chemistry | 2011 |
TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes
L Guo, L Fan, Z Pang, J Ren, Y Ren, J Li, J Chen, Z Wen, X Jiang |
Journal of Controlled Release | 2011 |
PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy
HH Jiang, TH Kim, S Lee, X Chen, YS Youn, KC Lee |
Biomaterials | 2011 |
Emerging roles of cathepsin E in host defense mechanisms
K Yamamoto, T Kawakubo, A Yasukochi, T Tsukuba |
Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics | 2011 |
Radiotherapy and TRAIL for cancer therapy
OM Niemoeller, C Belka |
Cancer Letters | 2011 |
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
Y Pan, R Xu, M Peach, CP Huang, D Branstetter, W Novotny, RS Herbst, SG Eckhardt, PM Holland |
British Journal of Cancer | 2011 |
Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1)
M Åberg, M Johnell, M Wickström, A Siegbahn |
Thrombosis Research | 2011 |
Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin
MJ Yoon, SS Park, YJ Kang, IY Kim, JA Lee, JS Lee, EG Kim, CW Lee, KS Choi |
Carcinogenesis | 2011 |
Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis
D Vindrieux, M Réveiller, J Chantepie, S Yakoub, C Deschildre, A Ruffion, M Devonec, M Benahmed, R Grataroli |
Cancer Cell International | 2011 |
Advances in Cancer Research
M Lemaire, S Deleu, ED Bruyne, EV Valckenborgh, E Menu, K Vanderkerken |
Advances in Cancer Research Volume 110 | 2011 |
ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
G Wang, Y Zhan, H Wang, W Li |
Cancer Chemotherapy and Pharmacology | 2011 |
Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL
L Piggott, N Omidvar, SM Pérez, M Eberl, RW Clarkson |
Breast Cancer Research | 2011 |
J7, a methyl jasmonate derivative, enhances TRAIL-mediated apoptosis through up-regulation of reactive oxygen species generation in human hepatoma HepG2 cells
C Park, CY Jin, HJ Hwang, GY Kim, JH Jung, WJ Kim, YH Yoo, YH Choi |
Toxicology in Vitro | 2011 |
An intermittent approach for cancer chemoprevention
X Wu, SM Lippman |
Nature Reviews Cancer | 2011 |
B Lymphocytes Are Resistant to Death Receptor 5-induced Apoptosis
RN Crowder, H Zhao, WW Chatham, T Zhou, RH Carter |
Clinical Immunology | 2011 |
Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy
CY Kim, SH Park, M Jeong, OS Kwon, H Doh, SH Kang, PD Robbins, BM Kim, DW Seol, BG Kim |
Experimental & molecular medicine | 2011 |
Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB signaling pathway
EP Jane, DR Premkumar, IF Pollack |
Molecular cancer therapeutics | 2011 |
Targeting Apoptosis Signaling Pathways for Anticancer Therapy
S Fulda |
Frontiers in Oncology | 2011 |
Cisplatin Restores TRAIL apoptotic pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP
L Ding, C Yuan, F Wei, G Wang, J Zhang, AC Bellail, Z Zhang, JJ Olson, C Hao |
Cancer Investigation | 2011 |
p53-independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: A mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis
DW Seol |
Biochemical and Biophysical Research Communications | 2011 |
IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells
CK Büneker, R Yu, L Deedigan, A Mohr, RM Zwacka |
Cancer Letters | 2011 |
Expression of Human Soluble Trail Protein in Transgenic Tobacco Nc89
D Wang, X Bai, C Ren, Y Bai, Y Wang |
Procedia Environmental Sciences | 2011 |
Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation
M Horinaka, T Yoshida, S Nakata, T Shiraishi, M Tomosugi, S Yoshikawa, M Wakada, T Sakai |
Cancer Science | 2011 |
Luteolin enhances TNF-related apoptosis-inducing ligand’s anticancer activity in a lung cancer xenograft mouse model
J Yan, Q Wang, X Zheng, H Sun, Y Zhou, D Li, Y Lin, X Wang |
Biochemical and Biophysical Research Communications | 2011 |
Enhancement of TRAIL-Mediated Apoptosis by Genistein in Human Hepatocellular Carcinoma Hep3B Cells: Roles of p38 MAPK Signaling Pathway
CY Jin, C Park, SE Park, SH Hong, YH Choi |
Journal of Life Science | 2011 |
Targeted ovarian cancer treatment: the TRAILs of resistance
NG Khaider, D Lane, I Matte, C Rancourt, A Piché |
American journal of cancer research | 2011 |
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment
G Picarda, V Trichet, S Téletchéa, D Heymann, F Rédini |
American journal of cancer research | 2011 |
Screening of genetic parameters for soluble protein expression in Escherichia coli
E Vernet, A Kotzsch, B Voldborg, M Sundström |
Protein Expression and Purification | 2011 |
Delivery of intracellular-acting biologics in pro-apoptotic therapies
H Li, CE Nelson, BC Evans, CL Duvall |
Current pharmaceutical design | 2011 |
Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer
L Norian, B James, T Griffith |
Cancers | 2011 |
Gomisin N enhances TRAIL-induced apoptosis via reactive oxygen species-mediated up-regulation of death receptors 4 and 5
H Inoue, P Waiwut, I Saiki, Y Shimada, H Sakurai |
International journal of oncology | 2011 |
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis
SV Garimella, A Rocca, S Lipkowitz |
Molecular cancer research : MCR | 2011 |
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis
F Xu, Y Tian, Y Huang, LL Zhang, ZZ Guo, JJ Huang, TY Lin |
Chinese journal of cancer | 2011 |
miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma
N Razumilava, SF Bronk, RL Smoot, CD Fingas, NW Werneburg, LR Roberts, JL Mott |
Hepatology | 2011 |
Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells
LC Li, S Jayaram, L Ganesh, L Qian, J Rotmensch, AV Maker, BS Prabhakar |
American Journal of Obstetrics and Gynecology | 2011 |
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts
IV Balyasnikova, SD Ferguson, Y Han, F Liu, MS Lesniak |
Cancer Letters | 2011 |
Cytokines, inflammation and colon cancer
L Klampfer |
Current cancer drug targets | 2011 |
Efficient In Vitro TRAIL-Gene Delivery in Drug-Resistant A2780/DDP Ovarian Cancer Cell Line via Magnetofection
F Li, S Niu, J Sun, H Zhu, Q Ba, Y Guo, D Shi |
Journal of Nanomaterials | 2011 |
Induction of Apoptosis in Lung Cancer Cells by TRAIL and L-leucyl-L-leucine Methyl Ester
XS Sun, L Bandura-Morgan, W Zacharias |
Journal of Cancer Therapy | 2011 |
Naturally occurring, tumor-specific, therapeutic proteins
K Argiris, C Panethymitaki, M Tavassoli |
Experimental biology and medicine (Maywood, N.J.) | 2011 |
Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
JC Soria, Z Márk, P Zatloukal, B Szima, I Albert, E Juhász, JL Pujol, J Kozielski, N Baker, D Smethurst, Y Hei, A Ashkenazi, H Stern, L Amler, Y Pan, F Blackhall |
Journal of Clinical Oncology | 2011 |
Modulation of CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)-dependent DR5 Expression by Nelfinavir Sensitizes Glioblastoma Multiforme Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
X Tian, J Ye, M Alonso-Basanta, SM Hahn, C Koumenis, JF Dorsey |
The Journal of biological chemistry | 2011 |
Implicación de NF-κB y p53 en la expresión de receptores de muerte-TRAIL y apoptosis por procianidinas en células metastásicas humanas SW620
ME Maldonado, S Bousserouel, F Gossé, A Lobstein, F Raul |
Biomédica | 2011 |
Tumors of the Central Nervous System, Volume 1
MA Hayat |
2011 | |
Attenuated, Oncolytic, but Not Wild-Type Measles Virus Infection Has Pleiotropic Effects on Human Neutrophil Function
Y Zhang, B Patel, A Dey, E Ghorani, L Rai, M Elham, AZ Castleton, AK Fielding |
Journal of immunology (Baltimore, Md. : 1950) | 2011 |
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL
B Pennarun, JH Kleibeuker, T Oenema, JH Stegehuis, EG de Vries, S de Jong |
Cellular Oncology | 2011 |
An intermittent approach for cancer chemoprevention.
Wu X, Lippman SM |
Nature reviews. Cancer | 2011 |
Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA
J Zhang, S Huang, H Zhang, H Wang, H Guo, G Qian, X Fan, J Lu, AR Hoffman, JF Hu, S Ge |
International Journal of Cancer | 2010 |
Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid
S Schneider-Jakob, N Corazza, A Badmann, D Sidler, R Stuber-Roos, A Keogh, S Frese, M Tschan, T Brunner |
Cell Death and Disease | 2010 |
Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo
M Nagane, S Shimizu, E Mori, S Kataoka, Y Shiokawa |
Neuro-Oncology | 2010 |
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature
C Lavazza, C Carlo-Stella, A Giacomini, L Cleris, M Righi, D Sia, MD Nicola, M Magni, P Longoni, M Milanesi, M Francolini, A Gloghini, A Carbone, F Formelli, AM Gianni |
Blood | 2010 |
Ursolic Acid, a Pentacyclin Triterpene, Potentiates TRAIL-induced Apoptosis through p53-independent Up-regulation of Death Receptors
S Prasad, VR Yadav, R Kannappan, BB Aggarwal |
The Journal of biological chemistry | 2010 |
“Combination-oriented molecular-targeting prevention” of cancer: a model involving the combination of TRAIL and a DR5 inducer
T Yoshida, M Horinaka, T Sakai |
Environmental Health and Preventive Medicine | 2010 |
Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells
P Kaler, V Galea, L Augenlicht, L Klampfer |
PloS one | 2010 |
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL
R Yerbes, A López-Rivas |
Investigational New Drugs | 2010 |
Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo
CH Lee, KJ Park, ES Sung, A Kim, JD Choi, JS Kim, SH Kim, MH Kwon, YS Kim |
Proceedings of the National Academy of Sciences | 2010 |
Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins
B Schneider, S Münkel, A Krippner-Heidenreich, I Grunwald, WS Wels, H Wajant, K Pfizenmaier, J Gerspach |
Cell Death and Disease | 2010 |
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin
TS Jani, J DeVecchio, T Mazumdar, A Agyeman, JA Houghton |
The Journal of biological chemistry | 2010 |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy
NL Fox, R Humphreys, TA Luster, J Klein, G Gallant |
Expert Opinion on Biological Therapy | 2010 |
Improved Antitumor Activity and Tumor Targeting of NH 2 -Terminal–Specific PEGylated Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand
SY Chae, TH Kim, K Park, CH Jin, S Son, S Lee, YS Youn, K Kim, DG Jo, IC Kwon, X Chen, KC Lee |
Molecular cancer therapeutics | 2010 |
New insights into apoptosis signaling by Apo2L/TRAIL
F Gonzalvez, A Ashkenazi |
Oncogene | 2010 |
TRAIL-Rezeptor-Agonisten, eine neue Klasse proapoptotischer Krebstherapeutika
K Papenfuss, S Prieske, H Walczak |
Onkopipeline | 2010 |
TRAILing death in cancer
G Mellier, S Huang, K Shenoy, S Pervaiz |
Molecular Aspects of Medicine | 2010 |
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
D Llobet, N Eritja, A Yeramian, J Pallares, A Sorolla, M Domingo, M Santacana, FJ Gonzalez-Tallada, X Matias-Guiu, X Dolcet |
European Journal of Cancer | 2010 |
APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo
G Eisele, P Roth, K Hasenbach, S Aulwurm, F Wolpert, G Tabatabai, W Wick, M Weller |
Neuro-Oncology | 2010 |
Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective
M Verheij, C Vens, B Triest |
Drug Resistance Updates | 2010 |
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
C Krakstad, M Chekenya |
Molecular Cancer | 2010 |
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
CR Reis, AM van der Sloot, A Natoni, E Szegezdi, R Setroikromo, M Meijer, K Sjollema, F Stricher, RH Cool, A Samali, L Serrano, WJ Quax |
Cell Death and Disease | 2010 |
Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5
YJ Kang, IY Kim, EH Kim, MJ Yoon, SU Kim, TK Kwon, KS Choi |
Experimental & molecular medicine | 2010 |
NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL
C Aydin, AD Sanlioglu, A Bisgin, B Yoldas, L Dertsiz, B Karacay, TS Griffith, S Sanlioglu |
BMC Cancer | 2010 |
Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis
D Finlay, RD Richardson, LK Landberg, AL Howes, K Vuori |
PloS one | 2010 |
Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis
R Tiwary, W Yu, J Li, SK Park, BG Sanders, K Kline |
PloS one | 2010 |
TRAIL treatment provokes mutations in surviving cells
MM Lovric, CJ Hawkins |
Oncogene | 2010 |
Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors
MA Alcala, K Park, J Yoo, DH Lee, BH Park, BC Lee, DL Bartlett, YJ Lee |
Journal of Cellular Biochemistry | 2010 |
Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL
A Vaculova, V Kaminskyy, E Jalalvand, O Surova, B Zhivotovsky |
Molecular Cancer | 2010 |
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)
A Forero-Torres, J Shah, T Wood, J Posey, R Carlisle, C Copigneaux, FR Luo, S Wojtowicz-Praga, I Percent, M Saleh |
Cancer Biotherapy & Radiopharmaceuticals | 2010 |
FasL gene-deficient mice display a limited disruption in spermatogenesis and inhibition of mono-(2-ethylhexyl) phthalate-induced germ cell apoptosis
YC Lin, PL Yao, JH Richburg |
Toxicological sciences : an official journal of the Society of Toxicology | 2010 |
Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5
YH Jung, J Heo, YJ Lee, TK Kwon, YH Kim |
Life Sciences | 2010 |
Tumor-targeted delivery of biologically active TRAIL protein
HY Zhang, JH Man, B Liang, T Zhou, CH Wang, T Li, HY Li, WH Li, BF Jin, PJ Zhang, J Zhao, X Pan, K He, WL Gong, XM Zhang, AL Li |
Cancer Gene Therapy | 2010 |
Gliomagenesis and the use of neural stem cells in brain tumor treatment
P Achanta, NI Roman, A Quiñones-Hinojosa |
Anti-cancer agents in medicinal chemistry | 2010 |
Resveratrol: Biological and pharmaceutical properties as anticancer molecule
T Hsieh, JM Wu |
BioFactors | 2010 |
Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells
J Li, Q Shen, R Peng, R Chen, P Jiang, Y Li, L Zhang, J Lu |
Journal of Huazhong University of Science and Technology [Medical Sciences] | 2010 |
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development
AB Lee-Sherick, RM Linger, L Gore, AK Keating, DK Graham |
British Journal of Haematology | 2010 |
The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma
Y Wang, F Huang, H Cai, Y Wu, G He, WS Tan |
Journal of Cancer Research and Clinical Oncology | 2010 |
Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis
PL Chen, AS Easton |
Biochemical and Biophysical Research Communications | 2010 |
Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines
K Bräutigam, J Biernath-Wüpping, DO Bauerschlag, CS Kaisenberg, W Jonat, N Maass, N Arnold, I Meinhold-Heerlein |
Journal of Cancer Research and Clinical Oncology | 2010 |
Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles
SA Cillessen, CJ Meijer, M Notoya, GJ Ossenkoppele, JJ Oudejans |
The Journal of Pathology | 2010 |
TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives
JH Stegehuis, LH Wilt, EG Vries, HJ Groen, S Jong, FA Kruyt |
Drug Resistance Updates | 2010 |
Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus
W Zhou, H Zhu, W Chen, X Hu, X Pang, J Zhang, X Huang, B Fang, C He |
Cancer Gene Therapy | 2010 |
Bortezomib Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells
J Liu, XJ Qu, L Xu, Y Zang, JL Qu, KZ Hou, YP Liu |
Digestive Diseases and Sciences | 2010 |
Synthetic constrained peptide selectively binds and antagonizes death receptor 5
J Vrielink, MS Heins, R Setroikromo, E Szegezdi, MM Mullally, A Samali, WJ Quax |
FEBS Journal | 2010 |
Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAIL-induced apoptosis in breast tumor cells
C Palacios, AI López-Pérez, A López-Rivas |
Cancer Letters | 2010 |
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis
H Zhuang, W Jiang, W Cheng, K Qian, W Dong, L Cao, Q Huang, S Li, F Dou, JF Chiu, XX Fang, M Lu, ZC Hua |
Lung Cancer | 2010 |
Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells
Y Hagiwara, T Kasukabe, Y Kaneko, N Niitsu, J Okabe-Kado |
International Journal of Hematology | 2010 |
Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer
M Grimm, M Kim, A Rosenwald, B Rahden, I Tsaur, E Meier, U Heemann, CT Germer, M Gasser, AM Waaga-Gasser |
European Journal of Cancer | 2010 |
Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?
G Jacquemin, S Shirley, O Micheau |
Cellular and Molecular Life Sciences | 2010 |
Synergistic Anti-Cancer Activity by the Combination of TRAIL/APO-2L and Celastrol
H Zhu, WJ Ding, R Wu, QJ Weng, JS Lou, RJ Jin, W Lu, B Yang, QJ He |
Cancer Investigation | 2010 |
Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma
L Gore, TM Trippett |
Current Hematologic Malignancy Reports | 2010 |
Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation
K Mizrahi, J Stein, M Pearl-Yafe, O Kaplan, I Yaniv, N Askenasy |
Leukemia | 2010 |
Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression
W Wang, J Zhao, H Wang, Y Sun, Z Peng, G Zhou, L Fan, X Wang, S Yang, R Wang, D Fang |
Experimental Cell Research | 2010 |
Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
T Doi, H Murakami, A Ohtsu, N Fuse, T Yoshino, N Yamamoto, N Boku, Y Onozawa, CP Hsu, KS Gorski, G Friberg, T Kawaguchi, T Sasaki |
Cancer Chemotherapy and Pharmacology | 2010 |
Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells
A Mohr, SM Albarenque, L Deedigan, R Yu, M Reidy, S Fulda, RM Zwacka |
Stem Cells | 2010 |
Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells
S Oh, D Kwon, HJ Lee, J Kim, E Lee |
Apoptosis | 2010 |
Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5
M Frese-Schaper, JA Schardt, T Sakai, GL Carboni, RA Schmid, S Frese |
FEBS Letters | 2010 |
Dryopteris crassirhizoma has anti-cancer effects through both extrinsic and intrinsic apoptotic pathways and G0/G1 phase arrest in human prostate cancer cells
SH Chang, JH Bae, DP Hong, KD Choi, SC Kim, E Her, SH Kim, CD Kang |
Journal of Ethnopharmacology | 2010 |
Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo
W Ding, T Cai, H Zhu, R Wu, C Tu, L Yang, W Lu, Q He, B Yang |
Cancer Letters | 2010 |
TRAIL and IFNα act synergistically to induce renal cell carcinoma apoptosis
PE Clark, DA Polosukhina, K Gyabaah, HL Moses, A Thorburn, R Zent |
The Journal of Urology | 2010 |
TRAIL protein expression in breast cancer cells correlates with nuclear grade
A Bilski, G Pasz-Walczak, R Kubiak, P Sek, J Chalubinska, W Fendler, K Wronski, A Piekarska, P Pluta, P Potemski, A Jeziorski, J Piekarski |
Archives of Medical Science : AMS | 2010 |
ROS and CHOP are Critical for Dibenzylideneacetone to Sensitize Tumor Cells to TRAIL Through Induction of Death Receptors and Downregulation of Cell Survival Proteins
S Prasad, VR Yadav, J Ravindran, BB Aggarwal |
Cancer research | 2010 |
HIV increases HCV-induced hepatocyte apoptosis
JY Jang, RX Shao, W Lin, E Weinberg, WJ Chung, WL Tsai, H Zhao, K Goto, L Zhang, J Mendez-Navarro, N Jilg, LF Peng, MA Brockman, RT Chung |
Journal of Hepatology | 2010 |
Programmed Cell Death 4 (PDCD4) Enhances the Sensitivity of Gastric Cancer Cells to TRAIL-Induced Apoptosis by Inhibiting the PI3K/Akt Signaling Pathway
WQ Wang, H Zhang, HB Wang, YG Sun, ZH Peng, G Zhou, SM Yang, RQ Wang, DC Fang |
Molecular diagnosis & therapy | 2010 |
Vitamins & Hormones
KJ Hare, FK Knop |
Vitamins & Hormones | 2010 |
Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells
M Horinaka, T Yoshida, A Kishi, K Akatani, T Yasuda, J Kouhara, M Wakada, T Sakai |
FEBS Letters | 2010 |
Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis
K Akahane, T Inukai, X Zhang, K Hirose, I Kuroda, K Goi, H Honna, K Kagami, S Nakazawa, K Endo, T Kubota, H Yagita, T Koyama-Okazaki, K Sugita |
Experimental Hematology | 2010 |
Exploring death receptor pathways as selective targets in cancer therapy
M Russo, A Mupo, C Spagnuolo, GL Russo |
Biochemical Pharmacology | 2010 |
Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma
KA Clawson, D Borja-Cacho, MB Antonoff, AK Saluja, SM Vickers |
The Journal of surgical research | 2010 |
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model
NV Rajeshkumar, ZA Rasheed, E García-García, F López-Ríos, K Fujiwara, WH Matsui, M Hidalgo |
Molecular cancer therapeutics | 2010 |
Targets for cancer therapy in childhood sarcomas
M Wachtel, BW Schäfer |
Cancer Treatment Reviews | 2010 |
TLR4 through IFN- Promotes Low Molecular Mass Hyaluronan-Induced Neutrophil Apoptosis
SW Leu, L Shi, C Xu, Y Zhao, B Liu, Y Li, A Shiedlin, C Xiang, H Shen, DA Quinn, CA Hales, H Zhao |
Journal of immunology (Baltimore, Md. : 1950) | 2010 |
PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors
E Benedetti, R Galzio, B D'Angelo, MP Cerù, A Cimini |
PPAR Research | 2010 |
Tumor Associated Macrophages Protect Colon Cancer Cells from TRAIL-Induced Apoptosis through IL-1β- Dependent Stabilization of Snail in Tumor Cells
P Kaler, V Galea, L Augenlicht, L Klampfer, DY Jin |
PloS one | 2010 |
Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis
D Finlay, RD Richardson, LK Landberg, AL Howes, K Vuori, AL Gartel |
PloS one | 2010 |
Role of Endoplasmic Reticulum Stress in α-TEA Mediated TRAIL/DR5 Death Receptor Dependent Apoptosis
R Tiwary, W Yu, J Li, SK Park, BG Sanders, K Kline, MV Blagosklonny |
PloS one | 2010 |
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
JC Soria, E Smit, D Khayat, B Besse, X Yang, CP Hsu, D Reese, J Wiezorek, F Blackhall |
Journal of Clinical Oncology | 2010 |
Ursolic Acid, a Pentacyclin Triterpene, Potentiates TRAIL-induced Apoptosis through p53-independent Up-regulation of Death Receptors: EVIDENCE FOR THE ROLE OF REACTIVE OXYGEN SPECIES AND JNK
S Prasad, VR Yadav, R Kannappan, BB Aggarwal |
The Journal of biological chemistry | 2010 |
Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin
TS Jani, J DeVecchio, T Mazumdar, A Agyeman, JA Houghton |
The Journal of biological chemistry | 2010 |
Acute toxicity of a single dose DATR, recombinant soluble human TRAIL mutant, in rodents and crab-eating macaques
YX Zou, XD Zhang, Y Mao, GC Lu, M Huang, BJ Yuan |
Human & Experimental Toxicology | 2010 |
Nitric Oxide (NO) and Cancer
B Bonavida |
2010 | |
BCL-2 Protein Family
C Hetz |
2010 | |
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
RS Herbst, R Kurzrock, DS Hong, M Valdivieso, CP Hsu, L Goyal, G Juan, YC Hwang, S Wong, JS Hill, G Friberg, PM LoRusso |
Clinical cancer research | 2010 |
Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer
A El-Gazzar, P Perco, E Eckelhart, M Anees, V Sexl, B Mayer, Y Liu, W Mikulits, R Horvat, T Pangerl, D Zheng, M Krainer |
Molecular cancer therapeutics | 2010 |
TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma In vivo
S Wang, W Ren, J Liu, G Lahat, K Torres, G Lopez, AJ Lazar, A Hayes-Jordan, K Liu, J Bankson, JD Hazle, D Lev |
Clinical cancer research | 2010 |
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
M de Bruyn, AA Rybczynska, Y Wei, M Schwenkert, GH Fey, RA Dierckx, A van Waarde, W Helfrich, E Bremer |
Molecular Cancer | 2010 |
6-Dehydrogingerdione Sensitizes Human Hepatoblastoma Hep G2 Cells to TRAIL-Induced Apoptosis via Reactive Oxygen Species-Mediated Increase of DR5
CY Chen, CJ Tai, JT Cheng, JJ Zheng, YZ Chen, TZ Liu, SJ Yiin, CL Chern |
Journal of Agricultural and Food Chemistry | 2010 |
Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.
Liu J, Qu XJ, Xu L, Zang Y, Qu JL, Hou KZ, Liu YP |
Digestive Diseases and Sciences | 2010 |
Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells.
Hagiwara Y, Kasukabe T, Kaneko Y, Niitsu N, Okabe-Kado J |
International Journal of Hematology | 2010 |
Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphoma.
Gore L, Trippett TM |
Current Hematologic Malignancy Reports | 2010 |
Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
Bräutigam K, Biernath-Wüpping J, Bauerschlag DO, von Kaisenberg CS, Jonat W, Maass N, Arnold N, Meinhold-Heerlein I |
Journal of Cancer Research and Clinical Oncology | 2010 |
Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing
TR Wilson, KM Redmond, KM McLaughlin, N Crawford, K Gately, K O'Byrne, C Le-Clorrenec, C Holohan, DA Fennell, PG Johnston, DB Longley |
Cell Death and Differentiation | 2009 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Therapeutic Targets of the TNF Superfamily
IS Grewal |
2009 | |
Regulation of CLU gene expression by oncogenes and epigenetic factors: Implications for tumorigenesis
A Sala, S Bettuzzi, S Pucci, O Chayka, M Dews, A Thomas-Tikhonenko |
Advances in cancer research | 2009 |
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma
A Labrinidis, P Diamond, S Martin, S Hay, V Liapis, I Zinonos, NA Sims, GJ Atkins, C Vincent, V Ponomarev, DM Findlay, AC Zannettino, A Evdokiou |
Clinical cancer research | 2009 |
Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1
P Moretto, SJ Hotte |
Expert Opinion on Investigational Drugs | 2009 |
Death Receptors and Cognate Ligands in Cancer
H Kalthoff |
2009 | |
Death Receptors and Cognate Ligands in Cancer
H Kalthoff |
2009 | |
Death Receptors and Cognate Ligands in Cancer
H Kalthoff |
2009 | |
Death Receptors and Cognate Ligands in Cancer
H Kalthoff |
2009 | |
Death Receptors and Cognate Ligands in Cancer
H Kalthoff |
2009 | |
Death Receptors and Cognate Ligands in Cancer
H Kalthoff |
2009 | |
Death Receptors and Cognate Ligands in Cancer
H Kalthoff |
2009 | |
Death Receptors and Cognate Ligands in Cancer
H Kalthoff |
2009 | |
Gene Therapy of Cancer
W Walther, US Stein |
Gene Therapy of Cancer | 2009 |
Gene Therapy of Cancer
W Walther, US Stein |
Gene Therapy of Cancer | 2009 |
Gene Therapy of Cancer
W Walther, US Stein |
Gene Therapy of Cancer | 2009 |
Gene Therapy of Cancer
W Walther, US Stein |
Gene Therapy of Cancer | 2009 |
Following TRAIL’s path in the immune system
C Falschlehner, U Schaefer, H Walczak |
Immunology | 2009 |
Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice
S Ganai, RB Arenas, NS Forbes |
British Journal of Cancer | 2009 |
Applications of neural and mesenchymal stem cells in the treatment of gliomas
T Kosztowski, HA Zaidi, A Quiñones-Hinojosa |
Expert Review of Anticancer Therapy | 2009 |
Life and death by death receptors
ME Guicciardi, GJ Gores |
The FASEB Journal | 2009 |
Cell death pathways – potential therapeutic targets
M MacFarlane |
Xenobiotica | 2009 |
Apoptosis in cancer: Key molecular signaling pathways and therapy targets
C Burz, I Berindan-Neagoe, O Balacescu, A Irimie |
Acta Oncologica | 2009 |
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B
W Tang, W Wang, Y Zhang, S Liu, Y Liu, D Zheng |
FEBS Journal | 2009 |
TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner
W Tang, W Wang, Y Zhang, S Liu, Y Liu, D Zheng |
Cell Research | 2009 |
Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence
J Luetzkendorf, LP Mueller, T Mueller, H Caysa, K Nerger, HJ Schmoll |
Journal of Cellular and Molecular Medicine | 2009 |
Programmed cell death pathways and current antitumor targets.
Tan ML, Ooi JP, Ismail N, Moad AI, Muhammad TS |
Pharmaceutical Research | 2009 |
Is TRAIL the holy grail of cancer therapy?
T Newsom-Davis, S Prieske, H Walczak |
Apoptosis | 2009 |
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
D Mahalingam, E Szegezdi, M Keane, S Jong, A Samali |
Cancer Treatment Reviews | 2009 |
Cell death in hematological tumors
S Fulda |
Apoptosis | 2009 |
Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia
S Fulda |
British Journal of Haematology | 2009 |
Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5
ME Gasparian, BV Chernyak, DA Dolgikh, AV Yagolovich, EN Popova, AM Sycheva, SA Moshkovskii, MP Kirpichnikov |
Apoptosis | 2009 |
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies
PA Holoch, TS Griffith |
European Journal of Pharmacology | 2009 |
Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents
KM Moxley, S Chengedza, DM Benbrook |
Gynecologic Oncology | 2009 |
Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL
JA Jiménez, X Li, YP Zhang, KH Bae, Y Mohammadi, P Pandya, C Kao, TA Gardner |
Cancer Gene Therapy | 2009 |
Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo
A Becerra, RV Warke, K Martin, K Xhaja, N Bosch, AL Rothman, I Bosch |
Journal of Medical Virology | 2009 |
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer
MR Loebinger, A Eddaoudi, D Davies, SM Janes |
Cancer research | 2009 |
The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells
G Guidicelli, B Chaigne-Delalande, MS Dilhuydy, B Pinson, W Mahfouf, JM Pasquet, FX Mahon, P Pourquier, JF Moreau, P Legembre |
PloS one | 2009 |
Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells
S Senthivinayagam, P Mishra, SK Paramasivam, S Yallapragada, M Chatterjee, L Wong, A Rana, B Rana |
The Journal of biological chemistry | 2009 |
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL
M Jeong, YS Kwon, SH Park, CY Kim, SS Jeun, KW Song, Y Ko, PD Robbins, TR Billiar, BM Kim, DW Seol |
PloS one | 2009 |
TRAIL gene therapy: from preclinical development to clinical application
TS Griffith, B Stokes, TA Kucaba, JK Earel, RL VanOosten, EL Brincks, LA Norian |
Current gene therapy | 2009 |
Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines
H Meng, L Li, H Liu, Y Wang, G Li, W Qian |
Acta Pharmacologica Sinica | 2009 |
Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs
JA Bauer, G Frye, A Bahr, J Gieg, P Brofman |
Investigational New Drugs | 2009 |
Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents
T Sánchez-Pérez, G Ortiz-Ferrón, A López-Rivas |
Cell Death and Differentiation | 2009 |
Serum soluble tumor necrosis factor-related apoptosis-inducing ligand level after allogeneic hematopoietic cell transplantation
T Toubai, Y Shono, S Tone, M Ibata, N Kato, C Malter, KP Lowler, S Ota, J Tanaka, M Asaka, M Imamura |
Leukemia & Lymphoma | 2009 |
Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy
LG Menon, K Kelly, HW Yang, SK Kim, PM Black, RS Carroll |
Stem Cells | 2009 |
Death receptor 5 targeting activity-guided isolation of isoflavones from Millettia brandisiana and Ardisia colorata and evaluation of ability to induce TRAIL-mediated apoptosis
H Kikuchi, T Ohtsuki, T Koyano, T Kowithayakorn, T Sakai, M Ishibashi |
Bioorganic & Medicinal Chemistry | 2009 |
Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1
S Huerta-Yepez, M Vega, SE Escoto-Chavez, B Murdock, T Sakai, S Baritaki, B Bonavida |
Nitric Oxide | 2009 |
Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation
JY Kim, EH Kim, SU Kim, TK Kwon, KS Choi |
Carcinogenesis | 2009 |
TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells
E Szliszka, B Mazur, G Żydowicz, ZP Czuba, W Król |
Folia Histochemica et Cytobiologica | 2009 |
Trimeric coiled-coil domain of human pulmonary surfactant protein D enhances zinc-binding ability and biologic activity of soluble TRAIL
X Wu, P Li, C Qian, O Li, Y Zhou |
Molecular Immunology | 2009 |
Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots toin vitroassays using TOP15 charts
J Petrak, O Toman, T Simonova, P Halada, R Cmejla, P Klener, J Zivny |
PROTEOMICS | 2009 |
Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells
M Li, H Li, C Li, S Zhou, L Guo, H Liu, W Jiang, X Liu, P Li, MA McNutt, G Li |
International Journal of Cancer | 2009 |
Efficacy of a Triple Treatment with Irradiation, Agonistic TRAIL Receptor Antibodies and EGFR Blockade
M Niyazi, P Marini, PT Daniel, R Humphreys, V Jendrossek, C Belka |
Strahlentherapie und Onkologie | 2009 |
Delivery of apoptotic signal to rolling cancer cells: A novel biomimetic technique using immobilized TRAIL and E-selectin
K Rana, JL Liesveld, MR King |
Biotechnology and Bioengineering | 2009 |
Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma
KH Lee, SW Lim, HG Kim, DY Kim, SY Ryu, JK Joo, JC Kim, JH Lee |
Langenbeck's Archives of Surgery | 2009 |
Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP
TJ Lee, HJ Um, DS Min, JW Park, KS Choi, TK Kwon |
Free radical biology & medicine | 2009 |
Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-κB signalling pathway in thyroid cancer cells
S Morello, R Sorrentino, A Porta, G Forte, A Popolo, A Petrella, A Pinto |
Journal of Cellular Physiology | 2009 |
Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth
B Hu, L Kou, C Li, LP Zhu, YR Fan, ZW Wu, JJ Wang, GX Xu |
Cancer Gene Therapy | 2009 |
Programmed Cell Death Pathways and Current Antitumor Targets
ML Tan, JP Ooi, N Ismail, AI Moad, TS Muhammad |
Pharmaceutical Research | 2009 |
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
B Cate, E Bremer, M Bruyn, T Bijma, D Samplonius, M Schwemmlein, G Huls, G Fey, W Helfrich |
Leukemia | 2009 |
The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis
A Dieterle, R Orth, M Daubrawa, A Grotemeier, S Alers, S Ullrich, R Lammers, S Wesselborg, B Stork |
International Journal of Cancer | 2009 |
TNF-related apoptosis-inducing ligand: Signalling of a ‘smart’ molecule
F Manzo, A Nebbioso, M Miceli, M Conte, FD Bellis, V Carafa, G Franci, FP Tambaro, L Altucci |
The International Journal of Biochemistry & Cell Biology | 2009 |
Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells
SH Kok, CC Yeh, ML Chen, MY Kuo |
Oral Oncology | 2009 |
The significance ofTP53in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target
KJ Cheung, DE Horsman, RD Gascoyne |
British Journal of Haematology | 2009 |
TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors
E Oikonomou, V Kosmidou, A Katseli, K Kothonidis, D Mourtzoukou, G Kontogeorgos, L Andera, G Zografos, A Pintzas |
International Journal of Cancer | 2009 |
Cell survival and apoptosis-related molecules in cancer cells in effusions: A comprehensive review
L Kleinberg, B Davidson, Z Baloch |
Diagnostic Cytopathology | 2009 |
Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage
CY Jin, C Park, SK Moon, GY Kim, TK Kwon, SJ Lee, WJ Kim, YH Choi |
Anti-Cancer Drugs | 2009 |
DUAL-TARGETED ANTITUMOR EFFECTS AGAINST BRAINSTEM GLIOMA BY INTRAVENOUS DELIVERY OF TUMOR NECROSIS FACTOR-RELATED, APOPTOSIS-INDUCING, LIGAND-ENGINEERED HUMAN MESENCHYMAL STEM CELLS
B Yang, X Wu, Y Mao, W Bao, L Gao, P Zhou, R Xie, L Zhou, J Zhu |
Neurosurgery | 2009 |
Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells
CY Jin, C Park, GY Kim, SJ Lee, WJ Kim, YH Choi |
Chemico-Biological Interactions | 2009 |
PDTC enables type I TRAIL signaling in type II follicular lymphoma cells
U Nuutinen, N Simelius, A Ropponen, J Eeva, M Mättö, M Eray, R Pellinen, J Wahlfors, J Pelkonen |
Leukemia Research | 2009 |
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
BD Shepard, AD Badley |
Anti-infective agents in medicinal chemistry | 2009 |
Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
RC Elders, SJ Baines, B Catchpole |
Veterinary Immunology and Immunopathology | 2009 |
Forcing Cancer Cells to Commit Suicide
C Vangestel, CV de Wiele, G Mees, M Peeters |
Cancer Biotherapy & Radiopharmaceuticals | 2009 |
Pharmacology and Therapeutics
BL Clarke, S Khosla |
Pharmacology & Therapeutics | 2009 |
TNF-related apoptosis-inducing ligand suppresses PRDX4 expression
HQ Wang, ZX Du, BQ Liu, YY Gao, X Meng, Y Guan, HY Zhang |
FEBS Letters | 2009 |
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
I Zinonos, A Labrinidis, M Lee, V Liapis, S Hay, V Ponomarev, P Diamond, AC Zannettino, DM Findlay, A Evdokiou |
Molecular cancer therapeutics | 2009 |
The expression of TRAIL and its receptors in osteosarcoma cells and the apoptosis effect of a combination of TRAIL, adriamycin and IFN-γ on MG-63 cells
C Deng, Z Shao, X Xiong, Z Liu, Z Zhang |
Journal of Nanjing Medical University | 2009 |
The Many Roles of FAS Receptor Signaling in the Immune System
A Strasser, PJ Jost, S Nagata |
Immunity | 2009 |
Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism
CL Dobson, S Main, P Newton, M Chodorge, K Cadwallader, RC Humphreys, V Albert, TJ Vaughan, RR Minter, BM Edwards |
mAbs | 2009 |
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
S Leong, RB Cohen, DL Gustafson, CJ Langer, DR Camidge, K Padavic, L Gore, M Smith, LQ Chow, M Mehren, C O'Bryant, S Hariharan, S Diab, NL Fox, R Miceli, SG Eckhardt |
Journal of Clinical Oncology | 2009 |
The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells
G Guidicelli, B Chaigne-Delalande, MS Dilhuydy, B Pinson, W Mahfouf, JM Pasquet, FX Mahon, P Pourquier, JF Moreau, P Legembre, GC Jagetia |
PloS one | 2009 |
Possible Novel Therapy for Malignant Gliomas with Secretable Trimeric TRAIL
M Jeong, YS Kwon, SH Park, CY Kim, SS Jeun, KW Song, Y Ko, PD Robbins, TR Billiar, BM Kim, DW Seol, X Wu |
PloS one | 2009 |
Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7
DD Cui, Y Huang, SH Mao, SC Chen, M Qiu, LL Ji, C Yi |
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] | 2009 |
Caspase-mediated Cleavage of β-Catenin Precedes Drug-induced Apoptosis in Resistant Cancer Cells
S Senthivinayagam, P Mishra, SK Paramasivam, S Yallapragada, M Chatterjee, L Wong, A Rana, B Rana |
The Journal of biological chemistry | 2009 |
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
I Zinonos, A Labrinidis, M Lee, V Liapis, S Hay, V Ponomarev, P Diamond, AC Zannettino, DM Findlay, A Evdokiou |
Molecular cancer therapeutics | 2009 |
Essentials of Apoptosis
Z Dong, XM Yin |
2009 | |
CNS Cancer
EG Meir |
2009 | |
Principles of Cancer Biotherapy
RK Oldham, RO Dillman |
2009 | |
Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease
D Satoh, N Inami, T Shimazu, T Kajiura, K Yamada, T Iwasaka, S Nomura |
Journal of Thrombosis and Thrombolysis | 2009 |
Pharmaceutical Perspectives of Cancer Therapeutics
Y Lu, RI Mahato |
2009 | |
Knockdown of IG20 Gene Expression Renders Thyroid Cancer Cells Susceptible to Apoptosis
M Subramanian, T Pilli, P Bhattacharya, F Pacini, YE Nikiforov, PV Kanteti, BS Prabhakar |
The Journal of clinical endocrinology and metabolism | 2009 |
Apoptosis in Carcinogenesis and Chemotherapy
GG Chen, PB Lai |
2009 | |
Enhancement of Antitumor Properties of rhTRAIL by Affinity Increase toward Its Death Receptors
CR Reis, AM van der Sloot, E Szegezdi, A Natoni, V Tur, RH Cool, A Samali, L Serrano, WJ Quax |
Biochemistry | 2009 |
Activity of Mangosteen Xanthones and Teleocidin A-2 in Death Receptor Expression Enhancement and Tumor Necrosis Factor Related Apoptosis-Inducing Ligand Assays
H Kikuchi, T Ohtsuki, T Koyano, T Kowithayakorn, T Sakai, M Ishibashi |
Journal of Natural Products | 2009 |
Targeted Quantitative Mass Spectrometric Identification of Differentially Expressed Proteins between Bax-Expressing and Deficient Colorectal Carcinoma Cells
P Wang, A Lo, JB Young, JH Song, R Lai, NM Kneteman, C Hao, L Li |
Journal of Proteome Research | 2009 |
2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2
H Liu, CC Jiang, CJ Lavis, A Croft, L Dong, HY Tseng, F Yang, KH Tay, P Hersey, XD Zhang |
Molecular Cancer | 2009 |
Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells
DV Rozanov, AY Savinov, VS Golubkov, OL Rozanova, TI Postnova, EA Sergienko, S Vasile, AE Aleshin, MF Rega, M Pellecchia, AY Strongin |
Molecular cancer therapeutics | 2009 |
Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade.
Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C |
2009 | |
Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma.
Lee KH, Lim SW, Kim HG, Kim DY, Ryu SY, Joo JK, Kim JC, Lee JH |
Langenbeck's Archives of Surgery | 2009 |
To Kill a Tumor Cell: the Potential of Pro-apoptotic Receptor Agonists
Avi Ashkenazi1, Roy S. Herbst2 |
Journal of Clinical Investigation | 2008 |
Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression
J Du, X Liang, Y Liu, Z Qu, L Gao, L Han, S Liu, M Cui, Y Shi, Z Zhang, L Yu, L Cao, C Ma, L Zhang, Y Chen, W Sun |
Cell Death and Differentiation | 2008 |
TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse
A Kahraman, FJ Barreyro, SF Bronk, NW Werneburg, JL Mott, Y Akazawa, HC Masuoka, CL Howe, GJ Gores |
Hepatology | 2008 |
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White |
2008 | |
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White |
2008 | |
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White |
2008 | |
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White |
2008 | |
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White |
2008 | |
Programmed Cell Death in Cancer Progression and Therapy
R Khosravi-Far, E White |
2008 | |
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3
K Ndebele, P Gona, TG Jin, N Benhaga, A Chalah, M Degli-Esposti, R Khosravi-Far |
Apoptosis : an international journal on programmed cell death | 2008 |
Targeted Therapies in Cancer
F Colotta, A Mantovani |
2008 | |
Targeted Therapies in Cancer
F Colotta, A Mantovani |
2008 | |
Targeted Therapies in Cancer
F Colotta, A Mantovani |
2008 | |
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
K Takeda, Y Kojima, K Ikejima, K Harada, S Yamashina, K Okumura, T Aoyama, S Frese, H Ikeda, NM Haynes, E Cretney, H Yagita, N Sueyoshi, N Sato, Y Nakanuma, MJ Smyth, K Okumura |
Proceedings of the National Academy of Sciences | 2008 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5
JB Fiveash, GY Gillespie, PG Oliver, T Zhou, ML Belenky, DJ Buchsbaum |
International journal of radiation oncology, biology, physics | 2008 |
Neutralization of tumor-derived soluble Glucocorticoid-Induced TNFR-Related Protein ligand increases NK cell anti-tumor reactivity
KM Baltz, M Krusch, T Baessler, BJ Schmiedel, A Bringmann, P Brossart, HR Salih |
Blood | 2008 |
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
AJ Frew, RK Lindemann, BP Martin, CJ Clarke, J Sharkey, DA Anthony, KM Banks, NM Haynes, P Gangatirkar, K Stanley, JE Bolden, K Takeda, H Yagita, JP Secrist, MJ Smyth, RW Johnstone |
Proceedings of the National Academy of Sciences | 2008 |
ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis
JH Song, K Kandasamy, AS Kraft |
The Journal of biological chemistry | 2008 |
Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells
T Yoshida, M Horinaka, M Takara, M Tsuchihashi, N Mukai, M Wakada, T Sakai |
Environmental Health and Preventive Medicine | 2008 |
The TRAIL apoptotic pathway in cancer onset, progression and therapy
RW Johnstone, AJ Frew, MJ Smyth |
Nature Reviews Cancer | 2008 |
The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway
S Wang |
Oncogene | 2008 |
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
A Ashkenazi |
Nature Reviews Drug Discovery | 2008 |
Wiley Encyclopedia of Chemical Biology
R Bittman |
Wiley Encyclopedia of Chemical Biology | 2008 |
Molecular targeted therapies for pancreatic cancer
D Borja-Cacho, EH Jensen, AK Saluja, DJ Buchsbaum, SM Vickers |
The American Journal of Surgery | 2008 |
Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts
K Sugamura, JF Gibbs, A Belicha-Villanueva, C Andrews, EA Repasky, BL Hylander |
Oncology | 2008 |
Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody
H Kim, DE Morgan, H Zeng, WE Grizzle, JM Warram, CR Stockard, D Wang, KR Zinn |
Radiology | 2008 |
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
H Schulze-Bergkamen, R Ehrenberg, L Hickmann, B Vick, T Urbanik, CC Schimanski, MR Berger, A Schad, A Weber, S Heeger, PR Galle, M Moehler |
World journal of gastroenterology : WJG | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
DM Ashley, CD Riffkin, MM Lovric, T Mikeska, A Dobrovic, JA Maxwell, HS Friedman, KJ Drummond, AH Kaye, HK Gan, TG Johns, CJ Hawkins |
British Journal of Cancer | 2008 |
Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells
TE Fandy, S Shankar, RK Srivastava |
Molecular Cancer | 2008 |
Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission
O Sordet, A Goldman, C Redon, S Solier, VA Rao, Y Pommier |
The Journal of biological chemistry | 2008 |
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
E Bremer, M Bruyn, DF Samplonius, T Bijma, B Cate, LF de Leij, W Helfrich |
Journal of Molecular Medicine | 2008 |
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5
CH Wu, CH Kao, AR Safa |
Human Gene Therapy | 2008 |
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
A Shanker, AD Brooks, CA Tristan, JW Wine, PJ Elliott, H Yagita, K Takeda, MJ Smyth, WJ Murphy, TJ Sayers |
Journal of the National Cancer Institute | 2008 |
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11
PG Oliver, AF LoBuglio, KR Zinn, H Kim, L Nan, T Zhou, W Wang, DJ Buchsbaum |
Clinical cancer research | 2008 |
Turning the gene tap off; implications of regulating gene expression for cancer therapeutics
JF Curtin, M Candolfi, W Xiong, PR Lowenstein, MG Castro |
Molecular cancer therapeutics | 2008 |
Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production
V Levina, AM Marrangoni, R DeMarco, E Gorelik, AE Lokshin |
Experimental Cell Research | 2008 |
FLIP as an anti-cancer therapeutic target
JK Yang |
Yonsei Medical Journal | 2008 |
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
S Shankar, S Ganapathy, Q Chen, RK Srivastava |
Molecular Cancer | 2008 |
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5
BZ Carter, DH Mak, WD Schober, MF Dietrich, C Pinilla, LT Vassilev, JC Reed, M Andreeff |
Blood | 2008 |
Targeting cell death in tumors by activating caspases
SH MacKenzie, AC Clark |
Current cancer drug targets | 2008 |
Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
E Szliszka, ZP Czuba, K Jernas, W Król |
International journal of molecular sciences | 2008 |
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness?
F Torre, L Bellis, A Delfino, N Pelli, P Contini, M Basso, C Puoti, A Picciotto |
Digestive and Liver Disease | 2008 |
Death receptors as targets for anti-cancer therapy
K Papenfuss, SM Cordier, H Walczak |
Journal of Cellular and Molecular Medicine | 2008 |
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update
SH Beachy, EA Repasky |
Cancer Immunology, Immunotherapy | 2008 |
Targeting the extrinsic apoptosis pathway in cancer
A Ashkenazi |
Cytokine & Growth Factor Reviews | 2008 |
Targeted manipulation of apoptosis in cancer treatment
JA Call, SG Eckhardt, DR Camidge |
The Lancet Oncology | 2008 |
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
C Adams, K Totpal, D Lawrence, S Marsters, R Pitti, S Yee, S Ross, L Deforge, H Koeppen, M Sagolla, D Compaan, H Lowman, S Hymowitz, A Ashkenazi |
Cell Death and Differentiation | 2008 |
Role and prognostic significance of tumor necrosis factor‐related apoptosis‐inducing ligand death receptor DR5 in nonsmall‐cell lung cancer and precursor lesions
WA Cooper, MR Kohonen‐Corish, L Zhuang, B McCaughan, C Kennedy, G Screaton, RL Sutherland, CS Lee |
Cancer | 2008 |
Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis
T Yoshida, M Konishi, M Horinaka, T Yasuda, AE Goda, H Taniguchi, K Yano, M Wakada, T Sakai |
Biochemical and Biophysical Research Communications | 2008 |
Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
DR Camidge |
Expert Opinion on Biological Therapy | 2008 |
β-Sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis
C PARK, D MOON, C RYU, B CHOI, W LEE, G KIM, Y CHOI |
Acta Pharmacologica Sinica | 2008 |
Expression, regulation and function of trail in atherosclerosis
MM Kavurma, MR Bennett |
Biochemical Pharmacology | 2008 |
Blockade of processing/activation of caspase-3 by hypoxia
SH Han, M Kim, K Park, TH Kim, DW Seol |
Biochemical and Biophysical Research Communications | 2008 |
Stem and progenitor cell-mediated tumor selective gene therapy
KS Aboody, J Najbauer, MK Danks |
Gene Therapy | 2008 |
Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism
G Ortiz-Ferrón, R Yerbes, A Eramo, AI López-Pérez, RD Maria, A López-Rivas |
Cell Research | 2008 |
Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway
S Shamimi-Noori, WS Yeow, MF Ziauddin, H Xin, TL Tran, J Xie, A Loehfelm, P Patel, J Yang, DS Schrump, BL Fang, DM Nguyen |
Cancer Gene Therapy | 2008 |
Cytoskeleton inhibitors combined with TRAIL induce apoptosis in HeLa carcinoma cells overexpressing antiapoptotic protein Bcl-2
ME Gasparian, LV Domnina, OY Ivanova, DS Izyumov, AY Lomakin, EN Popova, AV Yagolovich, OY Pletjushkina, DA Dolgikh, BV Chernyak |
Biochemistry (Moscow) | 2008 |
Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling
YJ Jeon, IK Kim, SH Hong, H Nan, HJ Kim, HJ Lee, ES Masuda, O Meyuhas, BH Oh, YK Jung |
Oncogene | 2008 |
Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells
J Yoo, SS Park, YJ Lee |
Journal of Cellular Biochemistry | 2008 |
Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL
J Rieger, D Lemke, G Maurer, M Weiler, B Frank, G Tabatabai, M Weller, W Wick |
Journal of Neurochemistry | 2008 |
Apoptotic Phenotype Alters the Capacity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand to Induce Human Vascular Endothelial Activation
PL Chen, A Easton |
Journal of Vascular Research | 2008 |
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model
JE Kendrick, JM Straughn, PG Oliver, W Wang, L Nan, WE Grizzle, CR Stockard, RD Alvarez, DJ Buchsbaum |
Gynecologic Oncology | 2008 |
Adriamycin sensitizes adriamycin-resistant HL-60/ADR cells to TRAIL-mediated apoptosis
H Ke, Y Wang, D Ren, L Wang |
Chinese Journal of Clinical Oncology | 2008 |
Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPSdown-regulation
JY Kim, EH Kim, SS Park, JH Lim, TK Kwon, KS Choi |
Journal of Cellular Biochemistry | 2008 |
TRAIL and cancer therapy
FA Kruyt |
Cancer Letters | 2008 |
Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2
J Li, MG Anderson, LA Tucker, Y Shen, KB Glaser, OJ Shah |
Cell Death and Differentiation | 2008 |
Immunohistochemical Analysis for the Expression of DR5 TRAIL Receptor and p53 in Non-small Cell Lung Cancer
KY Lee, JH Lee, SJ Kim, KH Yoo |
Tuberculosis and Respiratory Diseases | 2008 |
TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8
LL Belyanskaya, A Ziogas, S Hopkins-Donaldson, S Kurtz, HU Simon, R Stahel, U Zangemeister-Wittke |
Lung Cancer | 2008 |
Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC -independent mechanism in human malignant tumor cells
JH Lim, JW Park, KS Choi, YB Park, TK Kwon |
Carcinogenesis | 2008 |
The role of TRAIL death receptors in the treatment of hematological malignancies
ES Henson, JB Johnston, SB Gibson |
Leukemia & Lymphoma | 2008 |
Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein
E Bremer, GM van Dam, M Bruyn, M Riezen, M Dijkstra, G Kamps, W Helfrich, H Haisma |
Molecular Therapy | 2008 |
Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole
AE Goda, T Yoshida, M Horinaka, T Yasuda, T Shiraishi, M Wakada, T Sakai |
Oncogene | 2008 |
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
FA Greco, P Bonomi, J Crawford, K Kelly, Y Oh, W Halpern, L Lo, G Gallant, J Klein |
Lung Cancer | 2008 |
Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand
SJ Na, SY Chae, S Lee, K Park, K Kim, JH Park, IC Kwon, SY Jeong, KC Lee |
International Journal of Pharmaceutics | 2008 |
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas
V Granci, F Bibeau, A Kramar, F Boissière-Michot, S Thézénas, A Thirion, C Gongora, P Martineau, MD Rio, M Ychou |
European Journal of Cancer | 2008 |
New Drugs for the Treatment of Lymphoma
L Paoluzzi, Y Kitagawa, M Kalac, J Zain, OA O'Connor |
Hematology/Oncology Clinics of North America | 2008 |
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers
NL Booth, TJ Sayers, AD Brooks, CL Thomas, K Jacobsen, EI Goncharova, JB McMahon, CJ Henrich |
Cancer Immunology, Immunotherapy | 2008 |
Noninvasive Imaging of Therapeutic Gene Expression Using a Bi-directional Transcriptional Amplification Strategy
S Ray, R Paulmurugan, MR Patel, BC Ahn, L Wu, M Carey, SS Gambhir |
Molecular Therapy | 2008 |
A dual-step fluorescence resonance energy transfer-based quenching assay for screening of caspase-3 inhibitors
A Valanne, P Malmi, H Appelblom, P Niemelä, T Soukka |
Analytical Biochemistry | 2008 |
ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis
JH Song, K Kandasamy, AS Kraft |
The Journal of biological chemistry | 2008 |
TRAIL Stimulates Proliferation of Vascular Smooth Muscle Cells via Activation of NF-κB and Induction of Insulin-like Growth Factor-1 Receptor
MM Kavurma, M Schoppet, YV Bobryshev, LM Khachigian, MR Bennett |
The Journal of biological chemistry | 2008 |
DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design
V Tur, AM van der Sloot, CR Reis, E Szegezdi, RH Cool, A Samali, L Serrano, WJ Quax |
The Journal of biological chemistry | 2008 |
Topoisomerase I Requirement for Death Receptor-induced Apoptotic Nuclear Fission
O Sordet, A Goldman, C Redon, S Solier, VA Rao, Y Pommier |
The Journal of biological chemistry | 2008 |
Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
H Schulze-Bergkamen, R Ehrenberg, L Hickmann, B Vick, T Urbanik, CC Schimanski, MR Berger, A Schad, A Weber, S Heeger, PR Galle, M Moehler |
World journal of gastroenterology : WJG | 2008 |
Transforming Growth Factor-β in Cancer Therapy, Volume I
SB Jakowlew |
2008 | |
Principles of Molecular Oncology
MH Bronchud, MA Foote, G Giaccone, O Olopade, P Workman |
2008 | |
Myeloma Therapy
S Lonial |
2008 | |
RETRACTED ARTICLE: A single chain (scFv425):sTRAIL fusion protein with specificity for the EGF receptor is effective in vitro but not in an in vivo brain tumor animal model
JM Kuijlen, JJ Mooij, W Helfrich, WF den Dunnen |
Journal of Neuro-Oncology | 2008 |
Targeted Cancer Therapy
R Kurzrock, M Markman |
2008 | |
Molecular Targeting in Oncology
HL Kaufman, S Wadler, K Antman |
2008 | |
Apoptosis and Cancer
G Mor, AB Alvero |
2008 | |
Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
B Bonavida |
2008 | |
Targeted Therapies in Cancer
F Colotta, A Mantovani |
2008 | |
Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
SV Schaeybroeck, DM Kelly, J Kyula, S Stokesberry, DA Fennell, PG Johnston, DB Longley |
Cancer research | 2008 |
CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-κB Activation and Up-Regulation of c-FLIP and Bcl-x L
M Travert, P Ame-Thomas, C Pangault, A Morizot, O Micheau, G Semana, T Lamy, T Fest, K Tarte, T Guillaudeux |
Journal of immunology (Baltimore, Md. : 1950) | 2008 |
Early Therapy Evaluation of Combined Anti–Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging
H Kim, DE Morgan, DJ Buchsbaum, H Zeng, WE Grizzle, JM Warram, CR Stockard, LR McNally, JW Long, JC Sellers, A Forero, KR Zinn |
Cancer research | 2008 |
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update.
Beachy SH, Repasky EA |
Cancer Immunology, Immunotherapy | 2008 |
TRAIL-R deficiency enhances lymph node metastasis without affecting primary tumor development
Anne Grosse-Wilde, Oksana Voloshanenko, S. Lawrence Bailey, Gary M. Longton, Uta Schaefer, Andreea I. Csernok, Günther Schütz, Erich F. Greiner, Christopher J. Kemp, and Henning Walczak |
Journal of Clinical Investigation | 2007 |
On the TRAIL to therapeutic intervention in liver disease
I Herr, P Schemmer, MW Büchler |
Hepatology | 2007 |
Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax
X Liang, Y Liu, Q Zhang, L Gao, L Han, C Ma, L Zhang, YH Chen, W Sun |
Journal of immunology (Baltimore, Md. : 1950) | 2007 |
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
D Daniel, B Yang, DA Lawrence, K Totpal, I Balter, WP Lee, A Gogineni, MJ Cole, SF Yee, S Ross, A Ashkenazi |
Blood | 2007 |
Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling
JA Bauer, JA Lupica, H Schmidt, BH Morrison, RM Haney, RK Masci, RM Lee, JA Didonato, DJ Lindner |
PloS one | 2007 |
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage
C Dunn, M Brunetto, G Reynolds, T Christophides, PT Kennedy, P Lampertico, A Das, AR Lopes, P Borrow, K Williams, E Humphreys, S Afford, DH Adams, A Bertoletti, MK Maini |
Journal of Experimental Medicine | 2007 |
NK Cells and Cancer
L Zamai, C Ponti, P Mirandola, G Gobbi, S Papa, L Galeotti, L Cocco, M Vitale |
Journal of immunology (Baltimore, Md. : 1950) | 2007 |
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity
H Malhi, FJ Barreyro, H Isomoto, SF Bronk, GJ Gores |
Gut | 2007 |
The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2
X Liang, J Du, Y Liu, M Cui, C Ma, L Han, Z Qu, Z Zhang, Z Sun, L Zhang, YH Chen, W Sun |
Apoptosis | 2007 |
TRAIL in cancer therapy: present and future challenges
D Mérino, N Lalaoui, A Morizot, E Solary, O Micheau |
Expert Opinion on Therapeutic Targets | 2007 |
RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL)
M Tarrus, AM van der Sloot, K Temming, M Lacombe, F Opdam, WJ Quax, G Molema, K Poelstra, RJ Kok |
Apoptosis : an international journal on programmed cell death | 2007 |
Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis
S Shankar, Q Chen, K Sarva, I Siddiqui, RK Srivastava |
Journal of molecular signaling | 2007 |
Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential
S Shankar, Q Chen, I Siddiqui, K Sarva, RK Srivastava |
Journal of molecular signaling | 2007 |
Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression
N Vigneswaran, DC Baucum, J Wu, Y Lou, J Bouquot, S Muller, W Zacharias |
BMC Cancer | 2007 |
Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo
E Oikonomou, K Kothonidis, E Taoufik, E Probert, G Zografos, G Nasioulas, L Andera, A Pintzas |
British Journal of Cancer | 2007 |
Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells
D Lane, V Robert, R Grondin, C Rancourt, A Piché |
International Journal of Cancer | 2007 |
Apoptosis and chemo-resistance in colorectal cancer
SG Prabhudesai, S Rekhraj, G Roberts, AW Darzi, P Ziprin |
Journal of Surgical Oncology | 2007 |
Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms
K Ishiguro, T Ando, O Maeda, N Ohmiya, Y Niwa, K Kadomatsu, H Goto |
Biochemical and Biophysical Research Communications | 2007 |
Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
MS Lippa, LD Strockbine, TT Le, DG Branstetter, CA Strathdee, PM Holland |
Apoptosis | 2007 |
The promise of TRAIL—potential and risks of a novel anticancer therapy
R Koschny, H Walczak, TM Ganten |
Journal of Molecular Medicine | 2007 |
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis
T Yoshida, T Shiraishi, M Horinaka, S Nakata, T Yasuda, AE Goda, M Wakada, Y Mizutani, T Miki, A Nishikawa, T Sakai |
Cancer Science | 2007 |
Cutting-Edge Apoptosis-Based Therapeutics
U Fischer, K Janssen, K Schulze-Osthoff |
BioDrugs | 2007 |
Increased hepatotoxicity of tumor necrosis factor–related apoptosis-inducing ligand in diseased human liver
X Volkmann, U Fischer, MJ Bahr, M Ott, F Lehner, M MacFarlane, GM Cohen, MP Manns, K Schulze-Osthoff, H Bantel |
Hepatology | 2007 |
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling
A Thorburn |
Journal of Thoracic Oncology | 2007 |
Inducing rigid local structure around the zinc-binding region by hydrophobic interactions enhances the homotrimerization and apoptotic activity of zinc-free TRAIL
HW Lee, TI Kim, KH Chan, MH Kwon, JS Kim, M Jin, YS Kim |
Biochemical and Biophysical Research Communications | 2007 |
Profiling of Apoptotic Changes in Human Breast Cancer Cells Using SELDI-TOF Mass Spectrometry
S Leong, R Christopherson, R Baxter |
Cellular Physiology and Biochemistry | 2007 |
Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase
ME Gasparian, VG Ostapchenko, AV Yagolovich, IN Tsygannik, BV Chernyak, DA Dolgikh, MP Kirpichnikov |
Biotechnology Letters | 2007 |
Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor–related apoptosis-inducing ligand
M Nagane, WK Cavenee, Y Shiokawa |
Journal of Neurosurgery | 2007 |
Interferon-γ is produced by another player of innate immune responses: The interferon-producing killer dendritic cell (IKDC)
M Bonmort, E Ullrich, G Mignot, B Jacobs, N Chaput, L Zitvogel |
Biochimie | 2007 |
15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation
H Han, SW Shin, CY Seo, HC Kwon, JY Han, IH Kim, JY Kwak, JI Park |
Apoptosis | 2007 |
Enhanced proapoptotic effects of tumor necrosis factor–related apoptosis-inducing ligand on temozolomide-resistant glioma cells
M Uzzaman, G Keller, IM Germano |
Journal of Neurosurgery | 2007 |
Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells
J Wei, J Wahl, H Knauss, S Zeller, G Jarmy, G Fitze, KM Debatin, C Beltinger |
Cancer Gene Therapy | 2007 |
Targeting death-inducing receptors in cancer therapy
K Takeda, J Stagg, H Yagita, K Okumura, MJ Smyth |
Oncogene | 2007 |
Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
YS Youn, MJ Shin, SY Chae, CH Jin, TH Kim, KC Lee |
Biotechnology Letters | 2007 |
Treatment with IFN?in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients
H Tanaka, T Ito, T Kyo, A Kimura |
European Journal of Haematology | 2007 |
Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors
H Tsurushima, X Yuan, LE Dillehay, KW Leong |
Cancer Gene Therapy | 2007 |
Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines
M Russo, P Nigro, R Rosiello, R D'Arienzo, GL Russo |
Leukemia | 2007 |
Recombinant adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene suppresses human pancreatic cancer growth
R Tian, R Qin, Z Du, W Xia, C Shi |
The Chinese-German Journal of Clinical Oncology | 2007 |
TRAILs and tribulation
H Malhi |
Hepatology | 2007 |
Construction and characterization of two versions of bifunctional EGFP–sTRAIL fusion proteins
J Shen, Y Wu, L Shi, J Liu, S Liu, Z Guan, Z Yin |
Applied Microbiology and Biotechnology | 2007 |
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
KW Wagner, EA Punnoose, T Januario, DA Lawrence, RM Pitti, K Lancaster, D Lee, M Goetz, SF Yee, K Totpal, L Huw, V Katta, G Cavet, SG Hymowitz, L Amler, A Ashkenazi |
Nature Medicine | 2007 |
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms
C Gill, SE Walsh, C Morrissey, JM Fitzpatrick, RW Watson |
The Prostate | 2007 |
Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas
S Heikaus, E Casliskan, C Mahotka, HE Gabbert, U Ramp |
Apoptosis | 2007 |
Screening of a novel octamer peptide, CNSCWSKD, that induces caspase-dependent cell death
C Kaga, M Okochi, M Nakanishi, H Hayashi, R Kato, H Honda |
Biochemical and Biophysical Research Communications | 2007 |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers
JE Kendrick, JM Estes, JM Straughn, RD Alvarez, DJ Buchsbaum |
Gynecologic Oncology | 2007 |
α-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand
M Li, S Zhou, X Liu, P Li, MA McNutt, G Li |
Cancer Letters | 2007 |
Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia
M Moulin, C Dumontet, AP Arrigo |
Cancer Letters | 2007 |
Vitamin E analogues as a novel group of mitocans: Anti-cancer agents that act by targeting mitochondria
J Neuzil, LF Dong, L Ramanathapuram, T Hahn, M Chladova, XF Wang, R Zobalova, L Prochazka, M Gold, R Freeman, J Turanek, ET Akporiaye, JC Dyason, SJ Ralph |
Molecular Aspects of Medicine | 2007 |
TRAIL-receptor antibodies as a potential cancer treatment
DJ Buchsbaum, A Forero-Torres, AF LoBuglio |
Future Oncology | 2007 |
A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy- 12, 14 prostaglandin J2 production
H Hasegawa, Y Yamada, K Komiyama, M Hayashi, M Ishibashi, T Sunazuka, T Izuhara, K Sugahara, K Tsuruda, M Masuda, N Takasu, K Tsukasaki, M Tomonaga, S Kamihira |
Blood | 2007 |
Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway
E Cretney, K Takeda, MJ Smyth |
The International Journal of Biochemistry & Cell Biology | 2007 |
Emerging Approaches in Hepatocellular Carcinoma
LM Kulik, MF Mulcahy, RA Omary, R Salem |
Journal of Clinical Gastroenterology | 2007 |
Enhancement of Cell Death by TNF α-related Apoptosis-inducing Ligand (TRAIL) in Human Lung Carcinoma A549 Cells Exposed to X Rays under Hypoxia
M TAKAHASHI, O INANAMI, N KUBOTA, M TSUJITANI, H YASUI, A OGURA, M KUWABARA |
Journal of Radiation Research | 2007 |
The State of the Art in the Pathogenesis of ATL and New Potential Targets Associated with HTLV-1 and ATL
K Murata, Y Yamada |
International Reviews of Immunology | 2007 |
Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway
I Verbrugge, E Vries, SW Tait, EH Wissink, H Walczak, M Verheij, J Borst |
Oncogene | 2007 |
CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells
D Llobet, N Eritja, M Encinas, N Llecha, A Yeramian, J Pallares, A Sorolla, FJ Gonzalez-Tallada, X Matias-Guiu, X Dolcet |
Oncogene | 2007 |
Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver
M Ishii, M Iwai, Y Harada, T Kishida, H Asada, M Shin-Ya, Y Itoh, J Imanishi, T Okanoue, O Mazda |
Cancer Letters | 2007 |
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein
J Stieglmaier, E Bremer, C Kellner, TM Liebig, B Cate, M Peipp, H Schulze-Koops, M Pfeiffer, HJ Bühring, J Greil, F Oduncu, B Emmerich, GH Fey, W Helfrich |
Cancer Immunology, Immunotherapy | 2007 |
Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane
Š Šímová, M Klíma, L Cermak, V Šourková, L Anděra |
Apoptosis | 2007 |
MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release
A Mohr, C Büneker, RP Gough, RM Zwacka |
Oncogene | 2007 |
Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation
S Nomura, K Ishii, N Inami, N Uoshima, H Ishida, T Yoshihara, H Kitayama, K Hayashi |
Transplant Immunology | 2007 |
Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL
LE DeForge, DH Shih, D Kennedy, K Totpal, A Chuntharapai, GL Bennett, JH Drummond, P Siguenza, WL Wong |
Journal of Immunological Methods | 2007 |
Cytogenetic and molecular biological characterization of an adult medulloblastoma
H Holland, R Koschny, W Krupp, J Meixensberger, M Bauer, R Schober, H Kirsten, TM Ganten, P Ahnert |
Cancer Genetics and Cytogenetics | 2007 |
P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes
EN de Toni, C Kuntzen, AL Gerbes, WE Thasler, N Sonuc, SR Mucha, P Camaj, C Bruns, B Göke, ST Eichhorst |
Journal of Hepatology | 2007 |
Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis
M Kusaba, K Nakao, T Goto, D Nishimura, H Kawashimo, H Shibata, Y Motoyoshi, N Taura, T Ichikawa, K Hamasaki, K Eguchi |
Journal of Hepatology | 2007 |
Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells
MJ Wang, S Liu, Y Liu, D Zheng |
Neuroscience Research | 2007 |
Cutting-Edge Apoptosis-Based Therapeutics: A Panacea for Cancer?
U Fischer, K Janssen, K Schulze-Osthoff |
BioDrugs | 2007 |
NEURAL STEM CELLS AND ARMED DERIVATIVES: FATE AND THERAPEUTIC POTENTIAL IN THE BRAIN
K Shah |
Gene Therapy and Regulation | 2007 |
Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells
VN Ivanov, H Zhou, TK Hei |
Cancer research | 2007 |
The Potential of Death Receptor 4– and 5–Directed Therapies in the Treatment of Lung Cancer
DR Camidge |
Clinical Lung Cancer | 2007 |
Targeted Therapies in Oncology
L Ellis |
Targeted Therapies in Oncology | 2007 |
Brandisianins A−F, Isoflavonoids Isolated from Millettia brandisiana in a Screening Program for Death-Receptor Expression Enhancement Activity
H Kikuchi, T Ohtsuki, T Koyano, T Kowithayakorn, T Sakai, M Ishibashi |
Journal of Natural Products | 2007 |
Synergistic Effects in Apoptosis Induction by Taurolidine and TRAIL in HCT-15 Colon Carcinoma Cells
AM Chromik, A Daigeler, C Hilgert, D Bulut, A Geisler, V Liu, JM Otte, W Uhl, U Mittelkötter |
Journal of Investigative Surgery | 2007 |
Nitrosylcobalamin Potentiates the Anti-Neoplastic Effects of Chemotherapeutic Agents via Suppression of Survival Signaling
JA Bauer, JA Lupica, H Schmidt, BH Morrison, RM Haney, RK Masci, RM Lee, JA DiDonato, DJ Lindner, E Grimm |
PloS one | 2007 |
Tumor Necrosis Factor-related Apoptosis-inducing Ligand Activates a Lysosomal Pathway of Apoptosis That Is Regulated by Bcl-2 Proteins
NW Werneburg, ME Guicciardi, SF Bronk, SH Kaufmann, GJ Gores |
The Journal of biological chemistry | 2007 |
MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis: A MECHANISTIC BASIS FOR SORAFENIB (BAY 43-9006)-INDUCED TRAIL SENSITIZATION
XW Meng, SH Lee, H Dai, D Loegering, C Yu, K Flatten, P Schneider, NT Dai, SK Kumar, BD Smith, JE Karp, AA Adjei, SH Kaufmann |
The Journal of biological chemistry | 2007 |
Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding
L Bin, J Thorburn, LR Thomas, PE Clark, R Humphreys, A Thorburn |
The Journal of biological chemistry | 2007 |
Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-κB or Tumor Necrosis Factor-related Apoptosis-inducing Ligand: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS
S Vitovski, JS Phillips, J Sayers, PI Croucher |
The Journal of biological chemistry | 2007 |
Apoptosis, Senescence, and Cancer
DA Gewirtz, SE Holt, S Grant |
2007 | |
The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies
DM Nguyen, M Hussain |
Journal of Bioenergetics and Biomembranes | 2007 |
Apoptosis, Cell Signaling, and Human Diseases
R Srivastava |
2007 | |
Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents:
J SUN, Z FU, C FANG, J LI |
Chinese Medical Journal | 2007 |
Inhibition of Trail Gene Expression by Cyclopentenonic Prostaglandin 15-Deoxy-Δ 12,14 -Prostaglandin J 2 in T Lymphocytes
C Fionda, F Nappi, M Piccoli, L Frati, A Santoni, M Cippitelli |
Molecular pharmacology | 2007 |
Silibinin Sensitizes Human Glioma Cells to TRAIL-Mediated Apoptosis via DR5 Up-regulation and Down-regulation of c-FLIP and Survivin
Y Son, EH Kim, JY Kim, SU Kim, TK Kwon, AR Yoon, CO Yun, KS Choi |
Cancer research | 2007 |
Combination Treatment with TRA-8 Anti–Death Receptor 5 Antibody and CPT-11 Induces Tumor Regression in an Orthotopic Model of Pancreatic Cancer
LC DeRosier, DJ Buchsbaum, PG Oliver, ZQ Huang, JC Sellers, WE Grizzle, W Wang, T Zhou, KR Zinn, JW Long, SM Vickers |
Clinical cancer research | 2007 |
Curcumin [1,7-Bis(4-hydroxy-3-methoxyphenyl)-1–6-heptadine-3,5-dione; C 21 H 20 O 6 ] Sensitizes Human Prostate Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand/Apo2L-Induced Apoptosis by Suppressing Nuclear Factor-κB via Inhibition of the Prosurvival Akt Signaling Pathway
D Deeb, H Jiang, X Gao, S Al-Holou, AL Danyluk, SA Dulchavsky, SC Gautam |
The Journal of pharmacology and experimental therapeutics | 2007 |
Aspirin Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Hormone-Refractory Prostate Cancer Cells through Survivin Down-Regulation
J Yoo, YJ Lee |
Molecular pharmacology | 2007 |
Selective Inhibition of IκB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level
G Roué, P Pérez-Galán, M López-Guerra, N Villamor, E Campo, D Colomer |
Journal of immunology (Baltimore, Md. : 1950) | 2007 |
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W |
Cancer Immunology, Immunotherapy | 2007 |
Lipoxygenase inhibitors induce death receptor 5/TRAIL‐R2 expression and sensitize malignant tumor cells to TRAIL‐induced apoptosis
Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, Wakada M, Mizutani Y, Miki T, Nishikawa A, Sakai T |
Cancer Science | 2007 |
TRAIL receptor-mediated Jun kinase activation and Bim phosphorylation critically regulate Fas (CD95)-mediated liver damage and lethality
Nadia Corazza, Sabine Jakob, Corinne Schaer, Steffen Frese, Adrian Keogh, Deborah Stroka, Daniela Kassahn, Ralph Torgler, Christoph Mueller, Pascal Schneider, Thomas Brunner |
Journal of Clinical Investigation | 2006 |
TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque
K Sato, A Niessner, SL Kopecky, RL Frye, JJ Goronzy, CM Weyand |
Journal of Experimental Medicine | 2006 |
cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis
ME Guicciardi, SF Bronk, NW Werneburg, GJ Gores |
AJP Gastrointestinal and Liver Physiology | 2006 |
TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors
K Tateishi, M Ohta, B Guleng, F Kanai, Y Tanaka, Y Asaoka, A Jazag, J Imamura, T Imamura, H Ijichi, T Ikenoue, T Kawakami, Y Fukushima, M Washida, M Sata, M Miyagishi, K Taira, H Yoshida, T Kawabe, M Omata |
International Journal of Cancer | 2006 |
Antitumor Activity of Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
C Carlo-Stella, C Lavazza, MD Nicola, L Cleris, P Longoni, M Milanesi, M Magni, D Morelli, A Gloghini, A Carbone, AM Gianni |
Human Gene Therapy | 2006 |
Chemotherapeutic approaches for targeting cell death pathways
MS Ricci, WX Zong |
The oncologist | 2006 |
Modulating apoptosis as a target for effective therapy
A Fleischer, A Ghadiri, F Dessauge, M Duhamel, MP Rebollo, F Alvarez-Franco, A Rebollo |
Molecular Immunology | 2006 |
Shared biology of GVHD and GVT effects: Potential methods of separation
DH Fowler |
Critical Reviews in Oncology/Hematology | 2006 |
Apoptosis: mechanisms and implications for cancer therapeutics
MM Mita, AC Mita, AW Tolcher |
Targeted Oncology | 2006 |
Tnfsf10
E Kratz, A Ashkenazi |
AfCS-Nature Molecule Pages | 2006 |
Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis
P Clarke, KL Tyler |
Apoptosis : an international journal on programmed cell death | 2006 |
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2
D Mérino, N Lalaoui, A Morizot, P Schneider, E Solary, O Micheau |
Molecular and cellular biology | 2006 |
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor
AM van der Sloot, V Tur, E Szegezdi, MM Mullally, RH Cool, A Samali, L Serrano, WJ Quax |
Proceedings of the National Academy of Sciences | 2006 |
Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis
TO Garnett, M Filippova, PJ Duerksen-Hughes |
Cell Death and Differentiation | 2006 |
The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells
E Choi, Y Kim, K Kim |
Yonsei Medical Journal | 2006 |
The proteasome is required for rapid initiation of death receptor-induced apoptosis
D Sohn, G Totzke, F Essmann, K Schulze-Osthoff, B Levkau, RU Jänicke |
Molecular and cellular biology | 2006 |
Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation
MF Ziauddin, WS Yeow, JB Maxhimer, A Baras, A Chua, RM Reddy, W Tsai, GW Cole, DS Schrump, DM Nguyen |
Neoplasia (New York, N.Y.) | 2006 |
Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines
K Miyazaki, T Shibahara, D Sato, K Uchida, H Suzuki, H Matsui, A Yanaka, A Nakahara, Y Matsuzaki |
Journal of Gastroenterology | 2006 |
Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells
S Gillespie, J Borrow, XD Zhang, P Hersey |
Apoptosis | 2006 |
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL
A Pathil, S Armeanu, S Venturelli, P Mascagni, TS Weiss, M Gregor, UM Lauer, M Bitzer |
Hepatology | 2006 |
Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation
A Hamaï, C Richon, F Meslin, F Faure, A Kauffmann, Y Lecluse, A Jalil, L Larue, MF Avril, S Chouaib, M Mehrpour |
Oncogene | 2006 |
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
A Trauzold, D Siegmund, B Schniewind, B Sipos, J Egberts, D Zorenkov, D Emme, C Röder, H Kalthoff, H Wajant |
Oncogene | 2006 |
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
S Fulda, KM Debatin |
Oncogene | 2006 |
The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria
G Ortiz-Ferrón, SW Tait, G Robledo, E Vries, J Borst, A López-Rivas |
Cell Death and Differentiation | 2006 |
Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
C Carlo-Stella, C Lavazza, MD Nicola, L Cleris, P Longoni, M Milanesi, M Magni, D Morelli, A Gloghini, A Carbone, AM Gianni |
Human Gene Therapy | 2006 |
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer
FA Sinicrope |
Molecular Carcinogenesis | 2006 |
Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain
K Taylor, D Micha, M Ranson, C Dive |
Expert Opinion on Investigational Drugs | 2006 |
Caspase-8 dependent trail-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase
I Perez-Cruz, JM Cárcamo, DW Golde |
Apoptosis | 2006 |
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade
RM Reddy, WS Yeow, A Chua, DM Nguyen, A Baras, MF Ziauddin, SM Shamimi-Noori, JB Maxhimer, DS Schrump, DM Nguyen |
Apoptosis | 2006 |
Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases
JN Shin, SY Park, JH Cha, JY Park, BR Lee, SA Jung, ST Lee, CW Yun, DW Seol, TH Kim |
Experimental Cell Research | 2006 |
Long lasting heat shock stimulation of TRAIL-induced apoptosis in transformed T lymphocytes
M Moulin, AP Arrigo |
Experimental Cell Research | 2006 |
TRAIL-R4-β: A new splice variant of TRAIL-receptor 4 lacking the cysteine rich domain 1
A Krieg, JS 2nd, U Ramp, SB Hosch, WT Knoefel, HE Gabbert, C Mahotka |
Biochemical and Biophysical Research Communications | 2006 |
Soluble Tumor Necrosis Factor-Related Ligand (sTRAIL) Levels and Kinetics During Antiviral Treatment in Chronic Hepatitis C
N Pelli, F Torre, A Delfino, M Basso, A Picciotto |
Journal of Interferon & Cytokine Research | 2006 |
Functional solubilization of aggregation-prone TRAIL protein facilitated by coexpressing with protein isoaspartate methyltranferase
H Zhu, RJ Pan, TW Wang, YL Shen, DZ Wei |
Applied Microbiology and Biotechnology | 2006 |
TRAIL receptor-targeted therapy
DJ Buchsbaum, T Zhou, AF LoBuglio |
Future Oncology | 2006 |
Implication of TNF-Related Apoptosis-Inducing Ligand in Inflammatory Intestinal Epithelial Lesions
B Begue, H Wajant, JC Bambou, L Dubuquoy, D Siegmund, JF Beaulieu, D Canioni, D Berrebi, N Brousse, P Desreumaux, J Schmitz, MJ Lentze, O Goulet, N Cerf–Bensussan, FM Ruemmele |
Gastroenterology | 2006 |
The Essential Role of the Mitochondria-Dependent Death-Signaling Cascade in Chemotherapy-Induced Potentiation of Apo2L/TRAIL Cytotoxicity in Cultured Thoracic Cancer Cells
DM Nguyen, WS Yeow, MF Ziauddin, A Baras, W Tsai, RM Reddy, A Chua, GW Cole, DS Schrump |
The Cancer Journal | 2006 |
Gene Therapy Strategies for Hepatocellular Carcinoma
LH Hwang |
Journal of Biomedical Science | 2006 |
Testicular germ cell sensitivity to TRAIL-induced apoptosis is dependent upon p53 expression and is synergistically enhanced by DR5 agonistic antibody treatment
CM McKee, Y Ye, JH Richburg |
Apoptosis | 2006 |
The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer
A Dutton, LS Young, PG Murray |
Expert Opinion on Therapeutic Targets | 2006 |
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
LM Butler, V Liapis, S Bouralexis, K Welldon, S Hay, LM Thai, A Labrinidis, WD Tilley, DM Findlay, A Evdokiou |
International Journal of Cancer | 2006 |
Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo
P Liu, H Mao, P Hou |
International Journal of Gynecological Cancer | 2006 |
Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model
J Yoo, S Choi, KS Hwang, WK Cho, CR Jung, ST Kwon, DS Im |
The Journal of Gene Medicine | 2006 |
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis
BM Hougardy, JH Maduro, AG van der Zee, DJ de Groot, FA van Heuvel, EG de Vries, S Jong |
International Journal of Cancer | 2006 |
Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay
SA Cillessen, CJ Meijer, GJ Ossenkoppele, KC Castricum, AH Westra, P Niesten, JJ Muris, HF Nijdam, KG van der Hem, M Flens, E Hooijberg, JJ Oudejans |
British Journal of Haematology | 2006 |
TRAIL gene reorganizes the cytoskeleton and decreases the motility of human leukemic Jurkat cells
Y Jiang, K Chen, Z Tang, Z Zeng, W Yao, D Sun, W Ka, D He, Z Wen, S Chien |
Cell Motility and the Cytoskeleton | 2006 |
The Role of Death Receptor Signaling in Testicular Germ-Cell Apoptosis Triggered by Mono-(2-ethylhexyl) Phthalate (MEHP)-Induced Sertoli Cell Injury and Its Implications for Risk Assessment
JH Richburg |
Journal of Toxicology and Environmental Health, Part A | 2006 |
Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma
T Azuhata, D Scott, TS Griffith, M Miller, AD Sandler |
Journal of Pediatric Surgery | 2006 |
Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo
P Marini, S Denzinger, D Schiller, S Kauder, S Welz, R Humphreys, PT Daniel, V Jendrossek, W Budach, C Belka |
Oncogene | 2006 |
Over-expressed estrogen receptor-α up-regulates hTNF-α gene expression and down-regulates β-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells
HH Hsu, SF Cheng, LM Chen, JY Liu, CH Chu, YJ Weng, ZY Li, CS Lin, SD Lee, WW Kuo, CY Huang |
Molecular and Cellular Biochemistry | 2006 |
Expression of TNF-related Apoptosis-inducing Ligand (TRAIL) and TRAIL Receptor 1 on Cancer and Normal Tissues in Patients with Non-small Cell Lung Cancer
T Kawashima, R Matsumura, K Umemiya, S Kawashima, K Kikkawa, Y Nishi, T Goto, Y Matsuzawa, H Tomioka, H Yamakawa |
Haigan | 2006 |
TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis
CA Dumitru, E Gulbins |
Oncogene | 2006 |
Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-κB
AC Williams, H Smartt, AM H-Zadeh, M MacFarlane, C Paraskeva, TJ Collard |
Cell Death and Differentiation | 2006 |
Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors
T Wenger, J Mattern, R Penzel, N Gassler, TL Haas, MR Sprick, H Walczak, PH Krammer, KM Debatin, I Herr |
Cell Death and Differentiation | 2006 |
Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin
K Schultze, B Böck, A Eckert, L Oevermann, D Ramacher, O Wiestler, W Roth |
Apoptosis | 2006 |
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity
RL VanOosten, JK Earel, TS Griffith |
Apoptosis | 2006 |
Adenoviral-mediated interferon α overcomes resistance to the interferon protein in various cancer types and has marked bystander effects
X Zhang, Z Yang, L Dong, A Papageorgiou, DJ McConkey, WF Benedict |
Cancer Gene Therapy | 2006 |
The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors
JM Kuijlen, BJ Haan, W Helfrich, JF Boer, D Samplonius, JJ Mooij, P Vos |
Journal of Neuro-Oncology | 2006 |
Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy
A Crijns, E Duiker, S JONG, P Willemse, AG der ZEE, EG VRIES |
International Journal of Gynecological Cancer | 2006 |
TRAIL-mediated Cytotoxicity: Impacts of sTRAIL and vTRAIL Microvesicles
AF ., SJ ., YY ., YA ., TA ., TK . |
Journal of Biological Sciences | 2006 |
Cancer gene-therapy: clinical trials
DH Palmer, LS Young, V Mautner |
Trends in Biotechnology | 2006 |
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model
JM Straughn, PG Oliver, T Zhou, W Wang, RD Alvarez, WE Grizzle, DJ Buchsbaum |
Gynecologic Oncology | 2006 |
TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme
JM Kuijlen, JJ Mooij, I Platteel, EW Hoving, WT Graaf, MM Span, H Hollema, WF Dunnen |
Journal of Neuro-Oncology | 2006 |
TRAIL, caspases and maturation of normal and leukemic myeloid precursors
F Corallini, D Milani, V Nicolin, P Secchiero |
Leukemia & Lymphoma | 2006 |
Immunomodulatory neural stem cells for brain tumour therapy
JJ Yu, X Sun, X Yuan, JW Lee, EY Snyder, JS Yu |
Expert Opinion on Biological Therapy | 2006 |
Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor–related apoptosis-inducing ligand
WS Yeow, A Baras, A Chua, DM Nguyen, SS Sehgal, DS Schrump, DM Nguyen |
The Journal of Thoracic and Cardiovascular Surgery | 2006 |
A CD40–CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95
C Assohou-Luty, J Gerspach, D Siegmund, N Müller, B Huard, G Tiegs, K Pfizenmaier, H Wajant |
Journal of Molecular Medicine | 2006 |
Targeting Death Receptors in Bladder, Prostate and Renal Cancer
HF O’Kane, CJ Watson, SR Johnston, I Petak, R William, G Watson, KE Williamson |
The Journal of Urology | 2006 |
Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor–related apoptosis-inducing ligand
L Zhuang, CS Lee, RA Scolyer, SW McCarthy, XD Zhang, JF Thompson, G Screaton, P Hersey |
Human Pathology | 2006 |
In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma
JQ Tian, ZP Wang, R Rodriguez, JS Fu, JZ Lu, BL Ma |
Urology | 2006 |
Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis
S Boehrer, D Nowak, E Puccetti, M Ruthardt, N Sattler, B Trepohl, B Schneider, D Hoelzer, PS Mitrou, KU Chow |
Leukemia Research | 2006 |
Activation of the Proapoptotic Death Receptor DR5 by Oligomeric Peptide and Antibody Agonists
B Li, SJ Russell, DM Compaan, K Totpal, SA Marsters, A Ashkenazi, AG Cochran, SG Hymowitz, SS Sidhu |
Journal of Molecular Biology | 2006 |
TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway
A Jurewicz, M Matysiak, S Andrzejak, K Selmaj |
Glia | 2006 |
TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy
EH Wissink, I Verbrugge, SR Vink, MB Schader, U Schaefer, H Walczak, J Borst, M Verheij |
Radiotherapy and Oncology | 2006 |
Death ligands and autoimmune demyelination
O Aktas, T Prozorovski, F Zipp |
The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry | 2006 |
The clinical trail of TRAIL
EW Duiker, CH Mom, S Jong, PH Willemse, JA Gietema, AG der Zee, EG Vries |
European Journal of Cancer | 2006 |
Differential response of neuroblastoma cells to TRAIL is independent of PI3K/AKT
PA Efron, MK Chen, M Iyengar, W Dai, A Nagaram, EA Beierle |
Journal of Pediatric Surgery | 2006 |
Immunoplacental therapy, a potential multi-epitope cancer vaccine
A Harandi |
Medical Hypotheses | 2006 |
Colorectal Cancer
G Chong, D Cunningham |
Colorectal Cancer | 2006 |
Hyperthermia enhances tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human cancer cells
J Yoo, HR Kim, YJ Lee |
International Journal of Hyperthermia | 2006 |
Gene Expression Analysis on the Dicyclanil-Induced Hepatocellular Tumors in Mice
M Moto, M Okamura, M Muguruma, T Ito, M Jin, Y Kashida, K Mitsumori |
Toxicologic pathology | 2006 |
Prognostic Significance of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients
CM van Geelen, JL Westra, EG de Vries, WB Ek, N Zwart, H Hollema, HM Boezen, NH Mulder, JT Plukker, S Jong, JH Kleibeuker, JJ Koornstra |
Journal of Clinical Oncology | 2006 |
Perspectivas de novos tratamentos para o carcinoma tireoidiano avançado
A Rodrigues |
Revista do Colégio Brasileiro de Cirurgiões | 2006 |
Evidence for Two Modes of Development of Acquired Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance: INVOLVEMENT OF Bcl-xL
JJ Song, JY An, YT Kwon, YJ Lee |
The Journal of biological chemistry | 2006 |
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
N Ishimura, H Isomoto, SF Bronk, GJ Gores |
AJP Gastrointestinal and Liver Physiology | 2006 |
TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression
NJ Clemons, RL Anderson |
Cell Stress and Chaperones | 2006 |
The Link Between Inflammation and Cancer
AG Dalgleish, B Haefner |
2006 | |
TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract
A Sadarangani, S Kato, N Espinoza, S Lange, C Llados, M Espinosa, M Villalón, S Lipkowitz, M Cuello, GI Owen |
Apoptosis | 2006 |
Breast Cancer and Molecular Medicine
MJ Piccart, MC Hung, LJ Solin, F Cardoso, WC Wood |
2006 | |
Selective TRAIL-Induced Apoptosis in Dysplastic Neoplasia of the Colon May Lead to New Neoadjuvant or Adjuvant Therapies
N Finnberg, WS El-Deiry |
Clinical cancer research | 2006 |
Inducible Resistance of Tumor Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2–Mediated Apoptosis by Generation of a Blockade at the Death Domain Function
Y Li, H Wang, Z Wang, S Makhija, D Buchsbaum, A LoBuglio, R Kimberly, T Zhou |
Cancer research | 2006 |
Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand–Armed Oncolytic Adenovirus
F Dong, L Wang, JJ Davis, W Hu, L Zhang, W Guo, F Teraishi, L Ji, B Fang |
Clinical cancer research | 2006 |
A Novel Selective Progesterone Receptor Modulator Asoprisnil Activates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Signaling Pathway in Cultured Human Uterine Leiomyoma Cells in the Absence of Comparable Effects on Myometrial Cells
H Sasaki, N Ohara, Q Xu, J Wang, DA DeManno, K Chwalisz, S Yoshida, T Maruo |
The Journal of clinical endocrinology and metabolism | 2006 |
Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma
MM McCarthy, KA DiVito, M Sznol, D Kovacs, R Halaban, AJ Berger, KT Flaherty, RL Camp, R Lazova, DL Rimm, HM Kluger |
Clinical cancer research | 2006 |
Wogonin sensitizes resistant malignant cells to TNFα- and TRAIL-induced apoptosis
SC Fas, S Baumann, JY Zhu, M Giaisi, MK Treiber, U Mahlknecht, PH Krammer, M Li-Weber |
Blood | 2006 |
Transduction of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand into Hematopoietic Cells Leads to Inhibition of Syngeneic Tumor Growth In vivo
K Song, N Benhaga, RL Anderson, R Khosravi-Far |
Cancer research | 2006 |
TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM, Mooij JJ, Platteel I, Hoving EW, van der Graaf WT, Span MM, Hollema H, den Dunnen WF |
Journal of Neuro-Oncology | 2006 |
The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors.
Kuijlen JM, de Haan BJ, Helfrich W, de Boer JF, Samplonius D, Mooij JJ, de Vos P |
Journal of Neuro-Oncology | 2006 |
Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells.
Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH, Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW, Huang CY |
Molecular and Cellular Biochemistry | 2006 |
Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).
Yang F, Shi P, Xi X, Yi S, Li H, Sun Q, Sun M |
Medical Oncology | 2006 |
A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.
Assohou-Luty C, Gerspach J, Siegmund D, Müller N, Huard B, Tiegs G, Pfizenmaier K, Wajant H |
Journal of Molecular Medicine | 2006 |
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells
P Secchiero, M Tiribelli, E Barbarotto, C Celeghini, A Michelutti, P Masolini, R Fanin, G Zauli |
Journal of Cellular Physiology | 2005 |
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
TR Singh, S Shankar, RK Srivastava |
Oncogene | 2005 |
New Approaches and Therapeutics Targeting Apoptosis in Disease
U Fischer, K Schulze-Osthoff |
Pharmacological reviews | 2005 |
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Alters Mitochondrial Membrane Lipids
F Sandra, MD Esposti, K Ndebele, P Gona, D Knight, M Rosenquist, R Khosravi-Far |
Cancer research | 2005 |
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells
LY Dimberg, AI Dimberg, K Ivarsson, T Strömberg, A Österborg, K Nilsson, F Öberg, HJ Wiklund |
Blood | 2005 |
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake
B Mundt, T Wirth, L Zender, M Waltemathe, C Trautwein, MP Manns, F Kühnel, S Kubicka |
Gut | 2005 |
Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL
O Aktas, A Smorodchenko, S Brocke, C Infante-Duarte, US Topphoff, J Vogt, T Prozorovski, S Meier, V Osmanova, E Pohl, I Bechmann, R Nitsch, F Zipp |
Neuron | 2005 |
Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer
M Jalving, JJ Koornstra, S Jong, EG Vries, JH Kleibeuker |
Alimentary Pharmacology and Therapeutics | 2005 |
A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells
H Matsukawa, T Kanai, M Naganuma, N Kamada, T Hisamatsu, H Takaishi, H Ogata, M Mukai, H Ishii, T Mimori, M Watanabe, T Hibi |
Journal of Gastroenterology | 2005 |
Increased Expression and a Potential Anti-Inflammatory Role of TRAIL in Atopic Dermatitis
E Vassina, M Leverkus, S Yousefi, LR Braathen, HU Simon, D Simon |
Journal of Investigative Dermatology | 2005 |
Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease
B Fadeel, S Orrenius |
Journal of Internal Medicine | 2005 |
Angiogenesis and apoptosis in glioma: Two arenas for promising new therapies
O Bögler, T Mikkelsen |
Journal of Cellular Biochemistry | 2005 |
Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells
KU Kim, SY Seo, KY Heo, YH Yoo, HJ Kim, HS Lee, SS Choi, TH Hwang, HJ Lee |
Journal of Korean Medical Science | 2005 |
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis
L Clancy, K Mruk, K Archer, M Woelfel, J Mongkolsapaya, G Screaton, MJ Lenardo, FK Chan |
Proceedings of the National Academy of Sciences | 2005 |
Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8
S Shin, Y Lee, W Kim, H Ko, H Choi, K Kim |
The EMBO Journal | 2005 |
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance
KU Kim, SM Wilson, KS Abayasiriwardana, R Collins, L Fjellbirkeland, Z Xu, DM Jablons, SL Nishimura, VC Broaddus |
American journal of respiratory cell and molecular biology | 2005 |
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
BL Hylander, R Pitoniak, RB Penetrante, JF Gibbs, D Oktay, J Cheng, EA Repasky |
Journal of Translational Medicine | 2005 |
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac, P Kanakaraj, R Humphreys, R Alderson, M Bloom, C Sung, T Riccobene, R Johnson, M Fiscella, A Mahoney, J Carrell, E Boyd, XT Yao, L Zhang, L Zhong, A Kerczek, L Shepard, T Vaughan, B Edwards, C Dobson, T Salcedo, V Albert |
British Journal of Cancer | 2005 |
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes
D Campioni, P Secchiero, F Corallini, E Melloni, S Capitani, F Lanza, G Zauli |
The American Journal of Pathology | 2005 |
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis
P Marini, A Schmid, V Jendrossek, H Faltin, PT Daniel, W Budach, C Belka |
BMC Cancer | 2005 |
Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines
T Matsuda, A Almasan, M Tomita, J Uchihara, M Masuda, K Ohshiro, N Takasu, H Yagita, T Ohta, N Mori |
Journal of virology | 2005 |
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts
A El-Zawahry, J McKillop, C Voelkel-Johnson |
BMC Cancer | 2005 |
Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development
E Melloni, P Secchiero, C Celeghini, D Campioni, V Grill, L Guidotti, G Zauli |
Journal of Cellular Physiology | 2005 |
Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis
A Hague, DJ Hicks, F Hasan, H Smartt, GM Cohen, C Paraskeva, M MacFarlane |
British Journal of Cancer | 2005 |
Apoptosis: mechanisms and relevance in cancer
K Vermeulen, DR Bockstaele, ZN Berneman |
Annals of Hematology | 2005 |
Chronic Lymphocytic Leukemia
N Chiorazzi, KR Rai, M Ferrarini |
New England Journal of Medicine | 2005 |
Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors Part 5: apoptosis and cell cycle
HB Newton |
Expert Review of Anticancer Therapy | 2005 |
Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors
HW Lee, SH Lee, HW Lee, YW Ryu, MH Kwon, YS Kim |
Biochemical and Biophysical Research Communications | 2005 |
The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells
M Horinaka, T Yoshida, T Shiraishi, S Nakata, M Wakada, R Nakanishi, H Nishino, T Sakai |
Biochemical and Biophysical Research Communications | 2005 |
Death squads enlisted by the tumour suppressor p53
E Michalak, A Villunger, M Erlacher, A Strasser |
Biochemical and Biophysical Research Communications | 2005 |
Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand
H Hasegawa, Y Yamada, H Harasawa, T Tsuji, K Murata, K Sugahara, K Tsuruda, S Ikeda, Y Imaizumi, M Tomonaga, M Masuda, N Takasu, S Kamihira |
British Journal of Haematology | 2005 |
Requirement of c-Jun NH2-terminal kinase activation in interferon-α-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells
N Yanase, K Hata, K Shimo, M Hayashida, BM Evers, J Mizuguchi |
Experimental Cell Research | 2005 |
Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice
H Ma, Y Liu, S Liu, R Xu, D Zheng |
Hepatology | 2005 |
Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand1
F FANG, A WANG, S YANG |
Acta Pharmacologica Sinica | 2005 |
Other Compounds and Targets in Non–Small Cell Lung Cancer
V Villaflor, P Bonomi |
Seminars in Oncology | 2005 |
Cancer gene therapy using a novel secretable trimeric TRAIL
CY Kim, M Jeong, H Mushiake, BM Kim, WB Kim, JP Ko, MH Kim, M Kim, TH Kim, PD Robbins, TR Billiar, DW Seol |
Gene Therapy | 2005 |
In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL
A El-Zawahry, P Lu, SJ White, C Voelkel-Johnson |
Cancer Gene Therapy | 2005 |
Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors
H Ma, Y Liu, S Liu, HF Kung, X Sun, D Zheng, R Xu |
International Journal of Cancer | 2005 |
On the TRAIL of a new therapy for leukemia
SH Kaufmann, DP Steensma |
Leukemia | 2005 |
Initiation factor modifications in the preapoptotic phase
SJ Morley, MJ Coldwell, MJ Clemens |
Cell Death and Differentiation | 2005 |
Extensive regions of the FADD death domain are required for binding to the TRAIL receptor DR5
LR Thomas, LM Bender, MJ Morgan, A Thorburn |
Cell Death and Differentiation | 2005 |
TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway
J Wendt, C Haefen, P Hemmati, C Belka, B Dörken, PT Daniel |
Oncogene | 2005 |
TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-β in cervical carcinoma cells
S Vannucchi, MV Chiantore, G Fiorucci, ZA Percario, S Leone, E Affabris, G Romeo |
Oncogene | 2005 |
Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas
H Kumamoto, K Ooya |
Journal of Oral Pathology and Medicine | 2005 |
Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults
JW Choi |
Annals of Hematology | 2005 |
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
M MacFarlane, S Inoue, SL Kohlhaas, A Majid, N Harper, DB Kennedy, MJ Dyer, GM Cohen |
Cell Death and Differentiation | 2005 |
A new TRAIL to therapy of hepatocellular carcinoma: Blocking the proteasome
A Anan, GJ Gores |
Hepatology | 2005 |
Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?
BM Reipert, S Tanneberger, A Pannetta, M Bedosti, M Poell, K Zimmermann, MT Stellamor |
Cancer Immunology, Immunotherapy | 2005 |
TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice
E Cretney, JL McQualter, N Kayagaki, H Yagita, CC Bernard, IS Grewal, A Ashkenazi, MJ Smyth |
Immunology and Cell Biology | 2005 |
Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP
EH Kim, HS Kim, SU Kim, EJ Noh, JS Lee, KS Choi |
Oncogene | 2005 |
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
TM Ganten, R Koschny, TL Haas, J Sykora, M Li-Weber, K Herzer, H Walczak |
Hepatology | 2005 |
Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells
K Herzer, TM Ganten, H Schulze-Bergkamen, A Grosse-Wilde, R Koschny, PH Krammer, H Walczak |
Hepatology | 2005 |
Promoting apoptosis as a strategy for cancer drug discovery
SW Fesik |
Nature Reviews Cancer | 2005 |
Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity
SA Kaliberov, S Chiz, LN Kaliberova, V Krendelchtchikova, DD Manna, T Zhou, DJ Buchsbaum |
Cancer Gene Therapy | 2005 |
Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor
S Ray, O Bucur, A Almasan |
Apoptosis | 2005 |
Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells
T Abdollahi, NM Robertson, A Abdollahi, G Litwack |
Apoptosis | 2005 |
Caspase 8 is absent or low in many ex vivo gliomas
DM Ashley, CD Riffkin, AM Muscat, MJ Knight, AH Kaye, U Novak, CJ Hawkins |
Cancer | 2005 |
Parenchymal regression in chronic pancreatitis spares islets reprogrammed for the expression of NFκB and IAPs
C Hasel, UK Bhanot, R Heydrich, J Sträter, P Möller |
Laboratory Investigation | 2005 |
Death Receptor Apoptosis Signaling Mediated by FADD in CD30-Positive Lymphoproliferative Disorders Involving the Skin
LE Clarke, MG Bayerl, RD Bruggeman, D Mauger, MD Ioffreda, A Abou-Elella, KF Helm |
The American Journal of Surgical Pathology | 2005 |
Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells
M Horinaka, T Yoshida, T Shiraishi, S Nakata, M Wakada, R Nakanishi, H Nishino, H Matsui, T Sakai |
Oncogene | 2005 |
FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis
X Dolcet, D Llobet, J Pallares, M Rue, JX Comella, X Matias-Guiu |
Laboratory Investigation | 2005 |
Apoptosis-based therapies and drug targets
U Fischer, K Schulze-Osthoff |
Cell Death and Differentiation | 2005 |
Characterisation of monoclonal antibodies to the TNF and TNF receptor families
PF Ch’en, XG Xu, XS Liu, Y Liu, CJ Song, GR Screaton, BQ Jin, XN Xu |
Cellular Immunology | 2005 |
Embryonic stem cell–derived astrocytes: a novel gene therapy vector for brain tumors
M Uzzaman, RJ Benveniste, G Keller, IM Germano |
Neurosurgical FOCUS | 2005 |
Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice
FJ Salguero, MA Sánchez-Martín, FD Segundo, A Avila, N Sevilla |
Virology | 2005 |
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study
N Reesink-Peters, BM Hougardy, FA Heuvel, KA Hoor, H Hollema, HM Boezen, EG Vries, S Jong, AG der Zee |
Gynecologic Oncology | 2005 |
Biology of plasma cells
S Chen-Kiang |
Best Practice & Research Clinical Haematology | 2005 |
Novel apoptosis inducing agents in cancer therapy
M Mita, AW Tolcher |
Current Problems in Cancer | 2005 |
Current status of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) targeting cancer therapy
E Mori, K Motoki, S Kataoka |
Annals of Cancer Research and Therapy | 2005 |
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
TJ Sayers, WJ Murphy |
Cancer Immunology, Immunotherapy | 2005 |
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: Potential targets for apoptosis induction
JJ Koornstra, M Jalving, FE Rijcken, J Westra, N Zwart, H Hollema, EG de Vries, RW Hofstra, JT Plukker, S Jong, JH Kleibeuker |
European Journal of Cancer | 2005 |
Selection for TRAIL resistance results in melanoma cells with high proliferative potential
JJ Wu, XD Zhang, S Gillespie, P Hersey |
FEBS Letters | 2005 |
Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis
E Mori, M Thomas, K Motoki, S Kataoka |
FEBS Letters | 2005 |
1'-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL
K Ito, T Nakazato, A Murakami, H Ohigashi, Y Ikeda, M Kizaki |
Biochemical and Biophysical Research Communications | 2005 |
Novel biological therapies for the treatment of multiple myeloma
PG Richardson, CS Mitsiades, T Hideshima, KC Anderson |
Best practice & research. Clinical haematology | 2005 |
Cell Death During HIV Infection
M Smith-Raska, M Lenardo, K Sakai |
Cell Death During HIV Infection: gp120 | 2005 |
TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation
VK Puduvalli, D Sampath, JM Bruner, J Nangia, R Xu, AP Kyritsis |
Apoptosis | 2005 |
Bcl-xL/Bax ratio is altered by IFNγ in TNFα- but not in TRAIL-induced apoptosis in colon cancer cell line
G Baillat, F Garrouste, M Remacle-Bonnet, J Marvaldi, G Pommier |
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | 2005 |
The Activation of ERK1/2 via a Tyrosine Kinase Pathway Attenuates Trail-Induced Apoptosis in HeLa Cells
MW Lee, JH Bach, HJ Lee, DY Lee, WS Joo, YS Kim, SC Park, KY Kim, WB Lee, SS Kim |
Cancer Investigation | 2005 |
Apoptosis and immaturity in acute myeloid leukemia
MI Principe, GD Poeta, A Venditti, F Buccisano, L Maurillo, C Mazzone, A Bruno, B Neri, MI Consalvo, FL Coco, S Amadori |
Hematology | 2005 |
Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating Agents
EK Rowinsky |
Journal of Clinical Oncology | 2005 |
Effective gene–virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5
XY Liu, SB Qiu, WG Zou, ZF Pei, JF Gu, CX Luo, HM Ruan, Y Chen, YP Qi, C Qian |
Molecular Therapy | 2005 |
Pretreatment of Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene Expression
KM Kim, JJ Song, JY An, YT Kwon, YJ Lee |
The Journal of biological chemistry | 2005 |
Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR
E Bremer, DF Samplonius, L Genne, MH Dijkstra, BJ Kroesen, LF de Leij, W Helfrich |
The Journal of biological chemistry | 2005 |
A Novel Anti-human DR5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase-dependent and Caspase-independent Cell Death
Y Guo, C Chen, Y Zheng, J Zhang, X Tao, S Liu, D Zheng, Y Liu |
The Journal of biological chemistry | 2005 |
A Peroxisome Proliferator-activated Receptor-γ Agonist, Troglitazone, Facilitates Caspase-8 and -9 Activities by Increasing the Enzymatic Activity of Protein-tyrosine Phosphatase-1B on Human Glioma Cells
Y Akasaki, G Liu, HH Matundan, H Ng, X Yuan, Z Zeng, KL Black, JS Yu |
The Journal of biological chemistry | 2005 |
Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines
K Izeradjene, L Douglas, A Delaney, JA Houghton |
Oncogene | 2005 |
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
S Bouralexis, DM Findlay, A Evdokiou |
Apoptosis | 2005 |
In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma
E Ciusani, D Croci, M Gelati, C Calatozzolo, F Sciacca, L Fumagalli, M Balzarotti, L Fariselli, A Boiardi, A Salmaggi |
Journal of Neuro-Oncology | 2005 |
Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases
M Los, SB Gibson |
2005 | |
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP
L Galligan, DB Longley, M McEwan, TR Wilson, K McLaughlin, PG Johnston |
Molecular cancer therapeutics | 2005 |
E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation
R Shao, DF Lee, Y Wen, Y Ding, W Xia, B Ping, H Yagita, B Spohn, MC Hung |
Molecular cancer research : MCR | 2005 |
Perturbation of the Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIP L and Deregulation of the Functional Receptors DR4 and DR5
P Horak, D Pils, A Kaider, A Pinter, K Elandt, C Sax, CC Zielinski, R Horvat, R Zeillinger, A Reinthaller, M Krainer |
Clinical cancer research | 2005 |
Target Cell–Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7
E Bremer, DF Samplonius, M Peipp, L van Genne, BJ Kroesen, GH Fey, M Gramatzki, LF de Leij, W Helfrich |
Cancer research | 2005 |
Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells
F Dicker, AP Kater, T Fukuda, TJ Kipps |
Blood | 2005 |
Caspase-10 Sensitizes Breast Carcinoma Cells to TRAIL-Induced but Not Tumor Necrosis Factor-Induced Apoptosis in a Caspase- 3-Dependent Manner
IH Engels, G Totzke, U Fischer, K Schulze-Osthoff, RU Jänicke |
Molecular and cellular biology | 2005 |
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
D Re, RK Thomas, K Behringer, V Diehl |
Blood | 2005 |
Apoptosis-based therapies for hematologic malignancies
JC Reed, M Pellecchia |
Blood | 2005 |
Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non–Small Cell Lung Cancer
X Zhang, RM Cheung, R Komaki, B Fang, JY Chang |
Clinical cancer research | 2005 |
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ, Murphy WJ |
Cancer Immunology, Immunotherapy | 2005 |
Sensitization of human glioblastomas to tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) by NF‐κB inhibitors
Kasuga C, Ebata T, Kayagaki N, Yagita H, Hishii M, Aral H, Sato K, Okumura K |
Cancer Science | 2005 |
AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression
A Mohr, G Henderson, L Dudus, I Herr, T Kuerschner, KM Debatin, H Weiher, KJ Fisher, RM Zwacka |
Gene Therapy | 2004 |
PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes
L Larribere, M Khaled, S Tartare-Deckert, R Busca, F Luciano, K Bille, G Valony, A Eychene, P Auberger, JP Ortonne, R Ballotti, C Bertolotto |
Cell Death and Differentiation | 2004 |
Lysosomes in cell death
ME Guicciardi, M Leist, GJ Gores |
Oncogene | 2004 |
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF
G Zauli, E Rimondi, V Nicolin, E Melloni, C Celeghini, P Secchiero |
Blood | 2004 |
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis
M Chawla-Sarkar, SI Bae, FJ Reu, BS Jacobs, DJ Lindner, EC Borden |
Cell Death and Differentiation | 2004 |
Blasts from the past
PA Insel, S Kornfeld, PW Majerus, AR Marks, PA Marks, AS Relman, BF Scharschmidt, TP Stossel, AP Varki, SJ Weiss, JD Wilson |
Journal of Clinical Investigation | 2004 |
Sensitization of Cells to TRAIL-induced Apoptosis by Decoy Receptor 3
YY Wu, YC Chang, TL Hsu, SL Hsieh, MZ Lai |
The Journal of biological chemistry | 2004 |
Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
K Takeda, N Yamaguchi, H Akiba, Y Kojima, Y Hayakawa, JE Tanner, TJ Sayers, N Seki, K Okumura, H Yagita, MJ Smyth |
Journal of Experimental Medicine | 2004 |
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Y Shao, Z Gao, PA Marks, X Jiang |
Proceedings of the National Academy of Sciences | 2004 |
Critical roles of TRAIL in hepatic cell death and hepatic inflammation
SJ Zheng, P Wang, G Tsabary, YH Chen |
Journal of Clinical Investigation | 2004 |
Apoptosis in cancer—implications for therapy
H Schulze-Bergkamen, PH Krammer |
Seminars in Oncology | 2004 |
Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system
G Eissner, W Kolch, P Scheurich |
Cytokine & Growth Factor Reviews | 2004 |
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity
MS Ricci, Z Jin, M Dews, D Yu, A Thomas-Tikhonenko, DT Dicker, WS El-Deiry |
Molecular and cellular biology | 2004 |
Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL
MA el Hassan, DC Mastenbroek, WR Gerritsen, G Giaccone, FA Kruyt |
British Journal of Cancer | 2004 |
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells
E Bremer, D Samplonius, BJ Kroesen, L Genne, L Leij, W Helfrich |
Neoplasia (New York, N.Y.) | 2004 |
Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand
P Secchiero, A Gonelli, E Carnevale, F Corallini, C Rizzardi, S Zacchigna, M Melato, G Zauli |
Neoplasia (New York, N.Y.) | 2004 |
Gene therapy strategies to improve the effectiveness of cancer radiotherapy
SO Freytag, JH Kim, SL Brown, K Barton, M Lu, M Chung |
Expert Opinion on Biological Therapy | 2004 |
eNOS protects prostate cancer cells from TRAIL-induced apoptosis
X Tong, H Li |
Cancer Letters | 2004 |
Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms
S Shankar, TR Singh, RK Srivastava |
The Prostate | 2004 |
Exploiting death receptor signaling pathways for tumor therapy
S Fulda, KM Debatin |
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2004 |
Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression
JL Luo, S Maeda, LC Hsu, H Yagita, M Karin |
Cancer Cell | 2004 |
The secretable form of trimeric TRAIL, a potent inducer of apoptosis
MH Kim, TR Billiar, DW Seol |
Biochemical and Biophysical Research Communications | 2004 |
Down-regulation of procaspase-8 expression by focal adhesion kinase protects HL-60 cells from TRAIL-induced apoptosis
Y Tamagiku, Y Sonoda, M Kunisawa, D Ichikawa, Y Murakami, E Aizu-Yokota, T Kasahara |
Biochemical and Biophysical Research Communications | 2004 |
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications
S Shankar, RK Srivastava |
Drug Resistance Updates | 2004 |
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice
Z Pei, L Chu, W Zou, Z Zhang, S Qiu, R Qi, J Gu, C Qian, X Liu |
Hepatology | 2004 |
Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2
E Bremer, J Kuijlen, D Samplonius, H Walczak, L Leij, W Helfrich |
International Journal of Cancer | 2004 |
Quantification of tumor tissue populations by multispectral analysis
RA Carano, AL Ross, J Ross, SP Williams, H Koeppen, RH Schwall, NV Bruggen |
Magnetic Resonance in Medicine | 2004 |
Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L
RD Pietro, G Zauli |
Journal of Cellular Physiology | 2004 |
Monocytes Stimulated with Group B Streptococci or Interferons Release Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand
O Halaas, NB Liabakk, R Vik, C Beninati, P Henneke, A Sundan, T Espevik |
Scandinavian Journal of Immunology | 2004 |
Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines
XX Wu, O Ogawa, Y Kakehi |
International Journal of Urology | 2004 |
Following a TRAIL: Update on a ligand and its five receptors
FC KIMBERLEY, GR SCREATON |
Cell Research | 2004 |
Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors
C Kasuga, T Ebata, N Kayagaki, H Yagita, M Hishii, H Aral, K Sato, K Okumura |
Cancer Science | 2004 |
TRAIL and its receptors as targets for cancer therapy
H Yagita, K Takeda, Y Hayakawa, MJ Smyth, K Okumura |
Cancer Science | 2004 |
Restricted expression of tumor necrosis factor-related apoptosis-inducing ligand receptor 4 in human peripheral blood lymphocytes
H Hasegawa, Y Yamada, H Harasawa, T Tsuji, K Murata, K Sugahara, K Tsuruda, M Masuda, N Takasu, S Kamihira |
Cellular Immunology | 2004 |
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
CM van Geelen, EG de Vries, S Jong |
Drug Resistance Updates | 2004 |
Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs
S Tomek, P Horak, I Pribill, G Haller, M Rössler, CC Zielinski, D Pils, M Krainer |
Gynecologic Oncology | 2004 |
Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma
HJ Arts, S Jong, H Hollema, K Hoor, AG der Zee, EG Vries |
Gynecologic Oncology | 2004 |
Combination of Targeting Gene-ViroTherapy with 5-FU Enhances Antitumor Efficacy in Malignant Colorectal Carcinoma
S Qiu, H Ruan, Z Pei, B Hu, P Lan, J Wang, Z Zhang, J Gu, L Sun, C Qian, X Liu, Y Qi |
Journal of Interferon & Cytokine Research | 2004 |
Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone
L Huang, J Xu, K Li, MH Zheng, SM Kumta |
Bone | 2004 |
Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor–related apoptosis-inducing ligand
RM Reddy, WS Tsai, MF Ziauddin, JT Zuo, GW Cole, JB Maxhimer, BL Fang, DS Schrump, DM Nguyen |
The Journal of Thoracic and Cardiovascular Surgery | 2004 |
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1
V Chopin, C Slomianny, H Hondermarck, XL Bourhis |
Experimental Cell Research | 2004 |
Influence of hypoxia on TRAIL-induced apoptosis in tumor cells
M Weinmann, P Marini, V Jendrossek, A Betsch, B Goecke, W Budach, C Belka |
International journal of radiation oncology, biology, physics | 2004 |
Apoptosis-modulating agents in combination with radiotherapy—current status and outlook
C Belka, V Jendrossek, M Pruschy, S Vink, M Verheij, W Budach |
International journal of radiation oncology, biology, physics | 2004 |
Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer
AC Mita, MM Mita, EK Rowinsky |
Clinical Colorectal Cancer | 2004 |
Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma
LP Bron, RA Scolyer, JF Thompson, P Hersey |
Pathology | 2004 |
Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects
C He |
World journal of gastroenterology : WJG | 2004 |
Induction of potent TRAIL-mediated tumoricidal activity by hFLEX/Furin/TRAIL recombinant DNA construct
X Wu, KM Hui |
Molecular Therapy | 2004 |
Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer
SA Kaliberov, LN Kaliberova, CR Stockard, WE Grizzle, DJ Buchsbaum |
Molecular Therapy | 2004 |
A Tumor-Targeted and Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL for Treatment of Liver Metastases
P Sova, XW Ren, S Ni, KM Bernt, J Mi, N Kiviat, A Lieber |
Molecular Therapy | 2004 |
The C-terminal Tails of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas Receptors Have Opposing Functions in Fas-associated Death Domain (FADD) Recruitment and Can Regulate Agonist-specific Mechanisms of Receptor Activation
LR Thomas, RL Johnson, JC Reed, A Thorburn |
The Journal of biological chemistry | 2004 |
Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells
SH Kim, K Kim, JG Kwagh, DT Dicker, M Herlyn, AK Rustgi, Y Chen, WS El-Deiry |
The Journal of biological chemistry | 2004 |
Direct Binding of Fas-associated Death Domain (FADD) to the Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor DR5 Is Regulated by the Death Effector Domain of FADD
LR Thomas, A Henson, JC Reed, FR Salsbury, A Thorburn |
The Journal of biological chemistry | 2004 |
Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling
RF Kelley, K Totpal, SH Lindstrom, M Mathieu, K Billeci, L DeForge, R Pai, SG Hymowitz, A Ashkenazi |
The Journal of biological chemistry | 2004 |
Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL
KD Burroughs, DB Kayda, K Sakhuja, Y Hudson, J Jakubczak, JA Bristol, D Ennist, P Hallenbeck, M Kaleko, S Connelly |
Cancer Gene Therapy | 2004 |
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs
TM Ganten, TL Haas, J Sykora, H Stahl, MR Sprick, SC Fas, A Krueger, MA Weigand, A Grosse-Wilde, W Stremmel, PH Krammer, H Walczak |
Cell Death and Differentiation | 2004 |
Death receptors in chemotherapy and cancer
KM Debatin, PH Krammer |
Oncogene | 2004 |
Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies
J Rudner, V Jendrossek, K Lauber, PT Daniel, S Wesselborg, C Belka |
Oncogene | 2004 |
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata, T Yoshida, M Horinaka, T Shiraishi, M Wakada, T Sakai |
Oncogene | 2004 |
Targets and mechanisms for the regulation of translation in malignant transformation
MJ Clemens |
Oncogene | 2004 |
Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP
EH Kim, SU Kim, DY Shin, KS Choi |
Oncogene | 2004 |
Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xL expression
S Huerta-Yepez, M Vega, A Jazirehi, H Garban, F Hongo, G Cheng, B Bonavida |
Oncogene | 2004 |
Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway
C Haefen, B Gillissen, PG Hemmati, J Wendt, D Güner, A Mrozek, C Belka, B Dörken, PT Daniel |
Oncogene | 2004 |
Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells
S Kaliberov, MA Stackhouse, L Kaliberova, T Zhou, DJ Buchsbaum |
Gene Therapy | 2004 |
Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells
J Han, LA Goldstein, BR Gastman, A Rabinovitz, GQ Wang, B Fang, H Rabinowich |
Leukemia | 2004 |
Type I interferon and TNFα cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells
A Abadie, F Besançon, J Wietzerbin |
Oncogene | 2004 |
Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP
EH Kim, SU Kim, KS Choi |
Oncogene | 2004 |
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas
J An, Y Sun, M Fisher, MB Rettig |
Leukemia | 2004 |
Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo
QL Fan, WY Zou, LH Song, W Wei |
Cancer Chemotherapy and Pharmacology | 2004 |
Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis
AD Brooks, TJ Sayers |
Cancer Immunology, Immunotherapy | 2004 |
ENDOTOXIN INCREASES PLASMA SOLUBLE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND LEVEL MEDIATED BY THE p38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY:
MN Hooge, S de Jong, C Vermot-Desroches, JE Tulleken, EG de Vries, JG Zijlstra |
Shock | 2004 |
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
WD Figg, HL McLeod |
2004 | |
Proteasome Inhibitors in Cancer Therapy
J Adams |
2004 | |
N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines
M Cuello, AO Coats, I Darko, SA Ettenberg, GJ Gardner, MM Nau, JR Liu, MJ Birrer, S Lipkowitz |
Cell Death and Differentiation | 2004 |
Interleukin-1β and Tumor Necrosis Factor (TNF)-α Sensitize Human Thyroid Epithelial Cells to TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis through Increases in Procaspase-7 and Bid, and the Down-Regulation of p44/42 Mitogen-Activated Protein Kinase Activity
E Mezosi, SH Wang, S Utsugi, L Bajnok, JD Bretz, PG Gauger, NW Thompson, JR Baker |
The Journal of clinical endocrinology and metabolism | 2004 |
Signal Transduction in Cancer
DA Frank |
2004 | |
IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells
C Tecchio, V Huber, P Scapini, F Calzetti, D Margotto, G Todeschini, L Pilla, G Martinelli, G Pizzolo, L Rivoltini, MA Cassatella |
Blood | 2004 |
TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE
H Xiang, CB Nguyen, SK Kelley, N Dybdal, E Escandón |
Drug Metabolism and Disposition | 2004 |
Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells
F Guo, C Sigua, J Tao, P Bali, P George, Y Li, S Wittmann, L Moscinski, P Atadja, K Bhalla |
Cancer research | 2004 |
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells
A Ballestrero, A Nencioni, D Boy, I Rocco, A Garuti, GS Mela, LV Parijs, P Brossart, S Wesselborg, F Patrone |
Clinical cancer research | 2004 |
Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol
S Fulda, KM Debatin |
Cancer research | 2004 |
Bax Mediates the Apoptosis-Sensitizing Effect of Maspin
J Liu, S Yin, N Reddy, C Spencer, S Sheng |
Cancer research | 2004 |
TRAIL regulates normal erythroid maturation through an ERK-dependent pathway
P Secchiero, E Melloni, M Heikinheimo, S Mannisto, RD Pietro, A Iacone, G Zauli |
Blood | 2004 |
Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects.
He C, Lao WF, Hu XT, Xu XM, Xu J, Fang BL |
World Journal of Gastroenterology | 2004 |
Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL
M Chawla-Sarkar, JA Bauer, JA Lupica, BH Morrison, Z Tang, RK Oates, A Almasan, JA DiDonato, EC Borden, DJ Lindner |
The Journal of biological chemistry | 2003 |
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
TJ Sayers, AD Brooks, CY Koh, W Ma, N Seki, A Raziuddin, BR Blazar, X Zhang, PJ Elliott, WJ Murphy |
Blood | 2003 |
Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice
QS Mi, D Ly, SE Lamhamedi-Cherradi, KV Salojin, L Zhou, M Grattan, C Meagher, P Zucker, YH Chen, J Nagle, D Taub, TL Delovitch |
Diabetes | 2003 |
Caspase- and Serine Protease-dependent Apoptosis by the Death Domain of FADD in Normal Epithelial Cells
J Thorburn, LM Bender, MJ Morgan, A Thorburn, M Raff |
Molecular biology of the cell | 2003 |
Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice
SE Lamhamedi-Cherradi, SJ Zheng, KA Maguschak, J Peschon, YH Chen |
Nature Immunology | 2003 |
Molecular pathology of tumor metastasis III: Target array and combinatorial therapies
J Tímár, A Ladányi, I Peták, A Jeney, L Kopper |
Pathology & Oncology Research | 2003 |
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
B Zheng, P Fiumara, YV Li, G Georgakis, V Snell, M Younes, JN Vauthey, A Carbone, A Younes |
Blood | 2003 |
Apoptosis: targets in pancreatic cancer
S Westphal, H Kalthoff |
Molecular Cancer | 2003 |
Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells
E Ucur, J Mattern, T Wenger, S Okouoyo, A Schroth, KM Debatin, I Herr |
British Journal of Cancer | 2003 |
Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma
Q Chen, S Ray, MA Hussein, G Srkalovic, A Almasan |
Leukemia & Lymphoma | 2003 |
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines
CM van Geelen, EG de Vries, TK Le, RP van Weeghel, S Jong |
British Journal of Cancer | 2003 |
Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy
S Bouralexis, DM Findlay, GJ Atkins, A Labrinidis, S Hay, A Evdokiou |
British Journal of Cancer | 2003 |
Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage
U Ramp, E Caliskan, C Mahotka, A Krieg, S Heikaus, HE Gabbert, CD Gerharz |
British Journal of Cancer | 2003 |
TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential
A Krieg, T Krieg, M Wenzel, M Schmitt, U Ramp, B Fang, HE Gabbert, CD Gerharz, C Mahotka |
British Journal of Cancer | 2003 |
Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2
IK Kim, YK Jung, DY Noh, YS Song, CH Choi, BH Oh, ES Masuda, YK Jung |
British Journal of Cancer | 2003 |
A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents
Y Arizono, H Yoshikawa, H Naganuma, Y Hamada, Y Nakajima, K Tasaka |
British Journal of Cancer | 2003 |
Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation
M Leverkus, MR Sprick, T Wachter, T Mengling, B Baumann, E Serfling, EB Bröcker, M Goebeler, M Neumann, H Walczak |
Molecular and cellular biology | 2003 |
Death receptors and their role in dermatology, with particular focus on tumor necrosis factor-related apoptosis-inducing ligand receptors
KJ Smith, H Diwan, H Skelton |
International Journal of Dermatology | 2003 |
Apoptosis and Plastic Surgery
BR Gastman, JW Futrell, EK Manders |
Plastic and Reconstructive Surgery | 2003 |
T-cell immune responses in the brain and their relevance for cerebral malignancies
PR Walker, T Calzascia, N Tribolet, PY Dietrich |
Brain Research Reviews | 2003 |
Cellular FLICE-inhibitory protein: an attractive therapeutic target?
O Micheau |
Expert Opinion on Therapeutic Targets | 2003 |
TRAIL Triggers Apoptosis in Human Malignant Glioma Cells Through Extrinsic and Intrinsic Pathways
JH Song, DK Song, B Pyrzynska, KC Petruk, EG Meir, C Hao |
Brain Pathology | 2003 |
Modulation of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Chemotherapy in Thyroid Cancer Cell Lines
JW Park, MG Wong, M Lobo, WC Hyun, QY Duh, OH Clark |
Thyroid | 2003 |
Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer
SH Lee, HS Kim, SY Kim, YS Lee, WS Park, SH Kim, JY Lee, NJ Yoo |
APMIS | 2003 |
Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design
M Los, CJ Burek, C Stroh, K Benedyk, H Hug, A Mackiewicz |
Drug Discovery Today | 2003 |
Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells
D Griffin, S Wittmann, F Guo, R Nimmanapalli, P Bali, HG Wang, K Bhalla |
Gynecologic Oncology | 2003 |
Nature's TRAIL—On a Path to Cancer Immunotherapy
MJ Smyth, K Takeda, Y Hayakawa, JJ Peschon, MR van Brink, H Yagita |
Immunity | 2003 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme
V Jendrossek, C Belka, M Bamberg |
Expert Opinion on Investigational Drugs | 2003 |
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand
DT Jones, K Ganeshaguru, WA Mitchell, L Foroni, RJ Baker, HG Prentice, AB Mehta, RG Wickremasinghe |
British Journal of Haematology | 2003 |
Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential
T Hotta, H Suzuki, S Nagai, K Yamamoto, A Imakiire, E Takada, M Itoh, J Mizuguchi |
Journal of Orthopaedic Research | 2003 |
Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas
NJ Yoo, HS Kim, SY Kim, WS Park, CH Park, HM Jeon, ES Jung, JY Lee, SH Lee |
APMIS | 2003 |
Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703
L Miao, P Yi, Y Wang, M Wu |
European Journal of Biochemistry | 2003 |
Upregulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers
SY Nam, GA Jung, GC Hur, HY Chung, WH Kim, DW Seol, BL Lee |
Cancer Science | 2003 |
Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma
X Yang, CJ Thiele |
Cancer Letters | 2003 |
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas
JJ Koornstra, JH Kleibeuker, CM van Geelen, FE Rijcken, H Hollema, EG de Vries, S Jong |
The Journal of Pathology | 2003 |
Bcl-2 and apoptosis in chronic lymphocytic leukemia
AD Schimmer, I Munk-Pedersen, MD Minden, JC Reed |
Current Treatment Options in Oncology | 2003 |
Molecular targets in therapy for human soft-tissue and bone sarcomas
DM Steinert, LJ Blakely, J Salganick, JC Trent |
Current Oncology Reports | 2003 |
Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines
RR Siervo-Sassi, AM Marrangoni, X Feng, N Naoumova, M Winans, RP Edwards, A Lokshin |
Cancer Letters | 2003 |
Macrophages From Cancer Patients: Analysis of TRAIL, TRAIL Receptors, and Colon Tumor Cell Apoptosis
JP Herbeuval, C Lambert, O Sabido, M Cottier, P Fournel, M Dy, C Genin |
JNCI Journal of the National Cancer Institute | 2003 |
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
A Almasan, A Ashkenazi |
Cytokine & Growth Factor Reviews | 2003 |
Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature
JJ Koornstra, S Jong, H Hollema, EG Vries, JH Kleibeuker |
Critical Reviews in Oncology/Hematology | 2003 |
Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes
S Ehrlich, C Infante-Duarte, B Seeger, F Zipp |
Cytokine | 2003 |
Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential
M Itoh, T Noutomi, H Toyota, J Mizuguchi |
Oral Oncology | 2003 |
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines
A Mouzakiti, G Packham |
British Journal of Haematology | 2003 |
Handbook of Cell Signaling
MF White |
Handbook of Cell Signaling | 2003 |
Apoptosis and Plastic Surgery:
BR Gastman, JW Futrell, EK Manders |
Plastic and Reconstructive Surgery | 2003 |
Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines
S Tomek, W Koestler, P Horak, T Grunt, T Brodowicz, I Pribill, J Halaschek, G Haller, C Wiltschke, CC Zielinski, M Krainer |
European Journal of Cancer | 2003 |
Molecular requirements for the combined effects of TRAIL and ionising radiation
P Marini, V Jendrossek, E Durand, C Gruber, W Budach, C Belka |
Radiotherapy and Oncology | 2003 |
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Enhances Collagen Production by Human Lung Fibroblasts
VV Yurovsky |
American journal of respiratory cell and molecular biology | 2003 |
Utilisation de la molécule pro-apoptotique « TRAIL » dans de nouvelles stratégies thérapeutiques anticancéreuses. Exemple du cancer de la prostate
V Hesry, JJ Patard, T Guillaudeux |
Pathologie Biologie | 2003 |
Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders: A short review
A Younes, BB Aggarwall |
Cancer | 2003 |
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
SH Kaufmann, DL Vaux |
Oncogene | 2003 |
Apoptosis-targeted therapies for cancer
John C Reed |
Cancer Cell | 2003 |
Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29
Xiang-Ming Xu, Chao He, Xiao-Tong Hu, Bing-Liang Fang |
World journal of gastroenterology : WJG | 2003 |
Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480
Li-Hong Xu, Chang-Sheng Deng, You-Qing Zhu, Shi-Quan Liu, Dong-Zhou Liu |
World journal of gastroenterology : WJG | 2003 |
Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells: TRAIL/Apo2L + Chemotherapy in Bone Tumour
FV Valen, S Fulda, KL Schäfer, B Truckenbrod, M Hotfilder, C Poremba, KM Debatin, W Winkelmann |
International Journal of Cancer | 2003 |
Actinomycin D renders cultured synovial fibroblasts susceptible to tumour necrosis factor related apoptosis‐inducing ligand (TRAIL)‐induced apoptosis
YW Park, JD Ji, JS Lee, DW Ryang, DH Yoo |
Scandinavian Journal of Rheumatology | 2003 |
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
A Younes, ME Kadin |
Journal of Clinical Oncology | 2003 |
Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas Stimulation
X Bian, TD Giordano, HJ Lin, G Solomon, VP Castle, AW Opipari |
The Journal of biological chemistry | 2003 |
c-Jun N-terminal Kinase Contributes to Apoptotic Synergy Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand plus DNA Damage in Chemoresistant, p53 Inactive Mesothelioma Cells
C Vivo, W Liu, VC Broaddus |
The Journal of biological chemistry | 2003 |
Protein Kinase C Modulates Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Targeting the Apical Events of Death Receptor Signaling
N Harper, MA Hughes, SN Farrow, GM Cohen, M MacFarlane |
The Journal of biological chemistry | 2003 |
NF-κB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells
M Hermisson, M Weller |
Cell Death and Differentiation | 2003 |
Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect
JY Seol, KH Park, CI Hwang, WY Park, CG Yoo, YW Kim, SK Han, YS Shim, CT Lee |
Cancer Gene Therapy | 2003 |
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines
CM van Geelen, EG de Vries, TK Le, RP van Weeghel, S Jong |
British Journal of Cancer | 2003 |
Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2
IK Kim, YK Jung, DY Noh, YS Song, CH Choi, BH Oh, ES Masuda, YK Jung |
British Journal of Cancer | 2003 |
A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents
Y Arizono, H Yoshikawa, H Naganuma, Y Hamada, Y Nakajima, K Tasaka |
British Journal of Cancer | 2003 |
TRAIL-β and TRAIL-γ: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential
A Krieg, T Krieg, M Wenzel, M Schmitt, U Ramp, B Fang, HE Gabbert, CD Gerharz, C Mahotka |
British Journal of Cancer | 2003 |
A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells
I Petak, R Vernes, KS Szucs, M Anozie, K Izeradjene, L Douglas, DM Tillman, DC Phillips, JA Houghton |
Cell Death and Differentiation | 2003 |
International Hermelin Brain Tumor Center Symposium on Apoptosis
O Bögler, M Weller |
Cell Death and Differentiation | 2003 |
Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2
E Mori, M Thomas, K Motoki, K Nakazawa, T Tahara, K Tomizuka, I Ishida, S Kataoka |
Cell Death and Differentiation | 2003 |
Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line
DC Spierings, EG de Vries, E Vellenga, S Jong |
Cell Death and Differentiation | 2003 |
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia
JB Johnston, AF Kabore, J Strutinsky, X Hu, JT Paul, DM Kropp, B Kuschak, A Begleiter, SB Gibson |
Oncogene | 2003 |
PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2
S Frese, F Pirnia, D Miescher, S Krajewski, MM Borner, JC Reed, RA Schmid |
Oncogene | 2003 |
Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis
Q He, JA Montalbano, C Corcoran, W Jin, Y Huang, MS Sheikh |
Oncogene | 2003 |
TRAIL and apoptosis induction by TNF-family death receptors
S Wang, WS El-Deiry |
Oncogene | 2003 |
Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells
S Lacour, O Micheau, A Hammann, V Drouineaud, J Tschopp, E Solary, MT Dimanche-Boitrel |
Oncogene | 2003 |
Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway
T Ohtsuka, D Buchsbaum, P Oliver, S Makhija, R Kimberly, T Zhou |
Oncogene | 2003 |
Interferon-α sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-κB inactivation
M Shigeno, K Nakao, T Ichikawa, K Suzuki, A Kawakami, S Abiru, S Miyazoe, Y Nakagawa, H Ishikawa, K Hamasaki, K Nakata, N Ishii, K Eguchi |
Oncogene | 2003 |
The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27Kip1 and control of cyclin D1 expression
A Cappellini, G Tabellini, M Zweyer, R Bortul, PL Tazzari, AM Billi, F Falà, L Cocco, AM Martelli |
Leukemia | 2003 |
Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation
R Bortul, PL Tazzari, A Cappellini, G Tabellini, AM Billi, R Bareggi, L Manzoli, L Cocco, AM Martelli |
Leukemia | 2003 |
Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria
XD Zhang, JM Borrow, XY Zhang, T Nguyen, P Hersey |
Oncogene | 2003 |
Death receptors and melanoma resistance to apoptosis
VN Ivanov, A Bhoumik, Z Ronai |
Oncogene | 2003 |
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-α promote the NF-κB-dependent maturation of normal and leukemic myeloid cells
P Secchiero, D Milani, A Gonelli, E Melloni, D Campioni, D Gibellini, S Capitani, G Zauli |
Journal of leukocyte biology | 2003 |
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
R Greil, G Anether, K Johrer, I Tinhofer |
Journal of leukocyte biology | 2003 |
Protein-based therapeutic approaches targeting death receptors
LE French, J Tschopp |
Cell Death and Differentiation | 2003 |
Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells
XX Wu, Y Kakehi, Y Mizutani, H Nishiyama, T Kamoto, Y Megumi, N Ito, O Ogawa |
International Journal of Cancer | 2003 |
Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells
Q He, Y Huang, MS Sheikh |
Oncogene | 2003 |
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc, A Ashkenazi |
Cell Death and Differentiation | 2003 |
Gene Therapy of Pancreatic Cancer With Green Fluorescent Protein and Tumor Necrosis Factor?Related Apoptosis-Inducing Ligand Fusion Gene Expression Driven by a Human Telomerase Reverse Transcriptase Promoter
MH Katz, DE Spivack, S Takimoto, B Fang, DW Burton, AR Moossa, RM Hoffman, M Bouvet |
Annals of Surgical Oncology | 2003 |
Allogeneic Stem Cell Transplantation
MJ Laughlin, HM Lazarus |
2003 | |
Grundlagen der Molekularen Medizin
D Ganten, K Ruckpaul |
2003 | |
Modification of Radiation Response
C Nieder, L Milas, KK Ang |
2003 | |
Molecular Mechanisms of Programmed Cell Death
Y Shi, JA Cidlowski, D Scott, JR Wu, YB Shi |
2003 | |
Pediatric Acute Lymphoblastic Leukemia
WL Carroll, D Bhojwani, DJ Min, E Raetz, M Relling, S Davies, JR Downing, CL Willman, JC Reed |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2003 |
Death receptors on reactive astrocytes: A key role in the fine tuning of brain inflammation?
PY Dietrich, PR Walker, P Saas |
Neurology | 2003 |
Monocytes Treated with Human Immunodeficiency Virus Tat Kill Uninfected CD4 + Cells by a Tumor Necrosis Factor-Related Apoptosis-Induced Ligand-Mediated Mechanism
Y Yang, I Tikhonov, TJ Ruckwardt, M Djavani, JC Zapata, CD Pauza, MS Salvato |
Journal of virology | 2003 |
Arsenic trioxide–induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL
Q Liu, S Hilsenbeck, Y Gazitt |
Blood | 2003 |
TRAIL Induces Apoptosis and Inflammatory Gene Expression in Human Endothelial Cells
JH Li, NC Kirkiles-Smith, JM McNiff, JS Pober |
Journal of immunology (Baltimore, Md. : 1950) | 2003 |
TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus
B Washburn, MA Weigand, A Grosse-Wilde, M Janke, H Stahl, E Rieser, MR Sprick, V Schirrmacher, H Walczak |
Journal of immunology (Baltimore, Md. : 1950) | 2003 |
Design, Construction, and In Vitro Analyses of Multivalent Antibodies
K Miller, G Meng, J Liu, A Hurst, V Hsei, WL Wong, R Ekert, D Lawrence, S Sherwood, L DeForge, J Gaudreault, G Keller, M Sliwkowski, A Ashkenazi, L Presta |
Journal of immunology (Baltimore, Md. : 1950) | 2003 |
Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP
V Hietakangas, M Poukkula, KM Heiskanen, JT Karvinen, L Sistonen, JE Eriksson |
Molecular and cellular biology | 2003 |
Plasmacytoid Dendritic Cell-Derived IFN-α Induces TNF-Related Apoptosis-Inducing Ligand/Apo-2L-Mediated Antitumor Activity by Human Monocytes Following CpG Oligodeoxynucleotide Stimulation
TJ Kemp, BD Elzey, TS Griffith |
Journal of immunology (Baltimore, Md. : 1950) | 2003 |
Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma
Ulrike Naumann, Robert Waltereit, Jörg B Schulz, Michael Weller |
Journal of Neuro-Oncology | 2003 |
Genes and Genomics of Autoimmune Inflammation: From Rel to TRAIL
YH Chen |
Immunologic Research | 2003 |
Molecular targets in therapy for human soft-tissue and bone sarcomas.
Steinert DM, Blakely LJ, Salganick J, Trent JC |
Current Oncology Reports | 2003 |
TRAIL, Bim, and thymic-negative selection.
Zheng SJ, Chen YH |
Immunologic research | 2003 |
Bcl-2 and apoptosis in chronic lymphocytic leukemia.
Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC |
Current Treatment Options in Oncology | 2003 |
Upregulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL‐induced apoptosis in human gastric cancers
Nam SY, Jung G, Hur G, Chung H, Kim WH, Seol D, Lee BL |
Cancer Science | 2003 |
Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P |
Oncogene | 2003 |
TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors
M Plasilova, J Zivny, J Jelinek, R Neuwirtova, J Cermak, E Necas, L Andera, T Stopka |
Leukemia | 2002 |
Wiley Encyclopedia of Molecular Medicine
WT Morgan |
Wiley Encyclopedia of Molecular Medicine | 2002 |
Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients
E Stylianou, A Yndestad, LI Sikkeland, V Bjerkeli, JK Damås, T Haug, HG Eiken, P Aukrust, SS Frøland |
Clinical & Experimental Immunology | 2002 |
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO
Y Deng, Y Lin, X Wu |
Genes & development | 2002 |
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells
V Poulaki, CS Mitsiades, V Kotoula, S Tseleni-Balafouta, A Ashkenazi, DA Koutras, N Mitsiades |
The American Journal of Pathology | 2002 |
Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector
J Lee, M Hampl, P Albert, HA Fine |
Neoplasia (New York, N.Y.) | 2002 |
Encyclopedia of Cancer
G Sgouros |
Encyclopedia of Cancer | 2002 |
Life and Death Signaling Pathways Contributing to Skin Cancer
BJ Nickoloff, JZ Qin, V Chaturvedi, P Bacon, J Panella, MF Denning |
Journal of Investigative Dermatology Symposium Proceedings | 2002 |
Electroporation-Mediated Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/Apo2L Gene Therapy for Hepatocellular Carcinoma
YI Yamashita, M Shimada, S Tanaka, M Okamamoto, JI Miyazaki, K Sugimachi |
Human Gene Therapy | 2002 |
T cells require TRAIL for optimal graft-versus-tumor activity
C Schmaltz, O Alpdogan, BJ Kappel, SJ Muriglan, JA Rotolo, J Ongchin, LM Willis, AS Greenberg, JM Eng, JM Crawford, GF Murphy, H Yagita, H Walczak, JJ Peschon, MR van Brink |
Nature Medicine | 2002 |
Death Receptor Ligands in Tumors
P Cappello, F Novelli, G Forni, M Giovarelli |
Journal of Immunotherapy | 2002 |
The biological role of the Fas/FasL system during tumor formation and progression
E Reichmann |
Seminars in Cancer Biology | 2002 |
Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL)
N Kayagaki, N Yamaguchi, M Abe, S Hirose, T Shirai, K Okumura, H Yagita |
Cellular Immunology | 2002 |
TRAIL-mediated apoptosis requires NF-kB inhibition and the mitochondrial permeability transition in human hepatoma cells
YS Kim, RF Schwabe, T Qian, JJ Lemasters, DA Brenner |
Hepatology | 2002 |
The RB and p53 pathways in cancer
CJ Sherr, F McCormick |
Cancer Cell | 2002 |
Focus on sarcomas
CL Mackall, PS Meltzer, LJ Helman |
Cancer Cell | 2002 |
Potential methods to circumvent blocks in apoptosis in lymphomas
R Ravi, A Bedi |
Current Opinion in Oncology | 2002 |
Induction of TRAIL-mediated glioma cell death by human T cells
J Dörr, S Waiczies, U Wendling, B Seeger, F Zipp |
Journal of Neuroimmunology | 2002 |
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail-induced apoptosis
A Evdokiou, S Bouralexis, GJ Atkins, F Chai, S Hay, M Clayer, DM Findlay |
International Journal of Cancer | 2002 |
Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study
SH Lee, HS Kim, WS Park, SY Kim, KY Lee, SH Kim, JY Lee, NJ Yoo |
APMIS | 2002 |
Combination therapy with imatinib mesylate (sti571): synopsis of in vitro studies
J Topaly, WJ Zeller, S Fruehauf |
British Journal of Haematology | 2002 |
Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers
JC Reed, S Kitada, Y Kim, J Byrd |
Seminars in Oncology | 2002 |
The involvement of oxidative stress in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells
MW Lee, SC Park, JH Kim, IK Kim, KS Han, KY Kim, WB Lee, YK Jung*, SS Kim |
Cancer Letters | 2002 |
Enhancement of Apo2L/TRAIL (tumor necrosis factor–related apoptosis-inducing ligand)–induced apoptosis in non–small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein
S Frese, T Brunner, M Gugger, A Uduehi, RA Schmid |
The Journal of Thoracic and Cardiovascular Surgery | 2002 |
On the TRAIL to apoptosis
TM Baetu, J Hiscott |
Cytokine & Growth Factor Reviews | 2002 |
Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis
GJ Atkins, S Bouralexis, A Evdokiou, S Hay, A Labrinidis, AC Zannettino, DR Haynes, DM Findlay |
Bone | 2002 |
Regulators of apoptosis as anticancer targets
AW Tolcher |
Hematology/Oncology Clinics of North America | 2002 |
Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma
TJ Zuzak, DF Steinhoff, LN Sutton, PC Phillips, A Eggert, MA Grotzer |
European Journal of Cancer | 2002 |
Evidence that the human death receptor 4 is regulated by activator protein 1
B Guan, P Yue, R Lotan, SY Sun |
Oncogene | 2002 |
Anticancer Drug Development
E Solary, N Droin, O Sordet, C Rebe, R Filomenko, A Wotawa, S Plenchette, P Ducoroy |
Anticancer Drug Development | 2002 |
The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis
L Bin, X Li, LG Xu, HB Shu |
FEBS Letters | 2002 |
Tumor necrosis factor-related, apoptosis-inducing ligand supports growth of mouse mastocytoma tumors by killing tumor-infiltrating macrophages
A Strebel, F Bachmann, M Wernli, P Erb |
International Journal of Cancer | 2002 |
The involvement of reactive oxygen species (ROS) and p38 mitogen-activated protein (MAP) kinase in TRAIL/Apo2L-induced apoptosis
MW Lee, SC Park, YG Yang, SO Yim, HS Chae, JH Bach, HJ Lee, KY Kim, WB Lee, SS Kim |
FEBS Letters | 2002 |
Gene Therapy of Cancer
IV Lebedeva, CA Stein |
Gene Therapy of Cancer | 2002 |
The Role of Apoptosis-Related Genes in non—small-Cell Lung Cancer
E Fokkema, HJ Groen, C Meijer, W Timens, S Jong, EG de Vries |
Clinical Lung Cancer | 2002 |
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi |
Nature Reviews Cancer | 2002 |
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia
M MacFarlane, N Harper, RT Snowden, MJ Dyer, GA Barnett, JH Pringle, GM Cohen |
Oncogene | 2002 |
Antitumor Activity and Prolonged Expression from a TRAIL-Expressing Adenoviral Vector
J Lee, M Hampl, P Albert, HA Fine |
Neoplasia (New York, N.Y.) | 2002 |
Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations
Jian-Zhong Qin, Patricia E Bacon, Vijaya Chaturvedi, Brian Bonish, Brian J Nickoloff |
Experimental Dermatology | 2002 |
Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development
K Takeda, MJ Smyth, E Cretney, Y Hayakawa, N Kayagaki, H Yagita, K Okumura |
Journal of Experimental Medicine | 2002 |
Induction of apoptosis in cancer: new therapeutic opportunities
HF Ding, DE Fisher |
Annals of Medicine | 2002 |
Detection of soluble TRAIL in HBV infected patients and its clinical implications
LH Han |
World journal of gastroenterology : WJG | 2002 |
Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer Cells
Q Wang, X Wang, A Hernandez, MR Hellmich, Z Gatalica, BM Evers |
The Journal of biological chemistry | 2002 |
Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
P Schneider, D Olson, A Tardivel, B Browning, A Lugovskoy, DH Gong, M Dobles, S Hertig, K Hofmann, HV Vlijmen, YM Hsu, LC Burkly, J Tschopp, TS Zheng |
The Journal of biological chemistry | 2002 |
An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis
Y Kim, N Suh, M Sporn, JC Reed |
The Journal of biological chemistry | 2002 |
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL
C Voelkel-Johnson, DL King, JS Norris |
Cancer Gene Therapy | 2002 |
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors
H Xiang, JA Fox, K Totpal, M Aikawa, K Dupree, D Sinicropi, J Lowe, E Escandón |
Oncogene | 2002 |
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
CS Mitsiades, N Mitsiades, V Poulaki, R Schlossman, M Akiyama, D Chauhan, T Hideshima, SP Treon, NC Munshi, PG Richardson, KC Anderson |
Oncogene | 2002 |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells
A Nesterov, Y Ivashchenko, AS Kraft |
Oncogene | 2002 |
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
S Fulda, W Wick, M Weller, KM Debatin |
Nature Medicine | 2002 |
Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells
Q He, X Luo, Y Huang, MS Sheikh |
Oncogene | 2002 |
TRAIL-mediated apoptosis requires NF-κB inhibition and the mitochondrial permeability transition in human hepatoma cells
Y Kim |
Hepatology | 2002 |
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance
CP Ng, A Zisman, B Bonavida |
The Prostate | 2002 |
Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
H LeBlanc, D Lawrence, E Varfolomeev, K Totpal, J Morlan, P Schow, S Fong, R Schwall, D Sinicropi, A Ashkenazi |
Nature Medicine | 2002 |
Apoptosis and cancer: When BAX is TRAILing away
W Roth, JC Reed |
Nature Medicine | 2002 |
Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis
D Siegmund, P Hadwiger, K Pfizenmaier, HP Vornlocher, H Wajant |
Molecular Medicine | 2002 |
Neuroinflammation — From Bench to Bedside
H Kettenmann, GA Burton, UJ Moenning |
2002 | |
Cholestasis Increases Tumor Necrosis Factor-Related Apoptotis-Inducing Ligand (TRAIL)-R2/DR5 Expression and Sensitizes the Liver to TRAIL-Mediated Cytotoxicity
H Higuchi, SF Bronk, M Taniai, A Canbay, GJ Gores |
The Journal of pharmacology and experimental therapeutics | 2002 |
Molekulare Medizin in der Frauenheilkunde
MW Beckmann, PA Fasching, P Dall, JS Krüssel, D Niederacher, B Tutschek |
2002 | |
Molecular and Cellular Biology of Neuroprotection in the CNS
C Alzheimer |
2002 | |
Dysregulation of apoptosis genes in hematopoietic malignancies
S Kitada, IM Pedersen, AD Schimmer, JC Reed |
Oncogene | 2002 |
Tumor-Infiltrating CD4 + T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-α on APO2L/TRAIL Expression and -Mediated Cytotoxicity
G Dorothée, I Vergnon, J Menez, H Echchakir, D Grunenwald, M Kubin, S Chouaib, F Mami-Chouaib |
Journal of immunology (Baltimore, Md. : 1950) | 2002 |
Intracellular regulation of tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis in human multiple myeloma cells
N Mitsiades, CS Mitsiades, V Poulaki, KC Anderson, SP Treon |
Blood | 2002 |
Death Ligand TRAIL Induces No Apoptosis but Inhibits Activation of Human (Auto)antigen-Specific T Cells
JD Lünemann, S Waiczies, S Ehrlich, U Wendling, B Seeger, T Kamradt, F Zipp |
Journal of immunology (Baltimore, Md. : 1950) | 2002 |
Tumor necrosis factor–related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway
P Secchiero, A Gonelli, P Mirandola, E Melloni, L Zamai, C Celeghini, D Milani, G Zauli |
Blood | 2002 |
Involvement of TRAIL and its receptors in viral hepatitis
B Mundt, F Kühnel, L Zender, Y Paul, H Tillmann, C Trautwein, MP Manns, S Kubicka |
The FASEB Journal | 2002 |
Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice
E Cretney, K Takeda, H Yagita, M Glaccum, JJ Peschon, MJ Smyth |
Journal of immunology (Baltimore, Md. : 1950) | 2002 |
Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative–(BMS 247550) and Apo-2L/TRAIL–induced apoptosis
F Guo, R Nimmanapalli, S Paranawithana, S Wittman, D Griffin, P Bali, E O'Bryan, C Fumero, HG Wang, K Bhalla |
Blood | 2002 |
TRAIL/Apo-2 Ligand Induces Primary Plasma Cell Apoptosis
J Ursini-Siegel, W Zhang, A Altmeyer, EN Hatada, RK Do, H Yagita, S Chen-Kiang |
Journal of immunology (Baltimore, Md. : 1950) | 2002 |
IFN-β Pretreatment Sensitizes Human Melanoma Cells to TRAIL/Apo2 Ligand-Induced Apoptosis
M Chawla-Sarkar, DW Leaman, BS Jacobs, EC Borden |
Journal of immunology (Baltimore, Md. : 1950) | 2002 |
Immunobiology of Tumor Necrosis Factor Receptor Superfamily
T Zhou, JD Mountz, RP Kimberly |
Immunologic Research | 2002 |
Detection of soluble TRAIL in HBV infected patients and its clinical implications.
Han LH, Sun WS, Ma CH, Zhang LN, Liu SX, Zhang Q, Gao LF, Chen YH |
World Journal of Gastroenterology | 2002 |
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
A Chuntharapai, K Dodge, K Grimmer, K Schroeder, SA Marsters, H Koeppen, A Ashkenazi, KJ Kim |
Journal of immunology (Baltimore, Md. : 1950) | 2001 |
Is Myelodysplastic Related Acute Myelogenous Leukemia a Distinct Entity from de novo Acute Myelogenous Leukemia? Potential for Targeted Therapies
C Rosenfeld, H Kantarjian |
Leukemia & Lymphoma | 2001 |
CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies
P Fiumara, A Younes |
British Journal of Haematology | 2001 |
Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes
AK Simon, O Williams, J Mongkolsapaya, B Jin, XN Xu, H Walczak, GR Screaton |
Proceedings of the National Academy of Sciences | 2001 |
TRAIL/Apo-2L: mechanisms and clinical applications in cancer
RK Srivastava |
Neoplasia (New York, N.Y.) | 2001 |
Targeting the Function of Mature Dendritic Cells by Human Cytomegalovirus
MJ Raftery, M Schwab, SM Eibert, Y Samstag, H Walczak, G Schönrich |
Immunity | 2001 |
Shared pathways: Death receptors and cytotoxic drugs in cancer therapy
I Petak, JA Houghton |
Pathology & Oncology Research | 2001 |
Mutations in apoptosis genes: a pathogenetic factor for human disease
L Müllauer, P Gruber, D Sebinger, J Buch, S Wohlfart, A Chott |
Mutation Research/Reviews in Mutation Research | 2001 |
Apoptosis and the response to anticancer therapy
BM Mow, AL Blajeski, J Chandra, SH Kaufmann |
Current Opinion in Oncology | 2001 |
Apoptosis and its clinical impact
BR Gastman |
Head & Neck | 2001 |
A Protective Role of PKCϵ against TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Glioma Cells
H Shinohara, N Kayagaki, H Yagita, N Oyaizu, M Ohba, T Kuroki, Y Ikawa |
Biochemical and Biophysical Research Communications | 2001 |
IFN-?induces cell death in human hepatoma cells through a trail/death receptor-mediated apoptotic pathway
EC Shin, JM Ahn, CH Kim, Y Choi, YS Ahn, H Kim, SJ Kim, JH Park |
International Journal of Cancer | 2001 |
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias
N Mitsiades, CS Mitsiades, V Poulaki, KC Anderson, SP Treon |
Expert Opinion on Investigational Drugs | 2001 |
Apoptosis: implications of basic research for clinical oncology
I Tamm, F Schriever, B Dörken |
The Lancet Oncology | 2001 |
Pancreatic Adenocarcinoma Cell Lines Show Variable Susceptibility to TRAIL-Mediated Cell Death
SM Ibrahim, J Ringel, C Schmidt, B Ringel, P Müller, D Koczan, HJ Thiesen, M Löhr |
Pancreas | 2001 |
Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis
A Zisman, CP Ng, AJ Pantuck, B Bonavida, AS Belldegrun |
Journal of Immunotherapy | 2001 |
Role of innate immunity in cancer
SJ Golby, J Spencer |
Current Opinion in Gastroenterology | 2001 |
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Its Receptor Expression and the Pathway of Apoptosis in Human Pancreatic Cancer
K Satoh, K Kaneko, M Hirota, A Masamune, A Satoh, T Shimosegawa |
Pancreas | 2001 |
Potential and caveats of TRAIL in cancer therapy
J Held, K Schulze-Osthoff |
Drug Resistance Updates | 2001 |
Apoptosis in oncology
XQ FAN, YJ GUO |
Cell Research | 2001 |
Molecular mechanisms of TRAIL-induced apoptosis of cancer cells
L Li, H Shu |
Chinese Science Bulletin | 2001 |
Recombinant soluble TRAIL induces apoptosis of cancer cells
L Lianyun, H Jiancheng, B Lianghua, L Lixia, Z Jikun, X Liangguo, Z Zhen, Z Zhonghe, S Hongbing |
Chinese Science Bulletin | 2001 |
Involvement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in NK Cell-Mediated and IFN-γ-Dependent Suppression of Subcutaneous Tumor Growth
K Takeda, MJ Smyth, E Cretney, Y Hayakawa, N Yamaguchi, H Yagita, K Okumura |
Cellular Immunology | 2001 |
Fas ligand and TRAIL augment the effect of photodynamic therapy on the induction of apoptosis in JURKAT cells
DJ Granville, H Jiang, BM McManus, DW Hunt |
International Immunopharmacology | 2001 |
Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene
T Yoshida, A Maeda, N Tani, T Sakai |
FEBS Letters | 2001 |
Hypericin photo-induced apoptosis involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8
CM Schempp, B Simon-Haarhaus, CC Termeer, JC Simon |
FEBS Letters | 2001 |
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Chemotherapy Cooperate to Induce Apoptosis in Mesothelioma Cell Lines
W Liu, E Bodle, JY Chen, M Gao, GD Rosen, VC Broaddus |
American journal of respiratory cell and molecular biology | 2001 |
The biology of apoptosis
FJ Geske, LE Gerschenson |
Human Pathology | 2001 |
TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer
RK Srivastava |
Neoplasia (New York, N.Y.) | 2001 |
Regression of Human Mammary Adenocarcinoma by Systemic Administration of a Recombinant Gene Encoding the hFlex-TRAIL Fusion Protein
X Wu, Y He, LD Falo, KM Hui, L Huang |
Molecular Therapy | 2001 |
Suppression of Tumor Growth Following Intralesional Therapy with TRAIL Recombinant Adenovirus
TS Griffith, EL Broghammer |
Molecular Therapy | 2001 |
Enhanced Apoptosis of Soft Tissue Sarcoma Cells with Chemotherapy: A Potential New Approach Using Trail
M Clayer, S Bouralexis, A Evdokiou, S Hay, GJ Atkins, DM Findlay |
Journal of Orthopaedic Surgery | 2001 |
Interferon-γ Sensitizes Human Myeloid Leukemia Cells to Death Receptor-mediated Apoptosis by a Pleiotropic Mechanism
N Varela, C Muñoz-Pinedo, C Ruiz-Ruiz, G Robledo, M Pedroso, A López-Rivas |
The Journal of biological chemistry | 2001 |
Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways
C Kumar-Sinha, S Varambally, A Sreekumar, AM Chinnaiyan |
The Journal of biological chemistry | 2001 |
Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis
A Nesterov, X Lu, M Johnson, GJ Miller, Y Ivashchenko, AS Kraft |
The Journal of biological chemistry | 2001 |
Ultraviolet Light (UV) Regulation of the TNF Family Decoy Receptors DcR2 and DcR3 in Human Keratinocytes
T Maeda, C Hao, VA Tron |
Journal of Cutaneous Medicine & Surgery | 2001 |
Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene
B Guan, P Yue, GL Clayman, SY Sun |
Journal of Cellular Physiology | 2001 |
Cytotoxicity of Tumor Necrosis Factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines
A Kumar, A Jasmin, MT Eby, PM Chaudhary |
Oncogene | 2001 |
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
X Chen, H Thakkar, F Tyan, S Gim, H Robinson, C Lee, SK Pandey, C Nwokorie, N Onwudiwe, RK Srivastava |
Oncogene | 2001 |
Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells
M Oya, M Ohtsubo, A Takayanagi, M Tachibana, N Shimizu, M Murai |
Oncogene | 2001 |
Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells
YJ Lee, KH Lee, HR Kim, JM Jessup, DW Seol, TH Kim, TR Billiar, YK Song |
Oncogene | 2001 |
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release
TA Röhn, B Wagenknecht, W Roth, U Naumann, E Gulbins, PH Krammer, H Walczak, M Weller |
Oncogene | 2001 |
The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels
CR de Almodóvar, C Ruiz-Ruiz, C Muñoz-Pinedo, G Robledo, A López-Rivas |
Oncogene | 2001 |
Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection
P Clarke, SM Meintzer, AC Spalding, GL Johnson, KL Tyler |
Oncogene | 2001 |
Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL
C Belka, B Schmid, P Marini, E Durand, J Rudner, H Faltin, M Bamberg, K Schulze-Osthoff, W Budach |
Oncogene | 2001 |
Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
H Wajant, D Moosmayer, T Wüest, T Bartke, E Gerlach, U Schönherr, N Peters, P Scheurich, K Pfizenmaier |
Oncogene | 2001 |
Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L
JJ Lum, AA Pilon, J Sanchez-Dardon, BN Phenix, JE Kim, J Mihowich, K Jamison, N Hawley-Foss, DH Lynch, AD Badley |
Journal of virology | 2001 |
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence, Z Shahrokh, S Marsters, K Achilles, D Shih, B Mounho, K Hillan, K Totpal, L DeForge, P Schow, J Hooley, S Sherwood, R Pai, S Leung, L Khan, B Gliniak, J Bussiere, CA Smith, SS Strom, S Kelley, JA Fox, D Thomas, A Ashkenazi |
Nature Medicine | 2001 |
Avoiding premature apoptosis of normal epidermal cells
J Qin, V Chaturvedi, B Bonish, BJ Nickoloff |
Nature Medicine | 2001 |
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
K Takeda, Y Hayakawa, MJ Smyth, N Kayagaki, N Yamaguchi, S Kakuta, Y Iwakura, H Yagita, K Okumura |
Nature Medicine | 2001 |
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa, W Liu, L Zhao, Z Wang, D Liu, T Ohtsuka, H Zhang, JD Mountz, WJ Koopman, RP Kimberly, T Zhou |
Nature Medicine | 2001 |
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
R Ravi, GC Bedi, LW Engstrom, Q Zeng, B Mookerjee, C Gélinas, EJ Fuchs, A Bedi |
Nature Cell Biology | 2001 |
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL
L Altucci, A Rossin, W Raffelsberger, A Reitmair, C Chomienne, H Gronemeyer |
Nature Medicine | 2001 |
The kiss of death: promises and failures of death receptors and ligands in cancer therapy
PT Daniel, T Wieder, I Sturm, K Schulze-Osthoff |
Leukemia | 2001 |
Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D
A Olsson, T Diaz, M Aguilar-Santelises, A Österborg, F Celsing, M Jondal, LM Osorio |
Leukemia | 2001 |
In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity
C Wuchter, D Krappmann, Z Cai, V Ruppert, C Scheidereit, B Dörken, WD Ludwig, L Karawajew |
Leukemia | 2001 |
TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy
LF Lincz, TX Yeh, A Spencer |
Leukemia | 2001 |
Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line
M Sarker, C Ruiz-Ruiz, A López-Rivas |
Cell Death and Differentiation | 2001 |
Brain Tumor Immunotherapy
LM Liau, DP Becker, TF Cloughesy, DD Bigner |
2001 | |
Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental Autoimmune Encephalomyelitis
B Hilliard, A Wilmen, C Seidel, TS Liu, R Göke, Y Chen |
Journal of immunology (Baltimore, Md. : 1950) | 2001 |
Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive Colon Carcinoma Cell Line SW480 Using a Genetic Approach
TF Burns, WS El-Deiry |
The Journal of biological chemistry | 2001 |
Apo2L/TRAIL and Bcl-2–related proteins regulate type I interferon–induced apoptosis in multiple myeloma
Q Chen, B Gong, AS Mahmoud-Ahmed, A Zhou, ED Hsi, M Hussein, A Almasan |
Blood | 2001 |
Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor–related apoptosis-inducing ligand–mediated cytotoxicity on hematologic malignancies
P Secchiero, A Gonelli, C Celeghini, P Mirandola, L Guidotti, G Visani, S Capitani, G Zauli |
Blood | 2001 |
Expression of tumor necrosis factor–related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis
DY Zang, RG Goodwin, MR Loken, E Bryant, HJ Deeg |
Blood | 2001 |
CD99 Signals Caspase-Independent T Cell Death
RD Pettersen, G Bernard, MK Olafsen, M Pourtein, SO Lie |
Journal of immunology (Baltimore, Md. : 1950) | 2001 |
Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view
AD Schimmer, DW Hedley, LZ Penn, MD Minden |
Blood | 2001 |
Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–mediated cytotoxicity by selective up-regulation of TRAIL-R1
RD Pietro, P Secchiero, R Rana, D Gibellini, G Visani, K Bemis, L Zamai, S Miscia, G Zauli |
Blood | 2001 |
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades, SP Treon, N Mitsiades, Y Shima, P Richardson, R Schlossman, T Hideshima, KC Anderson |
Blood | 2001 |
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
D Hanahan, G Bergers, E Bergsland |
Journal of Clinical Investigation | 2000 |
Apoptosis
S Afford, S Randhawa |
Molecular pathology : MP | 2000 |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
K Song, Y Chen, R Göke, A Wilmen, C Seidel, A Göke, B Hilliard, Y Chen |
Journal of Experimental Medicine | 2000 |
Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine
D Trabzuni, KS Famulski, M Ahmad |
Biochemical Journal | 2000 |
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
AM Chinnaiyan, U Prasad, S Shankar, DA Hamstra, M Shanaiah, TL Chenevert, BD Ross, A Rehemtulla |
Proceedings of the National Academy of Sciences | 2000 |
Genomic Organization and Transcriptional Regulation of Human Apo2/TRAIL Gene
B Gong, A Almasan |
Biochemical and Biophysical Research Communications | 2000 |
Significance of Fas Protein in Squamous Cell Carcinoma of the Larynx
Y Bayazit |
Acta Oto-laryngologica | 2000 |
FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2
MR Sprick, MA Weigand, E Rieser, CT Rauch, P Juo, J Blenis, PH Krammer, H Walczak |
Immunity | 2000 |
Isolation and Molecular Characterization of the 5′-Upstream Region of the Human TRAIL Gene
Q Wang, Y Ji, X Wang, BM Evers |
Biochemical and Biophysical Research Communications | 2000 |
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
FC Kischkel, DA Lawrence, A Chuntharapai, P Schow, KJ Kim, A Ashkenazi |
Immunity | 2000 |
T cell life and death signalling via TNF-receptor family members
G Screaton, XN Xu |
Current Opinion in Immunology | 2000 |
Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer
HS Ryu, KH Chang, SJ Chang, MS Kim, HJ Joo, KS Oh |
International Journal of Gynecological Cancer | 2000 |
Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis
S Hopkins-Donaldson, JL Bodmer, KB Bourloud, CB Brognara, J Tschopp, N Gross |
Medical and Pediatric Oncology | 2000 |
NF-?B kinetics predetermine TNF-? sensitivity of colorectal cancer cells
RM Zwacka, L Stark, MG Dunlop |
The Journal of Gene Medicine | 2000 |
Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells
K Clodi, D Wimmer, Y Li, R Goodwin, U Jaeger, G Mann, H Gadner, A Younes |
British Journal of Haematology | 2000 |
Pro-apoptotic treatment with an adenovirus encodingBax enhances the effect of chemotherapy in ovarian cancer
J Xiang, J G�mez-Navarro, W Arafat, B Liu, SD Barker, RD Alvarez, GP Siegal, DT Curiel |
The Journal of Gene Medicine | 2000 |
Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)
FV Valen, S Fulda, B Truckenbrod, V Eckervogt, J Sonnemann, A Hillmann, R Rödl, C Hoffmann, W Winkelmann, L Schäfer, B Dockhorn-Dworniczak, T Wessel, J Boos, KM Debatin, H Jürgens |
International Journal of Cancer | 2000 |
The Complexity of TNF-Related Apoptosis-Inducing Ligand
K Abe, A Kurakin, M Mohseni-Maybodi, B Kay, R Khosravi-Far |
Annals of the New York Academy of Sciences | 2000 |
Predicting human safety: screening and computational approaches
DE Johnson, GH Wolfgang |
Drug Discovery Today | 2000 |
Apoptosis in cancer: cause and cure
SH Kaufmann, GJ Gores |
BioEssays | 2000 |
Don't blaze the trailblazer TRAIL too early
EG Vries, WT der Graaf, FJ Heijenbrok, HJ Hoekstra, S Jong |
The Lancet | 2000 |
Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines
MM Keane, Y Rubinstein, M Cuello, SA Ettenberg, P Banerjee, MM Nau, S Lipkowitz |
Breast Cancer Research and Treatment | 2000 |
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression
K Song, Y Chen, R Goke, A Wilmen, C Seidel, A Goke, B Hilliard, Y Chen |
Journal of Experimental Medicine | 2000 |
Intracellular Mechanisms of TRAIL and Its Role in Cancer Therapy
RK Srivastava |
Molecular Cell Biology Research Communications | 2000 |
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
H Walczak, PH Krammer |
Experimental Cell Research | 2000 |
Induction of Apoptosis in Glioma Cells by Recombinant Human Fas Ligand
S Kawaguchi, T Mineta, M Ichinose, J Masuoka, T Shiraishi, K Tabuchi |
Neurosurgery | 2000 |
Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL
JL Bodmer, P Meier, J Tschopp, P Schneider |
The Journal of biological chemistry | 2000 |
Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity
SS Cha, BJ Sung, YA Kim, YL Song, HJ Kim, S Kim, MS Lee, BH Oh |
The Journal of biological chemistry | 2000 |
The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation
F Mühlenbeck, P Schneider, JL Bodmer, R Schwenzer, A Hauser, G Schubert, P Scheurich, D Moosmayer, J Tschopp, H Wajant |
The Journal of biological chemistry | 2000 |
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
M Déjosez, U Ramp, C Mahotka, A Krieg, H Walczak, HE Gabbert, CD Gerharz |
Cell Death and Differentiation | 2000 |
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
S Hinz, A Trauzold, L Boenicke, C Sandberg, S Beckmann, E Bayer, H Walczak, H Kalthoff, H Ungefroren |
Oncogene | 2000 |
Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression
MA Grotzer, A Eggert, TJ Zuzak, AJ Janss, S Marwaha, BR Wiewrodt, N Ikegaki, GM Brodeur, PC Phillips |
Oncogene | 2000 |
Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells
SY Sun, P Yue, R Lotan |
Oncogene | 2000 |
Steering anti-cancer drugs away from the TRAIL
S Nagata |
Nature Medicine | 2000 |
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-relatedapoptosis-inducing ligand
M Jo, TH Kim, DW Seol, JE Esplen, K Dorko, TR Billiar, SC Strom |
Nature Medicine | 2000 |
Expression and Antitumor Effects of TRAIL in Human Cholangiocarcinoma
S Tanaka, K Sugimachi, K Shirabe, M Shimada, JR Wands, K Sugimachi |
Hepatology | 2000 |
From bench to clinic with apoptosis-based therapeutic agents
DW Nicholson |
Nature | 2000 |
Programmed cell death regulation: basic mechanisms and therapeutic opportunities
DE Johnson |
Leukemia | 2000 |
Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies
E Solary, N Droin, A Bettaieb, L Corcos, MT Dimanche-Boitrel, C Garrido |
Leukemia | 2000 |
Chirurgisches Forum 2000 für experimentelle und klinische Forschung
A Encke, M Rothmund, W Hartel, HG Beger |
2000 | |
The Death Domain Kinase RIP Is Essential for TRAIL (Apo2L)-Induced Activation of IκB Kinase and c-Jun N-Terminal Kinase
Y Lin, A Devin, A Cook, MM Keane, M Kelliher, S Lipkowitz, Z Liu |
Molecular and cellular biology | 2000 |
A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL
SG Hymowitz, MP O'Connell, MH Ultsch, A Hurst, K Totpal, A Ashkenazi, AM de Vos, RF Kelley |
Biochemistry | 2000 |
Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis
TS Griffith, RD Anderson, BL Davidson, RD Williams, TL Ratliff |
Journal of immunology (Baltimore, Md. : 1950) | 2000 |
TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Melanoma Is Associated with Changes in Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria
WD Thomas, XD Zhang, AV Franco, T Nguyen, P Hersey |
Journal of immunology (Baltimore, Md. : 1950) | 2000 |
Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity
W Roth, S Isenmann, U Naumann, S Kügler, M Bähr, J Dichgans, A Ashkenazi, M Weller |
Biochemical and Biophysical Research Communications | 1999 |
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5
SG Hymowitz, HW Christinger, G Fuh, M Ultsch, M O'Connell, RF Kelley, A Ashkenazi, AM de Vos |
Molecular Cell | 1999 |
Cytokines and Cancer
E Tartour, WH Fridman |
International Reviews of Immunology | 1998 |